1	[	[	NN	_	2	compound
2	Interaction	interaction	NN	_	0	ROOT
3	between	between	IN	_	4	case
4	clopidogrel	clopidogrel	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	proton	proton	NN	_	8	compound
7	pump	pump	NN	_	8	compound
8	inhibitors	inhibitor	NNS	_	4	conj
9	]	]	NN	_	4	dep
10	.	.	.	_	2	punct

1	The	the	DT	_	3	det
2	drug	drug	NN	_	3	compound
3	interaction	interaction	NN	_	13	nsubj
4	between	between	IN	_	7	case
5	proton	proton	NN	_	7	compound
6	pump	pump	NN	_	7	compound
7	inhibitors	inhibitor	NNS	_	3	nmod
8	and	and	CC	_	7	cc
9	clopidogrel	clopidogrel	NN	_	7	conj
10	has	have	VBZ	_	13	aux
11	been	be	VBN	_	13	cop
12	the	the	DT	_	13	det
13	subject	subject	NN	_	0	ROOT
14	of	of	IN	_	16	case
15	much	much	JJ	_	16	amod
16	study	study	NN	_	13	nmod
17	in	in	IN	_	19	case
18	recent	recent	JJ	_	19	amod
19	years	year	NNS	_	13	nmod
20	.	.	.	_	13	punct

1	Contradictory	contradictory	JJ	_	2	amod
2	results	result	NNS	_	0	ROOT
3	regarding	regard	VBG	_	5	case
4	the	the	DT	_	5	det
5	effect	effect	NN	_	2	nmod
6	of	of	IN	_	9	case
7	proton	proton	NN	_	9	compound
8	pump	pump	NN	_	9	compound
9	inhibitors	inhibitor	NNS	_	5	nmod
10	on	on	IN	_	12	case
11	platelet	platelet	NN	_	12	compound
12	reactivity	reactivity	NN	_	5	nmod
13	and	and	CC	_	5	cc
14	on	on	IN	_	16	case
15	clinical	clinical	JJ	_	16	amod
16	outcome	outcome	NN	_	5	conj
17	in	in	IN	_	18	case
18	clopidogrel	clopidogrel	NN	_	16	nmod
19	-	-	:	_	5	punct
20	treated	treated	JJ	_	21	amod
21	patients	patient	NNS	_	24	nsubjpass
22	have	have	VBP	_	24	aux
23	been	be	VBN	_	24	auxpass
24	reported	report	VBN	_	5	acl:relcl
25	in	in	IN	_	26	case
26	literature	literature	NN	_	24	nmod
27	.	.	.	_	2	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	use	use	NN	_	8	nsubjpass
3	of	of	IN	_	4	case
4	omeprazole	omeprazole	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	clopidogrel	clopidogrel	NN	_	4	conj
7	was	be	VBD	_	8	auxpass
8	found	find	VBN	_	0	ROOT
9	to	to	TO	_	10	mark
10	decrease	decrease	VB	_	8	xcomp
11	the	the	DT	_	12	det
12	exposure	exposure	NN	_	10	dobj
13	(	(	CD	_	14	nummod
14	AUC	auc	NN	_	12	dep
15	)	)	CD	_	14	nummod
16	to	to	TO	_	21	case
17	clopidogrel	clopidogrel	NN	_	21	compound
18	'	'	''	_	21	punct
19	s	s	NNS	_	21	compound
20	active	active	JJ	_	21	amod
21	metabolite	metabolite	NN	_	12	nmod
22	by	by	IN	_	24	case
23	50	50	CD	_	24	nummod
24	%	%	NN	_	10	nmod
25	and	and	CC	_	10	cc
26	to	to	TO	_	28	mark
27	sharply	sharply	RB	_	28	advmod
28	increase	increase	VB	_	10	conj
29	platelet	platelet	NN	_	30	compound
30	reactivity	reactivity	NN	_	28	dobj
31	,	,	,	_	10	punct
32	as	as	IN	_	34	case
33	a	a	DT	_	34	det
34	result	result	NN	_	10	nmod
35	of	of	IN	_	36	case
36	inhibition	inhibition	NN	_	34	nmod
37	by	by	IN	_	38	case
38	omeprazole	omeprazole	NN	_	36	nmod
39	of	of	IN	_	40	case
40	CYP2C19	cyp2c19	NN	_	38	nmod
41	,	,	,	_	40	punct
42	a	a	DT	_	48	det
43	cytochrome	cytochrome	NN	_	48	compound
44	P450	p450	NN	_	48	compound
45	(	(	CD	_	48	nummod
46	CYP	cyp	NN	_	48	compound
47	)	)	CD	_	48	nummod
48	enzyme	enzyme	NN	_	40	appos
49	.	.	.	_	8	punct

1	Pantoprazole	Pantoprazole	NNP	_	2	nsubj
2	has	have	VBZ	_	0	ROOT
3	a	a	DT	_	6	det
4	much	much	JJ	_	6	amod
5	weaker	weaker	JJR	_	6	amod
6	effect	effect	NN	_	2	dobj
7	on	on	IN	_	11	case
8	clopidogrel	clopidogrel	NN	_	11	compound
9	'	'	''	_	11	punct
10	s	s	NNS	_	11	compound
11	pharmacokinetics	pharmacokinetic	NNS	_	6	nmod
12	and	and	CC	_	11	cc
13	on	on	IN	_	15	case
14	platelet	platelet	NN	_	15	compound
15	reactivity	reactivity	NN	_	11	conj
16	during	during	IN	_	18	case
17	concomitant	concomitant	JJ	_	18	amod
18	use	use	NN	_	15	nmod
19	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	influence	influence	NN	_	18	nsubjpass
3	of	of	IN	_	8	case
4	the	the	DT	_	8	det
5	other	other	JJ	_	8	amod
6	proton	proton	NN	_	8	compound
7	pump	pump	NN	_	8	compound
8	inhibitors	inhibitor	NNS	_	2	nmod
9	when	when	WRB	_	10	advmod
10	used	use	VBN	_	2	acl
11	simultaneously	simultaneously	RB	_	10	advmod
12	with	with	IN	_	13	case
13	clopidogrel	clopidogrel	NN	_	10	nmod
14	has	have	VBZ	_	18	aux
15	not	not	RB	_	18	neg
16	yet	yet	RB	_	18	advmod
17	been	be	VBN	_	18	auxpass
18	investigated	investigate	VBN	_	0	ROOT
19	in	in	IN	_	22	case
20	adequately	adequately	RB	_	21	advmod
21	randomized	randomize	VBN	_	22	amod
22	studies	study	NNS	_	18	nmod
23	.	.	.	_	18	punct

1	Regulatory	regulatory	JJ	_	2	amod
2	agencies	agency	NNS	_	3	nsubj
3	state	state	VBP	_	0	ROOT
4	that	that	IN	_	18	mark
5	the	the	DT	_	6	det
6	combination	combination	NN	_	18	nsubjpass
7	of	of	IN	_	8	case
8	clopidogrel	clopidogrel	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	the	the	DT	_	12	det
11	CYP2C19	cyp2c19	NN	_	12	compound
12	inhibitors	inhibitor	NNS	_	8	conj
13	omeprazole	omeprazole	NN	_	12	dep
14	and	and	CC	_	13	cc
15	esomeprazole	esomeprazole	NN	_	13	conj
16	should	should	MD	_	18	aux
17	be	be	VB	_	18	auxpass
18	avoided	avoid	VBN	_	3	ccomp
19	.	.	.	_	3	punct

1	To	to	TO	_	2	case
2	date	date	NN	_	5	nmod
3	,	,	,	_	5	punct
4	there	there	EX	_	5	expl
5	is	be	VBZ	_	0	ROOT
6	no	no	DT	_	8	neg
7	conclusive	conclusive	JJ	_	8	amod
8	evidence	evidence	NN	_	5	nsubj
9	of	of	IN	_	14	case
10	a	a	DT	_	14	det
11	clinically	clinically	RB	_	14	advmod
12	-	-	:	_	14	punct
13	relevant	relevant	JJ	_	14	amod
14	interaction	interaction	NN	_	8	nmod
15	between	between	IN	_	16	case
16	any	any	DT	_	14	nmod
17	of	of	IN	_	21	case
18	the	the	DT	_	21	det
19	proton	proton	NN	_	21	compound
20	pump	pump	NN	_	21	compound
21	inhibitors	inhibitor	NNS	_	16	nmod
22	and	and	CC	_	21	cc
23	clopidogrel	clopidogrel	NN	_	21	conj
24	.	.	.	_	5	punct

1	Interaction	interaction	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	dacarbazine	dacarbazine	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	imexon	imexon	NN	_	3	conj
6	,	,	,	_	1	punct
7	in	in	FW	_	8	compound
8	vitro	vitro	FW	_	9	advmod
9	and	and	CC	_	1	advmod
10	in	in	FW	_	11	compound
11	vivo	vivo	FW	_	9	advmod
12	,	,	,	_	1	punct
13	in	in	IN	_	17	case
14	human	human	JJ	_	17	amod
15	A375	a375	NN	_	17	compound
16	melanoma	melanoma	NN	_	17	compound
17	cells	cell	NNS	_	1	nmod
18	.	.	.	_	1	punct

1	We	we	PRP	_	2	nsubj
2	evaluated	evaluate	VBD	_	0	ROOT
3	mechanisms	mechanism	NNS	_	2	dobj
4	of	of	IN	_	5	case
5	interaction	interaction	NN	_	3	nmod
6	between	between	IN	_	13	case
7	the	the	DT	_	13	det
8	alkyating	alkyating	JJ	_	13	amod
9	agent	agent	NN	_	13	compound
10	dacarbazine	dacarbazine	NN	_	13	compound
11	(	(	CD	_	13	nummod
12	DTIC	dtic	NN	_	13	compound
13	)	)	NN	_	5	nmod
14	and	and	CC	_	13	cc
15	the	the	DT	_	20	det
16	pro	pro	NN	_	18	dep
17	-	-	:	_	18	punct
18	oxidant	oxidant	JJ	_	20	amod
19	,	,	,	_	18	punct
20	imexon	imexon	NN	_	13	conj
21	,	,	,	_	2	punct
22	in	in	IN	_	28	case
23	the	the	DT	_	28	det
24	human	human	JJ	_	28	amod
25	A375	a375	NN	_	28	compound
26	melanoma	melanoma	NN	_	28	compound
27	cell	cell	NN	_	28	compound
28	line	line	NN	_	2	nmod
29	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	14	nsubjpass
3	of	of	IN	_	4	case
4	DTIC	dtic	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	imexon	imexon	NN	_	4	conj
7	,	,	,	_	4	punct
8	alone	alone	RB	_	4	conj
9	and	and	CC	_	4	cc
10	in	in	IN	_	11	case
11	combination	combination	NN	_	4	conj
12	,	,	,	_	2	punct
13	was	be	VBD	_	14	auxpass
14	evaluated	evaluate	VBN	_	0	ROOT
15	for	for	IN	_	17	case
16	growth	growth	NN	_	17	compound
17	inhibition	inhibition	NN	_	14	nmod
18	(	(	CD	_	19	nummod
19	MTT	MTT	NNP	_	17	dep
20	)	)	CD	_	19	nummod
21	,	,	,	_	19	punct
22	radiolabeled	radiolabele	VBN	_	24	amod
23	drug	drug	NN	_	24	compound
24	uptake	uptake	NN	_	19	appos
25	,	,	,	_	19	punct
26	cellular	cellular	JJ	_	28	amod
27	thiol	thiol	NN	_	28	compound
28	content	content	NN	_	19	appos
29	(	(	CD	_	31	nummod
30	HPLC	hplc	NN	_	31	compound
31	)	)	NN	_	28	dep
32	,	,	,	_	19	punct
33	and	and	CC	_	19	cc
34	DNA	dna	NN	_	36	compound
35	strand	strand	NN	_	36	compound
36	breaks	break	NNS	_	40	dep
37	(	(	RB	_	40	advmod
38	Comet	Comet	NNP	_	40	compound
39	assay	assay	NN	_	40	compound
40	)	)	NN	_	19	conj
41	.	.	.	_	14	punct

1	Pharmacokinetic	pharmacokinetic	JJ	_	6	nsubjpass
2	and	and	CC	_	1	cc
3	antitumor	antitumor	JJ	_	1	conj
4	effects	effect	NNS	_	1	dep
5	were	be	VBD	_	6	auxpass
6	evaluated	evaluate	VBN	_	0	ROOT
7	in	in	IN	_	8	case
8	mice	mouse	NNS	_	6	nmod
9	.	.	.	_	6	punct

1	Growth	growth	NN	_	2	compound
2	inhibition	inhibition	NN	_	6	nsubj
3	in	in	FW	_	4	compound
4	vitro	vitro	FW	_	2	advmod
5	was	be	VBD	_	6	cop
6	additive	additive	JJ	_	0	ROOT
7	with	with	IN	_	10	case
8	the	the	DT	_	10	det
9	two	two	CD	_	10	nummod
10	drugs	drug	NNS	_	6	nmod
11	.	.	.	_	6	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	no	no	DT	_	4	neg
4	effect	effect	NN	_	2	nsubj
5	on	on	IN	_	7	case
6	drug	drug	NN	_	7	compound
7	uptake	uptake	NN	_	4	nmod
8	or	or	CC	_	7	cc
9	on	on	IN	_	11	case
10	the	the	DT	_	11	det
11	number	number	NN	_	7	conj
12	of	of	IN	_	15	case
13	DNA	dna	NN	_	15	compound
14	strand	strand	NN	_	15	compound
15	breaks	break	NNS	_	11	nmod
16	.	.	.	_	2	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	a	a	DT	_	6	det
4	>75	>75	CD	_	5	compound
5	%	%	NN	_	6	amod
6	reduction	reduction	NN	_	2	nsubj
7	in	in	IN	_	9	case
8	cellular	cellular	JJ	_	9	amod
9	glutathione	glutathione	NN	_	6	nmod
10	and	and	CC	_	9	cc
11	cysteine	cysteine	NN	_	9	conj
12	with	with	IN	_	13	case
13	imexon	imexon	NN	_	6	nmod
14	but	but	CC	_	15	cc
15	not	not	RB	_	13	cc
16	DTIC	dtic	NN	_	13	conj
17	.	.	.	_	2	punct

1	Co	Co	NNP	_	0	ROOT
2	-	-	:	_	1	punct
3	administration	administration	NN	_	10	nsubj
4	of	of	IN	_	7	case
5	the	the	DT	_	7	det
6	two	two	CD	_	7	nummod
7	drugs	drug	NNS	_	3	nmod
8	in	in	IN	_	9	case
9	mice	mouse	NNS	_	7	nmod
10	caused	cause	VBD	_	1	dep
11	an	a	DT	_	12	det
12	increase	increase	NN	_	10	dobj
13	in	in	IN	_	15	case
14	the	the	DT	_	15	det
15	area	area	NN	_	12	nmod
16	under	under	IN	_	18	case
17	the	the	DT	_	18	det
18	curve	curve	NN	_	12	nmod
19	of	of	IN	_	21	case
20	both	both	CC	_	21	det
21	drugs	drug	NNS	_	18	nmod
22	,	,	,	_	10	punct
23	but	but	CC	_	10	cc
24	the	the	DT	_	25	det
25	combination	combination	NN	_	28	nsubj
26	was	be	VBD	_	28	cop
27	not	not	RB	_	28	neg
28	effective	effective	JJ	_	10	conj
29	in	in	IN	_	30	mark
30	reducing	reduce	VBG	_	28	advcl
31	human	human	JJ	_	34	amod
32	A375	a375	NN	_	34	compound
33	melanoma	melanoma	NN	_	34	compound
34	tumors	tumor	NNS	_	30	dobj
35	in	in	FW	_	36	compound
36	vivo	vivo	FW	_	30	advmod
37	.	.	.	_	1	punct

1	Imexon	imexon	NN	_	4	nsubj
2	and	and	CC	_	1	cc
3	dacarbazine	dacarbazine	NN	_	1	conj
4	show	show	VBP	_	0	ROOT
5	additive	additive	JJ	_	6	amod
6	effects	effect	NNS	_	4	dobj
7	in	in	FW	_	8	compound
8	vitro	vitro	FW	_	4	advmod
9	but	but	CC	_	10	cc
10	not	not	RB	_	8	cc
11	in	in	FW	_	12	compound
12	vivo	vivo	FW	_	8	conj
13	in	in	IN	_	17	case
14	human	human	JJ	_	17	amod
15	A375	a375	NN	_	17	compound
16	melanoma	melanoma	NN	_	17	compound
17	cells	cell	NNS	_	4	nmod
18	.	.	.	_	4	punct

1	Enhancement	enhancement	NN	_	0	ROOT
2	of	of	IN	_	5	case
3	humoral	humoral	JJ	_	5	amod
4	immune	immune	JJ	_	5	amod
5	responses	response	NNS	_	1	nmod
6	to	to	TO	_	9	case
7	inactivated	inactivate	VBN	_	9	amod
8	Newcastle	Newcastle	NNP	_	9	compound
9	disease	disease	NN	_	5	nmod
10	and	and	CC	_	9	cc
11	avian	avian	JJ	_	13	amod
12	influenza	influenza	NN	_	13	compound
13	vaccines	vaccine	NNS	_	9	conj
14	by	by	IN	_	16	case
15	oral	oral	JJ	_	16	amod
16	administration	administration	NN	_	1	nmod
17	of	of	IN	_	19	case
18	ginseng	ginseng	NN	_	19	compound
19	stem	stem	NN	_	16	nmod
20	-	-	:	_	1	punct
21	and	and	CC	_	1	cc
22	-	-	:	_	24	punct
23	leaf	leaf	NN	_	24	compound
24	saponins	saponin	NNS	_	1	conj
25	in	in	IN	_	26	case
26	chickens	chicken	NNS	_	24	nmod
27	.	.	.	_	1	punct

1	Newcastle	newcastle	JJ	_	5	amod
2	disease	disease	NN	_	5	compound
3	(	(	NN	_	5	compound
4	ND	nd	NN	_	5	compound
5	)	)	NN	_	13	nsubj
6	and	and	CC	_	5	cc
7	avian	avian	JJ	_	11	amod
8	influenza	influenza	NN	_	11	compound
9	(	(	NN	_	11	compound
10	AI	ai	NN	_	11	compound
11	)	)	NN	_	5	conj
12	are	be	VBP	_	13	cop
13	common	common	JJ	_	0	ROOT
14	in	in	IN	_	17	case
15	the	the	DT	_	17	det
16	poultry	poultry	NN	_	17	compound
17	industry	industry	NN	_	13	nmod
18	.	.	.	_	13	punct

1	The	the	DT	_	2	det
2	objective	objective	NN	_	6	nsubj
3	of	of	IN	_	5	case
4	this	this	DT	_	5	det
5	study	study	NN	_	2	nmod
6	was	be	VBD	_	0	ROOT
7	to	to	TO	_	8	mark
8	evaluate	evaluate	VB	_	6	xcomp
9	the	the	DT	_	10	det
10	effect	effect	NN	_	8	dobj
11	of	of	IN	_	13	case
12	oral	oral	JJ	_	13	amod
13	administration	administration	NN	_	10	nmod
14	of	of	IN	_	16	case
15	ginseng	ginseng	NN	_	16	compound
16	stem	stem	NN	_	13	nmod
17	-	-	:	_	8	punct
18	and	and	CC	_	8	cc
19	-	-	:	_	8	punct
20	leaf	leaf	NN	_	21	compound
21	saponins	saponin	NNS	_	22	nsubj
22	(	(	VBP	_	8	conj
23	GSLS	gsls	NN	_	24	compound
24	)	)	NN	_	22	dobj
25	on	on	IN	_	29	case
26	the	the	DT	_	29	det
27	humoral	humoral	JJ	_	29	amod
28	immune	immune	JJ	_	29	amod
29	responses	response	NNS	_	22	nmod
30	of	of	IN	_	31	case
31	chickens	chicken	NNS	_	29	nmod
32	to	to	TO	_	34	case
33	inactivated	inactivate	VBN	_	34	amod
34	ND	nd	NN	_	29	nmod
35	and	and	CC	_	34	cc
36	AI	ai	NN	_	37	compound
37	vaccines	vaccine	NNS	_	34	conj
38	.	.	.	_	6	punct

1	In	in	IN	_	2	case
2	experiment	experiment	NN	_	35	nmod
3	1	1	CD	_	2	nummod
4	,	,	,	_	35	punct
5	oral	oral	JJ	_	6	amod
6	administration	administration	NN	_	35	nsubjpass
7	of	of	IN	_	8	case
8	GSLS	gsls	NN	_	6	nmod
9	at	at	IN	_	11	case
10	a	a	DT	_	11	det
11	dose	dose	NN	_	6	nmod
12	of	of	IN	_	14	case
13	5	5	CD	_	14	nummod
14	mg	mg	NN	_	11	nmod
15	/	/	:	_	16	punct
16	kg	kg	NN	_	35	nsubjpass
17	of	of	IN	_	18	case
18	BW	bw	NN	_	16	nmod
19	for	for	IN	_	21	case
20	7	7	CD	_	21	nummod
21	d	d	NN	_	16	nmod
22	on	on	IN	_	25	case
23	the	the	DT	_	25	det
24	immune	immune	JJ	_	25	amod
25	response	response	NN	_	16	nmod
26	in	in	IN	_	27	case
27	chickens	chicken	NNS	_	25	nmod
28	intramuscularly	intramuscularly	RB	_	29	advmod
29	injected	inject	VBN	_	27	acl
30	with	with	IN	_	33	case
31	inactivated	inactivate	VBN	_	33	amod
32	ND	nd	NN	_	33	compound
33	vaccine	vaccine	NN	_	29	nmod
34	was	be	VBD	_	35	auxpass
35	evaluated	evaluate	VBN	_	0	ROOT
36	.	.	.	_	35	punct

1	Results	result	NNS	_	2	nsubj
2	showed	show	VBD	_	0	ROOT
3	that	that	IN	_	6	mark
4	GSLS	gsls	NN	_	6	nsubj
5	significantly	significantly	RB	_	6	advmod
6	increased	increase	VBD	_	2	ccomp
7	the	the	DT	_	9	det
8	antibody	antibody	NN	_	9	compound
9	level	level	NN	_	6	dobj
10	against	against	IN	_	11	case
11	ND	nd	NN	_	9	nmod
12	in	in	IN	_	14	case
13	the	the	DT	_	14	det
14	serum	serum	NN	_	9	nmod
15	of	of	IN	_	16	case
16	chickens	chicken	NNS	_	14	nmod
17	.	.	.	_	2	punct

1	In	in	IN	_	2	case
2	experiment	experiment	NN	_	11	nmod
3	2	2	CD	_	2	nummod
4	,	,	,	_	11	punct
5	the	the	DT	_	7	det
6	same	same	JJ	_	7	amod
7	regimen	regimen	NN	_	11	nsubjpass
8	of	of	IN	_	9	case
9	GSLS	gsls	NN	_	7	nmod
10	was	be	VBD	_	11	auxpass
11	administered	administer	VBN	_	0	ROOT
12	to	to	TO	_	13	case
13	chickens	chicken	NNS	_	11	nmod
14	inoculated	inoculate	VBN	_	13	acl
15	with	with	IN	_	18	case
16	inactivated	inactivate	VBN	_	18	amod
17	AI	ai	NN	_	18	compound
18	vaccines	vaccine	NNS	_	14	nmod
19	,	,	,	_	11	punct
20	and	and	CC	_	11	cc
21	an	a	DT	_	25	det
22	enhanced	enhance	VBN	_	25	amod
23	serum	serum	NN	_	25	compound
24	antibody	antibody	NN	_	25	compound
25	response	response	NN	_	31	nsubjpass
26	to	to	TO	_	28	case
27	AI	AI	NNP	_	28	compound
28	vaccination	vaccination	NN	_	25	nmod
29	was	be	VBD	_	31	auxpass
30	also	also	RB	_	31	advmod
31	observed	observe	VBN	_	11	conj
32	.	.	.	_	11	punct

1	Considering	consider	VBG	_	23	advcl
2	the	the	DT	_	3	det
3	safety	safety	NN	_	1	dobj
4	of	of	IN	_	5	case
5	GSLS	GSLS	NNP	_	3	nmod
6	,	,	,	_	1	punct
7	because	because	IN	_	12	mark
8	no	no	DT	_	10	neg
9	adverse	adverse	JJ	_	10	amod
10	effect	effect	NN	_	12	nsubjpass
11	was	be	VBD	_	12	auxpass
12	found	find	VBN	_	1	advcl
13	throughout	throughout	IN	_	15	case
14	the	the	DT	_	15	det
15	experiments	experiment	NNS	_	12	nmod
16	,	,	,	_	23	punct
17	GSLS	gsl	NNS	_	23	nsubj
18	may	may	MD	_	23	aux
19	be	be	VB	_	23	cop
20	a	a	DT	_	23	det
21	promising	promising	JJ	_	23	amod
22	oral	oral	JJ	_	23	amod
23	adjuvant	adjuvant	JJ	_	0	ROOT
24	to	to	TO	_	25	mark
25	improve	improve	VB	_	23	xcomp
26	immunization	immunization	NN	_	25	dobj
27	in	in	IN	_	28	case
28	poultry	poultry	NN	_	26	nmod
29	.	.	.	_	23	punct

1	Protective	protective	JJ	_	2	amod
2	effect	effect	NN	_	0	ROOT
3	of	of	IN	_	6	case
4	acetyl	acetyl	NN	_	6	compound
5	-	-	:	_	6	punct
6	l	l	NN	_	2	nmod
7	-	-	:	_	6	punct
8	carnitine	carnitine	NN	_	6	dep
9	and	and	CC	_	8	cc
10	alpha	alpha	NN	_	12	compound
11	lipoic	lipoic	JJ	_	12	amod
12	acid	acid	NN	_	8	conj
13	against	against	IN	_	16	case
14	the	the	DT	_	16	det
15	acute	acute	JJ	_	16	amod
16	toxicity	toxicity	NN	_	2	nmod
17	of	of	IN	_	18	case
18	diepoxybutane	diepoxybutane	NN	_	16	nmod
19	to	to	TO	_	21	case
20	human	human	JJ	_	21	amod
21	lymphocytes	lymphocyte	NNS	_	16	nmod
22	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	biotransformation	biotransformation	NN	_	7	nsubj
3	and	and	CC	_	2	cc
4	oxidative	oxidative	JJ	_	5	amod
5	stress	stress	NN	_	2	conj
6	may	may	MD	_	7	aux
7	contribute	contribute	VB	_	0	ROOT
8	to	to	TO	_	9	case
9	1,2	1,2	CD	_	7	nmod
10	:	:	:	_	7	punct
11	3,4	3,4	CD	_	15	nummod
12	-	-	:	_	15	punct
13	diepoxybutane	diepoxybutane	NN	_	15	compound
14	(	(	CD	_	15	nummod
15	DEB	DEB	NNP	_	7	dep
16	)	)	SYM	_	15	punct
17	-	-	:	_	15	punct
18	induced	induce	VBN	_	19	amod
19	toxicity	toxicity	NN	_	15	dep
20	to	to	TO	_	22	case
21	human	human	JJ	_	22	amod
22	lymphocytes	lymphocyte	NNS	_	19	nmod
23	of	of	IN	_	27	case
24	Fanconi	Fanconi	NNP	_	27	compound
25	Anemia	Anemia	NNP	_	27	compound
26	(	(	CD	_	27	nummod
27	FA	FA	NNP	_	22	nmod
28	)	)	CD	_	29	nummod
29	patients	patient	NNS	_	27	dep
30	.	.	.	_	7	punct

1	Thus	thus	RB	_	31	advmod
2	,	,	,	_	31	punct
3	the	the	DT	_	4	det
4	identification	identification	NN	_	31	nsubj
5	of	of	IN	_	7	case
6	putative	putative	JJ	_	7	amod
7	inhibitors	inhibitor	NNS	_	4	nmod
8	of	of	IN	_	9	case
9	bioactivation	bioactivation	NN	_	7	nmod
10	,	,	,	_	7	punct
11	as	as	RB	_	7	cc
12	well	well	RB	_	11	mwe
13	as	as	IN	_	11	mwe
14	the	the	DT	_	15	det
15	determination	determination	NN	_	7	conj
16	of	of	IN	_	19	case
17	the	the	DT	_	19	det
18	protective	protective	JJ	_	19	amod
19	role	role	NN	_	15	nmod
20	of	of	IN	_	22	case
21	oxidant	oxidant	JJ	_	22	amod
22	defenses	defens	NNS	_	19	nmod
23	,	,	,	_	15	punct
24	on	on	IN	_	25	case
25	DEB	DEB	NNP	_	15	nmod
26	-	-	:	_	15	punct
27	induced	induce	VBD	_	28	amod
28	toxicity	toxicity	NN	_	15	dep
29	,	,	,	_	31	punct
30	can	can	MD	_	31	aux
31	help	help	VB	_	0	ROOT
32	to	to	TO	_	33	mark
33	understand	understand	VB	_	31	xcomp
34	what	what	WP	_	36	nsubj
35	is	be	VBZ	_	36	aux
36	failing	fail	VBG	_	33	ccomp
37	in	in	IN	_	39	case
38	FA	fa	NN	_	39	compound
39	cells	cell	NNS	_	36	nmod
40	.	.	.	_	31	punct

1	In	in	IN	_	4	case
2	the	the	DT	_	4	det
3	present	present	JJ	_	4	amod
4	work	work	NN	_	6	nmod
5	we	we	PRP	_	6	nsubj
6	studied	study	VBD	_	0	ROOT
7	the	the	DT	_	8	det
8	contribution	contribution	NN	_	6	dobj
9	of	of	IN	_	12	case
10	several	several	JJ	_	12	amod
11	biochemical	biochemical	JJ	_	12	amod
12	pathways	pathway	NNS	_	8	nmod
13	for	for	IN	_	14	case
14	DEB	DEB	NNP	_	12	nmod
15	-	-	:	_	8	punct
16	induced	induce	VBD	_	18	amod
17	acute	acute	JJ	_	18	amod
18	toxicity	toxicity	NN	_	8	dep
19	in	in	IN	_	22	case
20	human	human	JJ	_	22	amod
21	lymphocyte	lymphocyte	NN	_	22	compound
22	suspensions	suspension	NNS	_	18	nmod
23	,	,	,	_	8	punct
24	by	by	IN	_	25	mark
25	using	use	VBG	_	6	advcl
26	inhibitors	inhibitor	NNS	_	25	dobj
27	of	of	IN	_	29	case
28	epoxide	epoxide	NN	_	29	compound
29	hydrolases	hydrolase	NNS	_	26	nmod
30	,	,	,	_	26	punct
31	inhibitors	inhibitor	NNS	_	26	appos
32	of	of	IN	_	34	case
33	protective	protective	JJ	_	34	amod
34	enzymes	enzyme	NNS	_	31	nmod
35	as	as	IN	_	37	case
36	glutathione	glutathione	NN	_	37	compound
37	S	s	NN	_	31	nmod
38	-	-	:	_	37	punct
39	transferase	transferase	NN	_	37	dep
40	and	and	CC	_	39	cc
41	catalase	catalase	NN	_	39	conj
42	,	,	,	_	37	punct
43	the	the	DT	_	44	det
44	depletion	depletion	NN	_	37	conj
45	of	of	IN	_	49	case
46	glutathione	glutathione	NN	_	49	compound
47	(	(	CD	_	49	nummod
48	GSH	gsh	NN	_	49	compound
49	)	)	NN	_	44	nmod
50	,	,	,	_	37	punct
51	and	and	CC	_	37	cc
52	the	the	DT	_	53	det
53	inhibition	inhibition	NN	_	37	conj
54	of	of	IN	_	56	case
55	protein	protein	NN	_	56	compound
56	synthesis	synthesis	NN	_	53	nmod
57	;	;	:	_	6	punct

1	and	and	CC	_	0	ROOT
2	a	a	DT	_	3	det
3	variety	variety	NN	_	1	dep
4	of	of	IN	_	7	case
5	putative	putative	JJ	_	7	amod
6	protective	protective	JJ	_	7	amod
7	compounds	compound	NNS	_	3	nmod
8	,	,	,	_	7	punct
9	including	include	VBG	_	10	case
10	antioxidants	antioxidant	NNS	_	7	nmod
11	,	,	,	_	7	punct
12	and	and	CC	_	7	cc
13	mitochondrial	mitochondrial	JJ	_	15	amod
14	protective	protective	JJ	_	15	amod
15	agents	agent	NNS	_	7	conj
16	.	.	.	_	1	punct

1	The	the	DT	_	3	det
2	present	present	JJ	_	3	amod
3	study	study	NN	_	4	nsubj
4	reports	report	VBZ	_	0	ROOT
5	two	two	CD	_	7	nummod
6	novel	novel	JJ	_	7	amod
7	findings	finding	NNS	_	4	dobj
8	:	:	:	_	7	punct
9	(	(	CD	_	11	nummod
10	i	i	FW	_	11	compound
11	)	)	FW	_	7	dep
12	it	it	PRP	_	15	nsubjpass
13	was	be	VBD	_	15	auxpass
14	clearly	clearly	RB	_	15	advmod
15	evidenced	evidence	VBN	_	11	acl:relcl
16	,	,	,	_	11	punct
17	for	for	IN	_	20	case
18	the	the	DT	_	20	det
19	first	first	JJ	_	20	amod
20	time	time	NN	_	11	nmod
21	,	,	,	_	11	punct
22	that	that	IN	_	33	mark
23	the	the	DT	_	25	det
24	acute	acute	JJ	_	25	amod
25	exposure	exposure	NN	_	33	nsubj
26	of	of	IN	_	30	case
27	freshly	freshly	RB	_	28	advmod
28	isolated	isolate	VBN	_	30	amod
29	human	human	JJ	_	30	amod
30	lymphocytes	lymphocyte	NNS	_	25	nmod
31	to	to	TO	_	32	case
32	DEB	DEB	NNP	_	25	nmod
33	results	result	VBZ	_	11	ccomp
34	in	in	IN	_	37	case
35	severe	severe	JJ	_	37	amod
36	GSH	gsh	NN	_	37	compound
37	depletion	depletion	NN	_	33	nmod
38	and	and	CC	_	37	cc
39	loss	loss	NN	_	37	conj
40	of	of	IN	_	41	case
41	ATP	atp	NN	_	39	nmod
42	,	,	,	_	33	punct
43	followed	follow	VBN	_	33	dep
44	by	by	IN	_	46	case
45	cell	cell	NN	_	46	compound
46	death	death	NN	_	43	nmod
47	;	;	:	_	4	punct

1	(	(	RB	_	2	advmod
2	ii	ii	LS	_	0	ROOT
3	)	)	CD	_	4	nummod
4	acetyl	acetyl	NN	_	9	nsubj
5	-	-	:	_	4	punct
6	l	l	NN	_	4	dep
7	-	-	:	_	4	punct
8	carnitine	carnitine	NN	_	4	dep
9	elicits	elicit	VBZ	_	2	ccomp
10	a	a	DT	_	13	det
11	significant	significant	JJ	_	13	amod
12	protective	protective	JJ	_	13	amod
13	effect	effect	NN	_	9	dobj
14	on	on	IN	_	17	case
15	DEB	deb	NN	_	17	compound
16	induced	induce	VBD	_	17	amod
17	toxicity	toxicity	NN	_	13	nmod
18	,	,	,	_	17	punct
19	which	which	WDT	_	21	nsubjpass
20	was	be	VBD	_	21	auxpass
21	potentiated	potentiate	VBN	_	17	acl:relcl
22	by	by	IN	_	23	case
23	alpha	alpha	NN	_	21	nmod
24	-	-	:	_	23	punct
25	lipoic	lipoic	JJ	_	26	amod
26	acid	acid	NN	_	23	dep
27	.	.	.	_	2	punct

1	Collectively	collectively	RB	_	5	advmod
2	,	,	,	_	5	punct
3	these	these	DT	_	4	det
4	findings	finding	NNS	_	5	nsubj
5	contribute	contribute	VBP	_	0	ROOT
6	to	to	TO	_	7	mark
7	increase	increase	VB	_	5	xcomp
8	our	we	PRP$	_	9	nmod:poss
9	knowledge	knowledge	NN	_	7	dobj
10	of	of	IN	_	11	case
11	DEB	DEB	NNP	_	9	nmod
12	-	-	:	_	7	punct
13	induce	induce	VB	_	7	conj
14	toxicity	toxicity	NN	_	13	dobj
15	and	and	CC	_	5	cc
16	will	will	MD	_	19	aux
17	be	be	VB	_	19	cop
18	very	very	RB	_	19	advmod
19	useful	useful	JJ	_	5	conj
20	when	when	WRB	_	21	advmod
21	applied	apply	VBN	_	19	advcl
22	in	in	IN	_	23	case
23	studies	study	NNS	_	21	nmod
24	with	with	IN	_	25	case
25	lymphocytes	lymphocyte	NNS	_	23	nmod
26	from	from	IN	_	28	case
27	FA	fa	NN	_	28	compound
28	patients	patient	NNS	_	25	nmod
29	,	,	,	_	5	punct
30	in	in	IN	_	33	mark
31	order	order	NN	_	30	mwe
32	to	to	TO	_	33	mark
33	find	find	VB	_	5	advcl
34	out	out	RP	_	33	compound:prt
35	a	a	DT	_	37	det
36	protective	protective	JJ	_	37	amod
37	agent	agent	NN	_	33	dobj
38	against	against	IN	_	39	case
39	spontaneous	spontaneous	JJ	_	37	nmod
40	and	and	CC	_	39	cc
41	DEB	deb	NN	_	39	conj
42	-	-	:	_	37	punct
43	induced	induce	VBN	_	45	amod
44	chromosome	chromosome	NN	_	45	compound
45	instability	instability	NN	_	37	dep
46	.	.	.	_	5	punct

1	Metabotropic	metabotropic	JJ	_	5	amod
2	glutamate	glutamate	NN	_	5	compound
3	receptor	receptor	NN	_	5	compound
4	5	5	CD	_	5	nummod
5	antagonist	antagonist	NN	_	6	nsubj
6	protects	protect	VBZ	_	0	ROOT
7	dopaminergic	dopaminergic	JJ	_	10	amod
8	and	and	CC	_	7	cc
9	noradrenergic	noradrenergic	JJ	_	7	conj
10	neurons	neuron	NNS	_	6	dobj
11	from	from	IN	_	12	case
12	degeneration	degeneration	NN	_	6	nmod
13	in	in	IN	_	14	case
14	MPTP	mptp	NN	_	12	nmod
15	-	-	:	_	6	punct
16	treated	treat	VBN	_	17	amod
17	monkeys	monkey	NNS	_	6	dobj
18	.	.	.	_	6	punct

1	Degeneration	Degeneration	NNP	_	18	nsubj
2	of	of	IN	_	6	case
3	the	the	DT	_	6	det
4	dopaminergic	dopaminergic	JJ	_	6	amod
5	nigrostriatal	nigrostriatal	JJ	_	6	amod
6	system	system	NN	_	1	nmod
7	and	and	CC	_	1	cc
8	of	of	IN	_	10	case
9	noradrenergic	noradrenergic	JJ	_	10	amod
10	neurons	neuron	NNS	_	1	conj
11	in	in	IN	_	14	case
12	the	the	DT	_	14	det
13	locus	locus	NN	_	14	compound
14	coeruleus	coeruleus	NN	_	10	nmod
15	are	be	VBP	_	18	cop
16	important	important	JJ	_	18	amod
17	pathological	pathological	JJ	_	18	amod
18	features	feature	NNS	_	0	ROOT
19	of	of	IN	_	23	case
20	Parkinson	Parkinson	NNP	_	23	nmod:poss
21	'	'	POS	_	20	case
22	s	s	NNS	_	23	compound
23	disease	disease	NN	_	18	nmod
24	.	.	.	_	18	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	an	a	DT	_	5	det
4	urgent	urgent	JJ	_	5	amod
5	need	need	NN	_	2	nsubj
6	to	to	TO	_	7	mark
7	develop	develop	VB	_	5	acl
8	therapies	therapy	NNS	_	7	dobj
9	that	that	WDT	_	10	nsubj
10	slow	slow	VBP	_	8	acl:relcl
11	down	down	RP	_	10	compound:prt
12	the	the	DT	_	13	det
13	progression	progression	NN	_	10	dobj
14	of	of	IN	_	15	case
15	neurodegeneration	neurodegeneration	NN	_	13	nmod
16	in	in	IN	_	20	case
17	Parkinson	Parkinson	NNP	_	20	nmod:poss
18	'	'	POS	_	17	case
19	s	s	NNS	_	20	compound
20	disease	disease	NN	_	13	nmod
21	.	.	.	_	2	punct

1	In	in	IN	_	4	case
2	the	the	DT	_	4	det
3	present	present	JJ	_	4	amod
4	study	study	NN	_	7	nmod
5	,	,	,	_	7	punct
6	we	we	PRP	_	7	nsubj
7	tested	test	VBD	_	0	ROOT
8	whether	whether	IN	_	7	dobj
9	the	the	DT	_	14	det
10	highly	highly	RB	_	11	advmod
11	specific	specific	JJ	_	14	amod
12	metabotropic	metabotropic	JJ	_	14	amod
13	glutamate	glutamate	NN	_	14	compound
14	receptor	receptor	NN	_	8	dep
15	5	5	CD	_	14	nummod
16	antagonist	antagonist	NN	_	14	dep
17	,	,	,	_	14	punct
18	3	3	LS	_	14	dep
19	-	-	:	_	18	punct
20	[	[	CD	_	21	compound
21	(	(	CD	_	24	dep
22	2	2	LS	_	24	dep
23	-	-	:	_	24	punct
24	methyl	methyl	NN	_	18	dep
25	-	-	:	_	24	punct
26	1,3	1,3	SYM	_	24	dep
27	-	-	:	_	24	punct
28	thiazol	thiazol	NN	_	24	dep
29	-	-	:	_	24	punct
30	4	4	LS	_	38	dep
31	-	-	:	_	38	punct
32	yl	yl	NN	_	34	compound
33	)	)	NN	_	34	compound
34	ethynyl	ethynyl	NN	_	38	nsubj
35	]	]	CD	_	36	nummod
36	pyridine	pyridine	NN	_	34	dep
37	,	,	,	_	38	punct
38	reduces	reduce	VBZ	_	24	dep
39	dopaminergic	dopaminergic	JJ	_	43	amod
40	and	and	CC	_	39	cc
41	noradrenergic	noradrenergic	JJ	_	39	conj
42	neuronal	neuronal	JJ	_	43	amod
43	loss	loss	NN	_	38	dobj
44	in	in	IN	_	45	case
45	monkeys	monkey	NNS	_	38	nmod
46	rendered	render	VBN	_	45	acl
47	parkinsonian	parkinsonian	JJ	_	46	xcomp
48	by	by	IN	_	50	case
49	chronic	chronic	JJ	_	50	amod
50	treatment	treatment	NN	_	46	nmod
51	with	with	IN	_	53	case
52	low	low	JJ	_	53	amod
53	doses	dose	NNS	_	50	nmod
54	of	of	IN	_	57	case
55	1	1	LS	_	57	dep
56	-	-	:	_	57	punct
57	methyl	methyl	NN	_	53	nmod
58	-	-	:	_	24	punct
59	4	4	LS	_	24	dep
60	-	-	:	_	61	punct
61	phenyl	phenyl	NN	_	59	dep
62	-	-	:	_	61	punct
63	1,2,3,6	1,2,3,6	CD	_	65	nummod
64	-	-	:	_	65	punct
65	tetrahydropyridine	tetrahydropyridine	NN	_	61	dep
66	.	.	.	_	7	punct

1	Weekly	Weekly	NNP	_	0	ROOT
2	intramuscular	intramuscular	JJ	_	1	amod
3	1	1	LS	_	5	dep
4	-	-	:	_	5	punct
5	methyl	methyl	NN	_	2	dep
6	-	-	:	_	5	punct
7	4	4	LS	_	55	dep
8	-	-	:	_	9	punct
9	phenyl	phenyl	NN	_	55	nsubjpass
10	-	-	:	_	9	punct
11	1,2,3,6	1,2,3,6	CD	_	9	dep
12	-	-	:	_	9	punct
13	tetrahydropyridine	tetrahydropyridine	NN	_	14	compound
14	injections	injection	NNS	_	15	nsubj
15	(	(	VBP	_	9	dep
16	0.2	0.2	CD	_	19	nummod
17	-	-	:	_	19	punct
18	0.5	0.5	CD	_	19	nummod
19	mg	mg	NN	_	15	dobj
20	/	/	:	_	19	punct
21	kg	kg	NN	_	24	compound
22	body	body	NN	_	24	compound
23	weight	weight	NN	_	24	compound
24	)	)	NN	_	19	dep
25	,	,	,	_	19	punct
26	in	in	IN	_	27	case
27	combination	combination	NN	_	19	nmod
28	with	with	IN	_	30	case
29	daily	daily	JJ	_	30	amod
30	administration	administration	NN	_	27	nmod
31	of	of	IN	_	32	case
32	3	3	CD	_	30	nmod
33	-	-	:	_	32	punct
34	[	[	CD	_	35	nummod
35	(	(	CD	_	32	dep
36	2	2	LS	_	38	dep
37	-	-	:	_	38	punct
38	methyl	methyl	NN	_	35	dep
39	-	-	:	_	38	punct
40	1,3	1,3	SYM	_	38	dep
41	-	-	:	_	38	punct
42	thiazol	thiazol	NN	_	38	dep
43	-	-	:	_	38	punct
44	4	4	LS	_	48	dep
45	-	-	:	_	48	punct
46	yl	yl	NN	_	48	compound
47	)	)	NN	_	48	compound
48	ethynyl	ethynyl	NN	_	38	dep
49	]	]	CD	_	50	nummod
50	pyridine	pyridine	NN	_	48	dep
51	or	or	CC	_	50	cc
52	vehicle	vehicle	NN	_	50	conj
53	,	,	,	_	38	punct
54	were	be	VBD	_	55	auxpass
55	performed	perform	VBN	_	5	dep
56	until	until	IN	_	58	case
57	the	the	DT	_	58	det
58	development	development	NN	_	55	nmod
59	of	of	IN	_	62	case
60	parkinsonian	parkinsonian	JJ	_	62	amod
61	motor	motor	NN	_	62	compound
62	symptoms	symptom	NNS	_	58	nmod
63	in	in	IN	_	64	case
64	either	either	DT	_	62	nmod
65	of	of	IN	_	69	case
66	the	the	DT	_	69	det
67	two	two	CD	_	69	nummod
68	experimental	experimental	JJ	_	69	amod
69	groups	group	NNS	_	64	nmod
70	(	(	VBP	_	5	dep
71	1	1	LS	_	70	dobj
72	-	-	:	_	71	punct
73	methyl	methyl	NN	_	71	dep
74	-	-	:	_	75	punct
75	4	4	LS	_	73	dep
76	-	-	:	_	75	punct
77	phenyl	phenyl	NN	_	75	dep
78	-	-	:	_	77	punct
79	1,2,3,6	1,2,3,6	CD	_	77	dep
80	-	-	:	_	75	punct
81	tetrahydropyridine	tetrahydropyridine	NN	_	75	dep
82	/	/	:	_	83	punct
83	3	3	LS	_	81	dep
84	-	-	:	_	83	punct
85	[	[	CD	_	86	compound
86	(	(	CD	_	89	dep
87	2	2	LS	_	89	dep
88	-	-	:	_	89	punct
89	methyl	methyl	NN	_	83	dep
90	-	-	:	_	89	punct
91	1,3	1,3	SYM	_	89	dep
92	-	-	:	_	89	punct
93	thiazol	thiazol	NN	_	89	dep
94	-	-	:	_	89	punct
95	4	4	LS	_	101	dep
96	-	-	:	_	101	punct
97	yl	yl	NN	_	101	compound
98	)	)	NN	_	101	compound
99	ethynyl	ethynyl	NN	_	101	compound
100	]	]	CD	_	101	nummod
101	pyridine	pyridine	NN	_	89	dep
102	versus	versus	CC	_	101	cc
103	1	1	LS	_	105	dep
104	-	-	:	_	105	punct
105	methyl	methyl	NN	_	101	conj
106	-	-	:	_	89	punct
107	4	4	LS	_	109	dep
108	-	-	:	_	109	punct
109	phenyl	phenyl	NN	_	89	dep
110	-	-	:	_	109	punct
111	1,2,3,6	1,2,3,6	CD	_	109	dep
112	-	-	:	_	109	punct
113	tetrahydropyridine	tetrahydropyridine	NN	_	109	dep
114	/	/	:	_	109	punct
115	vehicle	vehicle	NN	_	116	compound
116	)	)	NN	_	109	dep
117	.	.	.	_	1	punct

1	After	after	IN	_	3	case
2	21	21	CD	_	3	nummod
3	weeks	week	NNS	_	0	ROOT
4	of	of	IN	_	7	case
5	1	1	LS	_	7	dep
6	-	-	:	_	7	punct
7	methyl	methyl	NN	_	3	nmod
8	-	-	:	_	9	punct
9	4	4	LS	_	3	dep
10	-	-	:	_	9	punct
11	phenyl	phenyl	NN	_	9	dep
12	-	-	:	_	11	punct
13	1,2,3,6	1,2,3,6	CD	_	11	dep
14	-	-	:	_	11	punct
15	tetrahydropyridine	tetrahydropyridine	NN	_	16	compound
16	treatment	treatment	NN	_	11	dep
17	,	,	,	_	11	punct
18	all	all	DT	_	21	dep
19	1	1	LS	_	21	dep
20	-	-	:	_	21	punct
21	methyl	methyl	NN	_	11	dep
22	-	-	:	_	21	punct
23	4	4	LS	_	35	dep
24	-	-	:	_	25	punct
25	phenyl	phenyl	NN	_	35	dep
26	-	-	:	_	25	punct
27	1,2,3,6	1,2,3,6	CD	_	25	dep
28	-	-	:	_	25	punct
29	tetrahydropyridine	tetrahydropyridine	NN	_	25	dep
30	/	/	:	_	25	punct
31	vehicle	vehicle	NN	_	25	dep
32	-	-	:	_	25	punct
33	treated	treat	VBN	_	34	amod
34	animals	animal	NNS	_	35	nsubj
35	displayed	display	VBD	_	21	dep
36	parkinsonian	parkinsonian	JJ	_	37	amod
37	symptoms	symptom	NNS	_	35	dobj
38	,	,	,	_	11	punct
39	whereas	whereas	IN	_	11	dep
40	none	none	NN	_	11	dep
41	of	of	IN	_	45	case
42	the	the	DT	_	45	det
43	1	1	CD	_	45	nummod
44	-	-	:	_	45	punct
45	methyl	methyl	NN	_	40	nmod
46	-	-	:	_	40	punct
47	4	4	LS	_	49	dep
48	-	-	:	_	49	punct
49	phenyl	phenyl	NN	_	40	dep
50	-	-	:	_	49	punct
51	1,2,3,6	1,2,3,6	CD	_	49	dep
52	-	-	:	_	49	punct
53	tetrahydropyridine	tetrahydropyridine	NN	_	49	dep
54	/	/	:	_	49	punct
55	3	3	LS	_	49	dep
56	-	-	:	_	55	punct
57	[	[	CD	_	58	compound
58	(	(	CD	_	61	dep
59	2	2	LS	_	61	dep
60	-	-	:	_	61	punct
61	methyl	methyl	NN	_	55	dep
62	-	-	:	_	61	punct
63	1,3	1,3	SYM	_	61	dep
64	-	-	:	_	61	punct
65	thiazol	thiazol	NN	_	61	dep
66	-	-	:	_	61	punct
67	4	4	LS	_	73	dep
68	-	-	:	_	73	punct
69	yl	yl	NN	_	73	compound
70	)	)	NN	_	73	compound
71	ethynyl	ethynyl	NN	_	73	compound
72	]	]	CD	_	73	nummod
73	pyridine	pyridine	NN	_	61	dep
74	-	-	:	_	73	punct
75	treated	treat	VBN	_	76	amod
76	monkeys	monkey	NNS	_	79	nsubjpass
77	were	be	VBD	_	79	auxpass
78	significantly	significantly	RB	_	79	advmod
79	affected	affect	VBN	_	73	dep
80	.	.	.	_	3	punct

1	These	these	DT	_	3	det
2	behavioural	behavioural	JJ	_	3	amod
3	observations	observation	NNS	_	5	nsubj
4	were	be	VBD	_	5	cop
5	consistent	consistent	JJ	_	0	ROOT
6	with	with	IN	_	15	case
7	in	in	FW	_	15	amod
8	vivo	vivo	FW	_	7	dep
9	positron	positron	FW	_	15	compound
10	emission	emission	NN	_	15	compound
11	tomography	tomography	NN	_	15	compound
12	dopamine	dopamine	NN	_	15	compound
13	transporter	transporter	NN	_	15	compound
14	imaging	imaging	NN	_	15	compound
15	data	datum	NNS	_	5	nmod
16	,	,	,	_	5	punct
17	and	and	CC	_	5	cc
18	with	with	IN	_	19	case
19	post	post	NN	_	5	conj
20	-	-	:	_	19	punct
21	mortem	mortem	FW	_	23	compound
22	stereological	stereological	JJ	_	23	amod
23	counts	count	NNS	_	19	dep
24	of	of	IN	_	27	case
25	midbrain	midbrain	JJ	_	27	amod
26	dopaminergic	dopaminergic	JJ	_	27	amod
27	neurons	neuron	NNS	_	23	nmod
28	,	,	,	_	23	punct
29	as	as	RB	_	23	cc
30	well	well	RB	_	29	mwe
31	as	as	IN	_	29	mwe
32	striatal	striatal	JJ	_	34	amod
33	intensity	intensity	NN	_	34	compound
34	measurements	measurement	NNS	_	23	conj
35	of	of	IN	_	37	case
36	dopamine	dopamine	NN	_	37	compound
37	transporter	transporter	NN	_	34	nmod
38	and	and	CC	_	37	cc
39	tyrosine	tyrosine	NN	_	41	compound
40	hydroxylase	hydroxylase	NN	_	41	compound
41	immunoreactivity	immunoreactivity	NN	_	37	conj
42	,	,	,	_	34	punct
43	which	which	WDT	_	47	nsubj
44	were	be	VBD	_	47	cop
45	all	all	DT	_	47	advmod
46	significantly	significantly	RB	_	47	advmod
47	higher	higher	JJR	_	34	acl:relcl
48	in	in	IN	_	49	case
49	1	1	CD	_	47	nmod
50	-	-	:	_	49	punct
51	methyl	methyl	NN	_	49	dep
52	-	-	:	_	49	punct
53	4	4	LS	_	55	dep
54	-	-	:	_	55	punct
55	phenyl	phenyl	NN	_	49	dep
56	-	-	:	_	55	punct
57	1,2,3,6	1,2,3,6	CD	_	55	dep
58	-	-	:	_	49	punct
59	tetrahydropyridine	tetrahydropyridine	NN	_	49	dep
60	/	/	:	_	5	punct
61	3	3	LS	_	5	dep
62	-	-	:	_	61	punct
63	[	[	CD	_	64	compound
64	(	(	CD	_	67	dep
65	2	2	LS	_	67	dep
66	-	-	:	_	67	punct
67	methyl	methyl	NN	_	61	dep
68	-	-	:	_	67	punct
69	1,3	1,3	SYM	_	67	dep
70	-	-	:	_	67	punct
71	thiazol	thiazol	NN	_	67	dep
72	-	-	:	_	67	punct
73	4	4	LS	_	79	dep
74	-	-	:	_	79	punct
75	yl	yl	NN	_	79	compound
76	)	)	NN	_	79	compound
77	ethynyl	ethynyl	NN	_	79	compound
78	]	]	CD	_	79	nummod
79	pyridine	pyridine	NN	_	67	dep
80	-	-	:	_	79	punct
81	treated	treat	VBN	_	82	amod
82	animals	animal	NNS	_	79	dep
83	than	than	IN	_	87	case
84	in	in	IN	_	87	case
85	1	1	LS	_	87	dep
86	-	-	:	_	87	punct
87	methyl	methyl	NN	_	82	nmod
88	-	-	:	_	79	punct
89	4	4	LS	_	79	dep
90	-	-	:	_	79	punct
91	phenyl	phenyl	NN	_	79	dep
92	-	-	:	_	79	punct
93	1,2,3,6	1,2,3,6	CD	_	79	dep
94	-	-	:	_	79	punct
95	tetrahydropyridine	tetrahydropyridine	NN	_	79	dep
96	/	/	:	_	79	punct
97	vehicle	vehicle	NN	_	79	dep
98	-	-	:	_	79	punct
99	treated	treat	VBN	_	100	amod
100	monkeys	monkey	NNS	_	79	dep
101	.	.	.	_	5	punct

1	The	the	DT	_	0	ROOT
2	3	3	LS	_	1	dep
3	-	-	:	_	2	punct
4	[	[	CD	_	5	nummod
5	(	(	CD	_	42	nummod
6	2	2	LS	_	8	dep
7	-	-	:	_	8	punct
8	methyl	methyl	NN	_	42	dep
9	-	-	:	_	8	punct
10	1,3	1,3	SYM	_	8	dep
11	-	-	:	_	8	punct
12	thiazol	thiazol	NN	_	8	dep
13	-	-	:	_	8	punct
14	4	4	LS	_	23	dep
15	-	-	:	_	23	punct
16	yl	yl	NN	_	21	compound
17	)	)	NN	_	21	compound
18	ethynyl	ethynyl	NN	_	21	compound
19	]	]	CD	_	21	nummod
20	pyridine	pyridine	NN	_	21	compound
21	treatment	treatment	NN	_	23	nsubj
22	also	also	RB	_	23	advmod
23	had	have	VBD	_	8	dep
24	a	a	DT	_	26	det
25	significant	significant	JJ	_	26	amod
26	effect	effect	NN	_	23	dobj
27	on	on	IN	_	31	case
28	the	the	DT	_	31	det
29	1	1	CD	_	31	nummod
30	-	-	:	_	31	punct
31	methyl	methyl	NN	_	23	nmod
32	-	-	:	_	8	punct
33	4	4	LS	_	42	dep
34	-	-	:	_	35	punct
35	phenyl	phenyl	NN	_	42	dep
36	-	-	:	_	35	punct
37	1,2,3,6	1,2,3,6	CD	_	35	dep
38	-	-	:	_	35	punct
39	tetrahydropyridine	tetrahydropyridine	NN	_	35	dep
40	-	-	:	_	35	punct
41	induced	induced	JJ	_	42	amod
42	loss	loss	NN	_	3	root
43	of	of	IN	_	45	case
44	norepinephrine	norepinephrine	NN	_	45	compound
45	neurons	neuron	NNS	_	42	nmod
46	in	in	IN	_	49	case
47	the	the	DT	_	49	det
48	locus	locus	NN	_	49	compound
49	coeruleus	coeruleus	NN	_	42	nmod
50	and	and	CC	_	42	cc
51	adjoining	adjoining	JJ	_	52	amod
52	A5	a5	NN	_	42	conj
53	and	and	CC	_	52	cc
54	A7	a7	NN	_	57	compound
55	noradrenaline	noradrenaline	NN	_	57	compound
56	cell	cell	NN	_	57	compound
57	groups	group	NNS	_	52	conj
58	.	.	.	_	42	punct

1	In	in	IN	_	4	case
2	1	1	LS	_	4	dep
3	-	-	:	_	4	punct
4	methyl	methyl	NN	_	0	ROOT
5	-	-	:	_	4	punct
6	4	4	LS	_	4	dep
7	-	-	:	_	8	punct
8	phenyl	phenyl	NN	_	6	root
9	-	-	:	_	8	punct
10	1,2,3,6	1,2,3,6	CD	_	8	dep
11	-	-	:	_	8	punct
12	tetrahydropyridine	tetrahydropyridine	NN	_	8	dep
13	/	/	:	_	8	punct
14	vehicle	vehicle	NN	_	8	dep
15	-	-	:	_	8	punct
16	treated	treat	VBN	_	17	amod
17	animals	animal	NNS	_	8	dep
18	,	,	,	_	8	punct
19	almost	almost	RB	_	20	advmod
20	40	40	CD	_	21	dep
21	%	%	NN	_	22	dep
22	loss	loss	NN	_	8	appos
23	of	of	IN	_	25	case
24	tyrosine	tyrosine	NN	_	25	compound
25	hydroxylase	hydroxylase	NN	_	22	nmod
26	-	-	:	_	8	punct
27	positive	positive	JJ	_	29	amod
28	norepinephrine	norepinephrine	NN	_	29	compound
29	neurons	neuron	NNS	_	31	nsubjpass
30	was	be	VBD	_	31	auxpass
31	found	find	VBN	_	8	dep
32	in	in	IN	_	34	case
33	locus	locus	NN	_	34	compound
34	coeruleus	coeruleus	NN	_	31	nmod
35	/	/	:	_	34	punct
36	A5	a5	NN	_	34	dep
37	/	/	:	_	34	punct
38	A7	a7	NN	_	41	compound
39	noradrenaline	noradrenaline	NN	_	41	compound
40	cell	cell	NN	_	41	compound
41	groups	group	NNS	_	34	dep
42	,	,	,	_	31	punct
43	whereas	whereas	IN	_	31	dep
44	the	the	DT	_	45	det
45	extent	extent	NN	_	50	nsubj
46	of	of	IN	_	48	case
47	neuronal	neuronal	JJ	_	48	amod
48	loss	loss	NN	_	45	nmod
49	was	be	VBD	_	50	cop
50	lower	lower	JJR	_	31	parataxis
51	than	than	IN	_	53	case
52	15	15	CD	_	53	nummod
53	%	%	NN	_	50	nmod
54	of	of	IN	_	56	case
55	control	control	NN	_	56	compound
56	values	value	NNS	_	53	nmod
57	in	in	IN	_	60	case
58	1	1	LS	_	60	dep
59	-	-	:	_	60	punct
60	methyl	methyl	NN	_	53	nmod
61	-	-	:	_	50	punct
62	4	4	LS	_	64	dep
63	-	-	:	_	64	punct
64	phenyl	phenyl	NN	_	50	dep
65	-	-	:	_	64	punct
66	1,2,3,6	1,2,3,6	CD	_	64	dep
67	-	-	:	_	64	punct
68	tetrahydropyridine	tetrahydropyridine	NN	_	64	dep
69	/	/	:	_	64	punct
70	3	3	LS	_	64	dep
71	-	-	:	_	70	punct
72	[	[	CD	_	73	compound
73	(	(	CD	_	76	dep
74	2	2	LS	_	76	dep
75	-	-	:	_	76	punct
76	methyl	methyl	NN	_	70	dep
77	-	-	:	_	76	punct
78	1,3	1,3	SYM	_	76	dep
79	-	-	:	_	76	punct
80	thiazol	thiazol	NN	_	76	dep
81	-	-	:	_	76	punct
82	4	4	LS	_	88	dep
83	-	-	:	_	88	punct
84	yl	yl	NN	_	88	compound
85	)	)	NN	_	88	compound
86	ethynyl	ethynyl	NN	_	88	compound
87	]	]	CD	_	88	nummod
88	pyridine	pyridine	NN	_	76	dep
89	-	-	:	_	88	punct
90	treated	treat	VBN	_	91	amod
91	monkeys	monkey	NNS	_	88	dep
92	.	.	.	_	8	punct

1	Our	we	PRP$	_	2	nmod:poss
2	data	datum	NNS	_	3	nsubj
3	demonstrate	demonstrate	VBP	_	0	ROOT
4	that	that	IN	_	3	dobj
5	chronic	chronic	JJ	_	6	amod
6	treatment	treatment	NN	_	4	dep
7	with	with	IN	_	11	case
8	the	the	DT	_	11	det
9	metabotropic	metabotropic	JJ	_	11	amod
10	glutamate	glutamate	NN	_	11	compound
11	receptor	receptor	NN	_	6	nmod
12	5	5	CD	_	13	nummod
13	antagonist	antagonist	NN	_	11	dep
14	,	,	,	_	6	punct
15	3	3	LS	_	6	acl
16	-	-	:	_	15	punct
17	[	[	CD	_	18	compound
18	(	(	CD	_	21	dep
19	2	2	LS	_	21	dep
20	-	-	:	_	21	punct
21	methyl	methyl	NN	_	15	dep
22	-	-	:	_	21	punct
23	1,3	1,3	SYM	_	21	dep
24	-	-	:	_	21	punct
25	thiazol	thiazol	NN	_	21	dep
26	-	-	:	_	21	punct
27	4	4	LS	_	36	dep
28	-	-	:	_	36	punct
29	yl	yl	NN	_	31	compound
30	)	)	NN	_	31	compound
31	ethynyl	ethynyl	NN	_	36	nsubj
32	]	]	CD	_	31	nummod
33	pyridine	pyridine	NN	_	31	dep
34	,	,	,	_	36	punct
35	significantly	significantly	RB	_	36	advmod
36	reduces	reduce	VBZ	_	21	dep
37	1	1	LS	_	36	dobj
38	-	-	:	_	37	punct
39	methyl	methyl	NN	_	37	dep
40	-	-	:	_	41	punct
41	4	4	LS	_	39	dep
42	-	-	:	_	41	punct
43	phenyl	phenyl	NN	_	41	dep
44	-	-	:	_	43	punct
45	1,2,3,6	1,2,3,6	CD	_	48	nummod
46	-	-	:	_	48	punct
47	tetrahydropyridine	tetrahydropyridine	NN	_	48	compound
48	toxicity	toxicity	NN	_	43	dep
49	towards	towards	IN	_	54	case
50	dopaminergic	dopaminergic	JJ	_	54	amod
51	and	and	CC	_	50	cc
52	noradrenergic	noradrenergic	JJ	_	50	conj
53	cell	cell	NN	_	54	compound
54	groups	group	NNS	_	48	nmod
55	in	in	IN	_	59	case
56	non	non	JJ	_	59	amod
57	-	-	:	_	59	punct
58	human	human	JJ	_	59	amod
59	primates	primate	NNS	_	54	nmod
60	.	.	.	_	3	punct

1	This	this	DT	_	2	nsubj
2	suggests	suggest	VBZ	_	0	ROOT
3	that	that	IN	_	16	mark
4	the	the	DT	_	5	det
5	use	use	NN	_	16	nsubj
6	of	of	IN	_	11	case
7	metabotropic	metabotropic	JJ	_	11	amod
8	glutamate	glutamate	NN	_	11	compound
9	receptor	receptor	NN	_	11	compound
10	5	5	CD	_	11	nummod
11	antagonists	antagonist	NNS	_	5	nmod
12	may	may	MD	_	16	aux
13	be	be	VB	_	16	cop
14	a	a	DT	_	16	det
15	useful	useful	JJ	_	16	amod
16	strategy	strategy	NN	_	2	ccomp
17	to	to	TO	_	18	mark
18	reduce	reduce	VB	_	16	acl
19	degeneration	degeneration	NN	_	18	dobj
20	of	of	IN	_	22	case
21	catecholaminergic	catecholaminergic	JJ	_	22	amod
22	neurons	neuron	NNS	_	19	nmod
23	in	in	IN	_	27	case
24	Parkinson	Parkinson	NNP	_	27	nmod:poss
25	'	'	POS	_	24	case
26	s	s	NNS	_	27	compound
27	disease	disease	NN	_	18	nmod
28	.	.	.	_	2	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	activity	activity	NN	_	0	ROOT
4	of	of	IN	_	5	case
5	minocycline	minocycline	NN	_	3	nmod
6	combined	combine	VBN	_	3	acl
7	with	with	IN	_	8	case
8	fosfomycin	fosfomycin	NN	_	6	nmod
9	against	against	IN	_	11	case
10	clinical	clinical	JJ	_	11	amod
11	isolates	isolate	NNS	_	8	nmod
12	of	of	IN	_	13	case
13	methicillin	methicillin	NN	_	11	nmod
14	-	-	:	_	3	punct
15	resistant	resistant	JJ	_	17	amod
16	Staphylococcus	staphylococcus	FW	_	17	compound
17	aureus	aureus	FW	_	3	dep
18	.	.	.	_	3	punct

1	This	this	DT	_	2	det
2	study	study	NN	_	0	ROOT
3	aimed	aim	VBN	_	2	acl
4	to	to	TO	_	5	mark
5	evaluate	evaluate	VB	_	3	xcomp
6	the	the	DT	_	9	det
7	in	in	FW	_	9	amod
8	vitro	vitro	FW	_	7	dep
9	activity	activity	NN	_	5	dobj
10	of	of	IN	_	11	case
11	minocycline	minocycline	NN	_	9	nmod
12	combined	combine	VBN	_	11	acl
13	with	with	IN	_	14	case
14	fosfomycin	fosfomycin	NN	_	12	nmod
15	against	against	IN	_	16	case
16	isolates	isolate	NNS	_	14	nmod
17	of	of	IN	_	18	case
18	methicillin	methicillin	NN	_	16	nmod
19	-	-	:	_	2	punct
20	resistant	resistant	JJ	_	25	amod
21	Staphylococcus	staphylococcus	FW	_	25	compound
22	aureus	aureus	FW	_	25	compound
23	(	(	FW	_	25	compound
24	MRSA	mrsa	NN	_	25	compound
25	)	)	NN	_	2	dep
26	.	.	.	_	2	punct

1	A	a	DT	_	2	det
2	total	total	NN	_	15	nsubjpass
3	of	of	IN	_	6	case
4	87	87	CD	_	6	nummod
5	clinical	clinical	JJ	_	6	amod
6	isolates	isolate	NNS	_	2	nmod
7	of	of	IN	_	8	case
8	MRSA	MRSA	NNP	_	6	nmod
9	collected	collect	VBN	_	2	acl
10	from	from	IN	_	13	case
11	three	three	CD	_	13	nummod
12	Chinese	chinese	JJ	_	13	amod
13	hospitals	hospital	NNS	_	9	nmod
14	were	be	VBD	_	15	auxpass
15	included	include	VBN	_	0	ROOT
16	in	in	IN	_	18	case
17	the	the	DT	_	18	det
18	study	study	NN	_	15	nmod
19	.	.	.	_	15	punct

1	The	the	DT	_	3	det
2	checkerboard	checkerboard	NN	_	3	compound
3	method	method	NN	_	15	nsubjpass
4	with	with	IN	_	5	case
5	determination	determination	NN	_	3	nmod
6	of	of	IN	_	10	case
7	the	the	DT	_	10	det
8	fractional	fractional	JJ	_	10	amod
9	IC	ic	NN	_	10	compound
10	index	index	NN	_	5	nmod
11	(	(	CD	_	13	nummod
12	FICI	fici	NN	_	13	compound
13	)	)	NN	_	10	dep
14	was	be	VBD	_	15	auxpass
15	used	use	VBN	_	0	ROOT
16	to	to	TO	_	17	mark
17	determine	determine	VB	_	15	xcomp
18	whether	whether	IN	_	21	mark
19	antibiotic	antibiotic	JJ	_	20	amod
20	combinations	combination	NNS	_	21	nsubj
21	act	act	VBP	_	17	ccomp
22	synergistically	synergistically	RB	_	21	advmod
23	against	against	IN	_	25	case
24	these	these	DT	_	25	det
25	isolates	isolate	NNS	_	21	nmod
26	.	.	.	_	15	punct

1	The	the	DT	_	2	det
2	susceptibility	susceptibility	NN	_	3	nsubj
3	results	result	VBZ	_	9	csubjpass
4	for	for	IN	_	5	case
5	minocycline	minocycline	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	fosfomycin	fosfomycin	NN	_	5	conj
8	were	be	VBD	_	9	auxpass
9	interpreted	interpret	VBN	_	0	ROOT
10	according	accord	VBG	_	15	case
11	to	to	TO	_	10	mwe
12	the	the	DT	_	15	det
13	most	most	RBS	_	14	advmod
14	relevant	relevant	JJ	_	15	amod
15	criteria	criterion	NNS	_	9	nmod
16	.	.	.	_	9	punct

1	The	the	DT	_	2	det
2	results	result	NNS	_	3	nsubj
3	demonstrated	demonstrate	VBD	_	0	ROOT
4	the	the	DT	_	6	det
5	following	following	JJ	_	6	amod
6	interactions	interaction	NNS	_	3	dobj
7	:	:	:	_	6	punct
8	76	76	CD	_	9	nummod
9	isolates	isolate	NNS	_	10	nsubj
10	(	(	VBP	_	6	dep
11	87.4	87.4	CD	_	12	nummod
12	%	%	NN	_	10	dobj
13	)	)	CD	_	12	nummod
14	showed	show	VBD	_	10	dep
15	synergistic	synergistic	JJ	_	16	amod
16	interactions	interaction	NNS	_	17	nsubj
17	(	(	VBP	_	14	ccomp
18	FICI	fici	NN	_	20	compound
19	0.5	0.5	CD	_	20	nummod
20	)	)	NN	_	24	nsubj
21	and	and	CC	_	20	cc
22	11	11	CD	_	23	nummod
23	isolates	isolate	NNS	_	20	conj
24	(	(	VBP	_	17	ccomp
25	12.6	12.6	CD	_	26	nummod
26	%	%	NN	_	24	dobj
27	)	)	CD	_	26	nummod
28	showed	show	VBD	_	10	dep
29	indifferent	indifferent	JJ	_	30	amod
30	interactions	interaction	NNS	_	31	nsubj
31	(	(	VBP	_	28	ccomp
32	0.5	0.5	CD	_	33	nummod
33	&amp	&amp	NN	_	31	dobj
34	;	;	:	_	31	punct
35	lt	lt	NN	_	31	dep
36	;	;	:	_	35	punct
37	FICI&amp	fici&amp	NN	_	35	conj
38	;	;	:	_	35	punct
39	lt	lt	NN	_	35	conj
40	;	;	:	_	35	punct
41	4	4	CD	_	42	nummod
42	)	)	NN	_	35	dep
43	.	.	.	_	3	punct

1	No	no	DT	_	3	neg
2	antagonistic	antagonistic	JJ	_	3	amod
3	interactions	interaction	NNS	_	4	nsubj
4	(	(	VBP	_	0	ROOT
5	FICI	fici	NN	_	7	compound
6	4	4	CD	_	7	nummod
7	)	)	NN	_	9	nsubjpass
8	were	be	VBD	_	9	auxpass
9	observed	observe	VBN	_	4	ccomp
10	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	combination	combination	NN	_	9	nsubj
3	of	of	IN	_	4	case
4	minocycline	minocycline	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	fosfomycin	fosfomycin	NN	_	4	conj
7	can	can	MD	_	9	aux
8	be	be	VB	_	9	cop
9	synergistic	synergistic	JJ	_	0	ROOT
10	against	against	IN	_	11	case
11	MRSA	MRSA	NNP	_	9	nmod
12	.	.	.	_	9	punct

1	Further	further	JJ	_	2	amod
2	studies	study	NNS	_	4	nsubjpass
3	are	be	VBP	_	4	auxpass
4	required	require	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	determine	determine	VB	_	4	xcomp
7	the	the	DT	_	10	det
8	potential	potential	JJ	_	10	amod
9	clinical	clinical	JJ	_	10	amod
10	role	role	NN	_	6	dobj
11	of	of	IN	_	14	case
12	this	this	DT	_	14	det
13	combination	combination	NN	_	14	compound
14	regimen	regimen	NN	_	10	nmod
15	as	as	IN	_	18	case
16	a	a	DT	_	18	det
17	therapeutic	therapeutic	JJ	_	18	amod
18	alternative	alternative	NN	_	10	nmod
19	for	for	IN	_	21	case
20	certain	certain	JJ	_	21	amod
21	types	type	NNS	_	18	nmod
22	of	of	IN	_	24	case
23	MRSA	mrsa	NN	_	24	compound
24	infections	infection	NNS	_	21	nmod
25	.	.	.	_	4	punct

1	Lapatinib	Lapatinib	NNP	_	2	nsubj
2	enhances	enhance	VBZ	_	0	ROOT
3	herceptin	herceptin	NN	_	10	dep
4	-	-	:	_	3	punct
5	mediated	mediated	JJ	_	6	amod
6	antibody	antibody	NN	_	3	dep
7	-	-	:	_	3	punct
8	dependent	dependent	JJ	_	10	amod
9	cellular	cellular	JJ	_	10	amod
10	cytotoxicity	cytotoxicity	NN	_	2	dobj
11	by	by	IN	_	12	case
12	up	up	RB	_	2	nmod
13	-	-	:	_	2	punct
14	regulation	regulation	NN	_	2	dobj
15	of	of	IN	_	19	case
16	cell	cell	NN	_	19	compound
17	surface	surface	NN	_	19	compound
18	HER2	her2	NN	_	19	compound
19	expression	expression	NN	_	14	nmod
20	.	.	.	_	2	punct

1	Although	although	IN	_	5	mark
2	it	it	PRP	_	5	nsubjpass
3	was	be	VBD	_	5	auxpass
4	previously	previously	RB	_	5	advmod
5	reported	report	VBN	_	38	advcl
6	that	that	IN	_	11	mark
7	lapatinib	lapatinib	NN	_	11	nsubj
8	combined	combine	VBN	_	7	acl
9	with	with	IN	_	10	case
10	Herceptin	herceptin	NN	_	8	nmod
11	improved	improve	VBD	_	5	ccomp
12	the	the	DT	_	13	det
13	progression	progression	NN	_	11	dobj
14	-	-	:	_	13	punct
15	free	free	JJ	_	17	amod
16	survival	survival	NN	_	17	compound
17	rate	rate	NN	_	13	dep
18	compared	compare	VBN	_	20	case
19	with	with	IN	_	20	case
20	lapatinib	lapatinib	NN	_	17	nmod
21	alone	alone	RB	_	20	advmod
22	for	for	IN	_	23	case
23	patients	patient	NNS	_	20	nmod
24	with	with	IN	_	25	case
25	Herceptin	herceptin	NN	_	23	nmod
26	-	-	:	_	13	punct
27	refractory	refractory	JJ	_	28	amod
28	HER2	her2	NN	_	13	dep
29	-	-	:	_	13	punct
30	positive	positive	JJ	_	33	amod
31	metastatic	metastatic	JJ	_	33	amod
32	breast	breast	NN	_	33	compound
33	cancer	cancer	NN	_	13	dep
34	,	,	,	_	38	punct
35	the	the	DT	_	36	det
36	mechanism	mechanism	NN	_	38	nsubj
37	is	be	VBZ	_	38	cop
38	purported	purported	JJ	_	0	ROOT
39	to	to	TO	_	43	mark
40	be	be	VB	_	43	cop
41	an	a	DT	_	43	det
42	antiproliferative	antiproliferative	JJ	_	43	amod
43	effect	effect	NN	_	38	xcomp
44	relating	relate	VBG	_	43	acl
45	to	to	TO	_	47	case
46	the	the	DT	_	47	det
47	synergism	synergism	NN	_	44	nmod
48	of	of	IN	_	51	case
49	these	these	DT	_	51	det
50	two	two	CD	_	51	nummod
51	agents	agent	NNS	_	47	nmod
52	.	.	.	_	38	punct

1	We	we	PRP	_	2	nsubj
2	evaluated	evaluate	VBD	_	0	ROOT
3	how	how	WRB	_	5	advmod
4	lapatinib	lapatinib	NN	_	5	nsubj
5	interacts	interact	VBZ	_	2	ccomp
6	with	with	IN	_	7	case
7	Herceptin	herceptin	NN	_	5	nmod
8	in	in	IN	_	9	case
9	HER2	her2	NN	_	5	nmod
10	-	-	:	_	9	punct
11	positive	positive	JJ	_	13	amod
12	breast	breast	NN	_	13	compound
13	cancer	cancer	NN	_	9	dep
14	,	,	,	_	5	punct
15	with	with	IN	_	18	case
16	a	a	DT	_	18	det
17	particular	particular	JJ	_	18	amod
18	focus	focus	NN	_	5	nmod
19	on	on	IN	_	20	case
20	Herceptin	Herceptin	NNP	_	18	nmod
21	-	-	:	_	20	punct
22	mediated	mediated	JJ	_	23	amod
23	antibody	antibody	NN	_	20	dep
24	-	-	:	_	20	punct
25	dependent	dependent	JJ	_	30	amod
26	cellular	cellular	JJ	_	30	amod
27	cytotoxicity	cytotoxicity	NN	_	30	compound
28	(	(	CD	_	30	nummod
29	ADCC	adcc	NN	_	30	compound
30	)	)	NN	_	20	dep
31	.	.	.	_	2	punct

1	In	in	IN	_	5	case
2	an	a	DT	_	5	det
3	in	in	FW	_	5	amod
4	vitro	vitro	FW	_	3	dep
5	assay	assay	NN	_	8	nmod
6	,	,	,	_	8	punct
7	lapatinib	lapatinib	NN	_	8	nsubj
8	induced	induce	VBD	_	0	ROOT
9	HER2	her2	NN	_	10	compound
10	expression	expression	NN	_	8	dobj
11	at	at	IN	_	14	case
12	the	the	DT	_	14	det
13	cell	cell	NN	_	14	compound
14	surface	surface	NN	_	8	nmod
15	of	of	IN	_	16	case
16	HER2	her2	NN	_	14	nmod
17	-	-	:	_	14	punct
18	positive	positive	JJ	_	22	amod
19	breast	breast	NN	_	22	compound
20	cancer	cancer	NN	_	22	compound
21	cell	cell	NN	_	22	compound
22	lines	line	NNS	_	14	dep
23	,	,	,	_	8	punct
24	leading	lead	VBG	_	8	advcl
25	to	to	TO	_	27	case
26	the	the	DT	_	27	det
27	enhancement	enhancement	NN	_	24	nmod
28	of	of	IN	_	29	case
29	Herceptin	Herceptin	NNP	_	27	nmod
30	-	-	:	_	27	punct
31	mediated	mediate	VBN	_	32	amod
32	ADCC	adcc	NN	_	27	dep
33	.	.	.	_	8	punct

1	Furthermore	furthermore	RB	_	4	advmod
2	,	,	,	_	4	punct
3	we	we	PRP	_	4	nsubj
4	present	present	VBP	_	0	ROOT
5	a	a	DT	_	7	det
6	case	case	NN	_	7	compound
7	report	report	NN	_	4	dobj
8	in	in	IN	_	9	case
9	which	which	WDT	_	16	nmod
10	a	a	DT	_	13	det
11	second	second	JJ	_	13	amod
12	Herceptin	herceptin	NN	_	13	compound
13	treatment	treatment	NN	_	16	nsubj
14	following	follow	VBG	_	15	case
15	lapatinib	lapatinib	NN	_	13	nmod
16	resulted	result	VBD	_	7	acl:relcl
17	in	in	IN	_	20	case
18	the	the	DT	_	20	det
19	marked	marked	JJ	_	20	amod
20	shrinkage	shrinkage	NN	_	16	nmod
21	of	of	IN	_	24	case
22	multiple	multiple	JJ	_	24	amod
23	metastatic	metastatic	JJ	_	24	amod
24	tumors	tumor	NNS	_	20	nmod
25	in	in	IN	_	26	case
26	HER2	her2	NN	_	20	nmod
27	-	-	:	_	20	punct
28	positive	positive	JJ	_	30	amod
29	breast	breast	NN	_	30	compound
30	cancer	cancer	NN	_	20	dep
31	.	.	.	_	4	punct

1	Lapatinib	Lapatinib	NNP	_	3	nsubj
2	may	may	MD	_	3	aux
3	have	have	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	potential	potential	JJ	_	3	dobj
6	to	to	TO	_	7	mark
7	convert	convert	VB	_	5	acl
8	Herceptin	Herceptin	NNP	_	25	dep
9	-	-	:	_	8	punct
10	refractory	refractory	JJ	_	8	amod
11	to	to	TO	_	12	case
12	Herceptin	Herceptin	NNP	_	10	nmod
13	-	-	:	_	8	punct
14	sensitive	sensitive	JJ	_	15	amod
15	tumors	tumor	NNS	_	8	dep
16	in	in	IN	_	17	case
17	HER2	her2	NN	_	15	nmod
18	-	-	:	_	8	punct
19	positive	positive	JJ	_	21	amod
20	breast	breast	NN	_	21	compound
21	cancer	cancer	NN	_	8	dep
22	by	by	IN	_	23	case
23	up	up	RB	_	21	nmod
24	-	-	:	_	8	punct
25	regulation	regulation	NN	_	7	dobj
26	of	of	IN	_	30	case
27	the	the	DT	_	30	det
28	cell	cell	NN	_	30	compound
29	surface	surface	NN	_	30	compound
30	expression	expression	NN	_	25	nmod
31	of	of	IN	_	32	case
32	HER2	her2	NN	_	30	nmod
33	.	.	.	_	3	punct

1	Improved	improve	VBN	_	4	amod
2	parathyroid	parathyroid	JJ	_	4	amod
3	hormone	hormone	NN	_	4	compound
4	control	control	NN	_	8	nsubjpass
5	by	by	IN	_	6	case
6	cinacalcet	cinacalcet	NN	_	4	nmod
7	is	be	VBZ	_	8	auxpass
8	associated	associate	VBN	_	0	ROOT
9	with	with	IN	_	10	case
10	reduction	reduction	NN	_	8	nmod
11	in	in	IN	_	13	case
12	darbepoetin	darbepoetin	NN	_	13	compound
13	requirement	requirement	NN	_	10	nmod
14	in	in	IN	_	15	case
15	patients	patient	NNS	_	13	nmod
16	with	with	IN	_	17	case
17	end	end	NN	_	15	nmod
18	-	-	:	_	8	punct
19	stage	stage	NN	_	21	compound
20	renal	renal	JJ	_	21	amod
21	disease	disease	NN	_	8	dep
22	.	.	.	_	8	punct

1	Uncontrolled	uncontrolled	JJ	_	2	amod
2	hy	hy	NN	_	0	ROOT
3	-	-	:	_	2	punct
4	per	per	IN	_	7	mark
5	-	-	:	_	7	punct
6	parathyroidism	parathyroidism	NN	_	7	nsubj
7	causes	cause	VBZ	_	2	dep
8	bone	bone	NN	_	10	compound
9	marrow	marrow	NN	_	10	compound
10	fibrosis	fibrosis	NN	_	7	dobj
11	,	,	,	_	7	punct
12	leading	lead	VBG	_	7	advcl
13	to	to	TO	_	14	case
14	erythropoietin	erythropoietin	NN	_	12	nmod
15	(	(	CD	_	18	nummod
16	EPO	EPO	NNP	_	18	compound
17	)	)	CD	_	18	nummod
18	resistance	resistance	NN	_	14	dep
19	.	.	.	_	2	punct

1	Medical	medical	JJ	_	2	amod
2	treatment	treatment	NN	_	6	nsubj
3	with	with	IN	_	4	case
4	cinacalcet	cinacalcet	NN	_	2	nmod
5	is	be	VBZ	_	6	cop
6	effective	effective	JJ	_	0	ROOT
7	in	in	IN	_	8	mark
8	reducing	reduce	VBG	_	6	advcl
9	plasma	plasma	NN	_	15	compound
10	parathyroid	parathyroid	JJ	_	15	amod
11	hormone	hormone	NN	_	15	compound
12	(	(	NN	_	15	compound
13	PTH	pth	NN	_	15	compound
14	)	)	NN	_	15	compound
15	levels	level	NNS	_	8	dobj
16	,	,	,	_	6	punct
17	but	but	CC	_	6	cc
18	its	its	PRP$	_	19	nmod:poss
19	effect	effect	NN	_	24	nsubj
20	on	on	IN	_	22	case
21	darbepoetin	darbepoetin	NN	_	22	compound
22	dosing	dosing	NN	_	19	nmod
23	is	be	VBZ	_	24	cop
24	unknown	unknown	JJ	_	6	conj
25	.	.	.	_	6	punct

1	METHODS	method	NNS	_	0	ROOT
2	AND	and	CC	_	1	cc
3	AIMS	aim	NNS	_	1	conj
4	:	:	:	_	1	punct
5	We	we	PRP	_	6	nsubj
6	conducted	conduct	VBD	_	1	dep
7	a	a	DT	_	10	det
8	retrospective	retrospective	JJ	_	10	amod
9	cohort	cohort	NN	_	10	compound
10	study	study	NN	_	6	dobj
11	of	of	IN	_	13	case
12	40	40	CD	_	13	nummod
13	end	end	NN	_	10	nmod
14	-	-	:	_	13	punct
15	stage	stage	NN	_	17	compound
16	renal	renal	JJ	_	17	amod
17	disease	disease	NN	_	13	dep
18	(	(	CD	_	19	nummod
19	ESRD	esrd	NN	_	17	dep
20	)	)	CD	_	21	nummod
21	patients	patient	NNS	_	19	dep
22	(	(	JJ	_	23	amod
23	age	age	NN	_	21	nmod:npmod
24	:	:	:	_	13	punct
25	55	55	CD	_	26	compound
26	14	14	CD	_	13	dep
27	;	;	:	_	6	punct
28	mean	mean	VB	_	6	parataxis
29	SD	sd	NN	_	28	dobj
30	;	;	:	_	29	punct
31	21	21	CD	_	29	dep
32	:	:	:	_	31	punct
33	male	male	JJ	_	34	amod
34	)	)	NN	_	31	dep
35	who	who	WP	_	36	nsubj
36	had	have	VBD	_	34	acl:relcl
37	at	at	IN	_	38	case
38	least	least	JJS	_	39	nmod:npmod
39	12	12	CD	_	40	nummod
40	months	month	NNS	_	36	dobj
41	of	of	IN	_	43	case
42	cinacalcet	cinacalcet	NN	_	43	compound
43	therapy	therapy	NN	_	40	nmod
44	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	distribution	distribution	NN	_	11	nsubj
3	of	of	IN	_	6	case
4	renal	renal	JJ	_	6	amod
5	replacement	replacement	NN	_	6	compound
6	therapies	therapy	NNS	_	2	nmod
7	were	be	VBD	_	11	cop
8	:	:	:	_	11	punct
9	14	14	CD	_	11	nummod
10	peritoneal	peritoneal	JJ	_	11	amod
11	dialysis	dialysis	NN	_	0	ROOT
12	,	,	,	_	11	punct
13	18	18	CD	_	15	nummod
14	conventional	conventional	JJ	_	15	amod
15	hemodialysis	hemodialysis	NN	_	11	conj
16	and	and	CC	_	11	cc
17	8	8	CD	_	19	nummod
18	nocturnal	nocturnal	JJ	_	19	amod
19	hemodialysis	hemodialysis	NN	_	11	conj
20	.	.	.	_	11	punct

1	Standard	Standard	NNP	_	5	compound
2	dialysis	dialysis	NN	_	5	compound
3	related	related	JJ	_	5	amod
4	biochemical	biochemical	JJ	_	5	amod
5	indices	index	NNS	_	10	nsubjpass
6	and	and	CC	_	5	cc
7	medications	medication	NNS	_	5	conj
8	used	use	VBN	_	5	acl
9	were	be	VBD	_	10	auxpass
10	recorded	record	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	The	the	DT	_	3	det
2	primary	primary	JJ	_	3	amod
3	objective	objective	NN	_	7	nsubj
4	of	of	IN	_	6	case
5	the	the	DT	_	6	det
6	study	study	NN	_	3	nmod
7	was	be	VBD	_	0	ROOT
8	to	to	TO	_	9	mark
9	ascertain	ascertain	VB	_	7	xcomp
10	the	the	DT	_	11	det
11	difference	difference	NN	_	9	dobj
12	in	in	IN	_	14	case
13	darbepoetin	darbepoetin	NN	_	14	compound
14	responsiveness	responsiveness	NN	_	11	nmod
15	before	before	IN	_	19	case
16	and	and	CC	_	15	cc
17	after	after	IN	_	15	conj
18	12	12	CD	_	19	nummod
19	months	month	NNS	_	9	nmod
20	of	of	IN	_	22	case
21	cinacalcet	cinacalcet	NN	_	22	compound
22	therapy	therapy	NN	_	19	nmod
23	.	.	.	_	7	punct

1	Our	we	PRP$	_	3	nmod:poss
2	secondary	secondary	JJ	_	3	amod
3	objective	objective	NN	_	4	nsubj
4	was	be	VBD	_	0	ROOT
5	to	to	TO	_	6	mark
6	determine	determine	VB	_	4	xcomp
7	if	if	IN	_	9	mark
8	there	there	EX	_	9	expl
9	was	be	VBD	_	6	advcl
10	a	a	DT	_	11	det
11	relationship	relationship	NN	_	9	nsubj
12	between	between	IN	_	14	case
13	the	the	DT	_	14	det
14	changes	change	NNS	_	11	nmod
15	in	in	IN	_	16	case
16	PTH	pth	NN	_	14	nmod
17	and	and	CC	_	16	cc
18	darbepoetin	darbepoetin	NN	_	19	compound
19	requirement	requirement	NN	_	16	conj
20	.	.	.	_	4	punct

1	Overall	overall	RB	_	5	advmod
2	,	,	,	_	5	punct
3	PTH	pth	NN	_	4	compound
4	levels	level	NNS	_	5	nsubj
5	decreased	decrease	VBD	_	0	ROOT
6	from	from	IN	_	9	case
7	197.5	197.5	CD	_	8	compound
8	(	(	CD	_	9	nummod
9	151.8	151.8	CD	_	5	nmod
10	;	;	:	_	9	punct
11	249.2	249.2	CD	_	14	compound
12	)	)	CD	_	14	compound
13	to	to	TO	_	14	dep
14	66.1	66.1	CD	_	9	dep
15	(	(	CD	_	16	compound
16	41.2	41.2	CD	_	14	nmod:npmod
17	;	;	:	_	9	punct
18	136.5	136.5	CD	_	19	compound
19	)	)	CD	_	21	nummod
20	(	(	NN	_	21	compound
21	median	median	NN	_	9	dep
22	(	(	CD	_	23	nummod
23	25th	25th	JJ	_	21	dep
24	;	;	:	_	21	punct
25	75th	75th	JJ	_	29	amod
26	percentile	percentile	JJ	_	29	amod
27	)	)	NN	_	29	compound
28	)	)	NN	_	29	compound
29	pmol	pmol	NN	_	21	dep
30	/	/	:	_	29	punct
31	l	l	NN	_	29	dep
32	;	;	:	_	5	punct

1	p	p	NN	_	2	compound
2	&amp	&amp	NN	_	0	ROOT
3	;	;	:	_	2	punct
4	lt	lt	NN	_	2	dep
5	;	;	:	_	2	punct

1	0.001	0.001	CD	_	0	ROOT
2	.	.	.	_	1	punct

1	Cinacalcet	Cinacalcet	NNP	_	2	compound
2	dose	dose	NN	_	3	nsubj
3	increased	increase	VBD	_	0	ROOT
4	from	from	IN	_	6	case
5	30.0	30.0	CD	_	6	compound
6	6	6	CD	_	3	nmod
7	to	to	TO	_	10	case
8	63	63	CD	_	10	nummod
9	25	25	CD	_	10	nummod
10	mg	mg	NN	_	3	nmod
11	/	/	:	_	10	punct
12	day	day	NN	_	10	dep
13	,	,	,	_	3	punct
14	p	p	NN	_	15	compound
15	&lt	&lt	NN	_	3	dobj
16	;	;	:	_	3	punct

1	0.05	0.05	CD	_	0	ROOT
2	.	.	.	_	1	punct

1	Hemoglobin	hemoglobin	NN	_	2	nsubj
2	remained	remain	VBD	_	0	ROOT
3	unchanged	unchanged	JJ	_	4	amod
4	(	(	NN	_	2	xcomp
5	116	116	CD	_	6	compound
6	13	13	CD	_	4	nummod
7	to	to	TO	_	4	dep
8	116	116	CD	_	9	compound
9	13	13	CD	_	10	nummod
10	g	g	NN	_	4	dep
11	/	/	:	_	4	punct
12	l	l	NN	_	13	compound
13	)	)	NN	_	4	dep
14	,	,	,	_	2	punct
15	while	while	IN	_	18	mark
16	darbepoetin	darbepoetin	NN	_	17	compound
17	requirement	requirement	NN	_	18	nsubj
18	decreased	decrease	VBD	_	2	advcl
19	from	from	IN	_	22	case
20	40	40	CD	_	21	compound
21	(	(	CD	_	22	nummod
22	20	20	CD	_	18	nmod
23	;	;	:	_	22	punct
24	60	60	CD	_	27	compound
25	)	)	CD	_	27	compound
26	to	to	TO	_	27	dep
27	24	24	CD	_	28	nummod
28	(	(	CD	_	22	dep
29	19	19	CD	_	28	dep
30	;	;	:	_	22	punct
31	59	59	CD	_	32	compound
32	)	)	CD	_	33	nummod
33	g	g	NN	_	35	dep
34	/	/	:	_	35	punct
35	week	week	NN	_	22	dep
36	,	,	,	_	35	punct
37	p	p	NN	_	38	nsubj
38	=	=	JJ	_	35	parataxis
39	0.02	0.02	CD	_	38	dobj
40	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	remainder	remainder	NN	_	0	ROOT
3	of	of	IN	_	5	case
4	the	the	DT	_	5	det
5	dialysis	dialysis	NN	_	2	nmod
6	-	-	:	_	5	punct
7	related	related	JJ	_	10	amod
8	biochemistry	biochemistry	NN	_	10	compound
9	(	(	CD	_	10	nummod
10	electrolytes	electrolyte	NNS	_	23	nsubj
11	,	,	,	_	10	punct
12	calcium	calcium	NN	_	10	conj
13	,	,	,	_	10	punct
14	phosphate	phosphate	NN	_	10	conj
15	,	,	,	_	10	punct
16	iron	iron	NN	_	18	compound
17	status	status	NN	_	18	compound
18	)	)	NN	_	10	conj
19	and	and	CC	_	10	cc
20	vitamin	vitamin	NN	_	22	compound
21	D	d	NN	_	22	compound
22	use	use	NN	_	10	conj
23	remained	remain	VBD	_	5	acl:relcl
24	unchanged	unchanged	JJ	_	23	xcomp
25	.	.	.	_	2	punct

1	A	a	DT	_	2	det
2	reduction	reduction	NN	_	12	nsubjpass
3	in	in	IN	_	5	case
4	PTH	pth	NN	_	5	compound
5	level	level	NN	_	2	nmod
6	of	of	IN	_	10	case
7	greater	greater	JJR	_	9	advmod
8	than	than	IN	_	9	advmod
9	30	30	CD	_	10	nummod
10	%	%	NN	_	5	nmod
11	was	be	VBD	_	12	auxpass
12	experienced	experience	VBN	_	0	ROOT
13	by	by	IN	_	15	case
14	82.5	82.5	CD	_	15	nummod
15	%	%	NN	_	12	nmod
16	(	(	CD	_	17	compound
17	33	33	CD	_	15	nummod
18	/	/	:	_	15	punct
19	40	40	CD	_	20	nummod
20	)	)	NN	_	15	dep
21	of	of	IN	_	23	case
22	our	we	PRP$	_	23	nmod:poss
23	cohort	cohort	NN	_	20	nmod
24	.	.	.	_	12	punct

1	Among	among	IN	_	3	case
2	the	the	DT	_	3	det
3	responders	responder	NNS	_	16	nmod
4	,	,	,	_	16	punct
5	the	the	DT	_	6	det
6	fall	fall	NN	_	16	nsubj
7	in	in	IN	_	8	case
8	PTH	pth	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	reduction	reduction	NN	_	12	compound
11	darbepoetin	darbepoetin	NN	_	12	compound
12	requirement	requirement	NN	_	8	conj
13	were	be	VBD	_	16	cop
14	related	related	JJ	_	16	amod
15	(	(	NN	_	16	compound
16	R	r	NN	_	0	ROOT
17	=	=	SYM	_	22	dep
18	-	-	:	_	22	punct
19	0.48	0.48	CD	_	22	dep
20	,	,	,	_	22	punct
21	p	p	NN	_	22	nsubj
22	=	=	JJ	_	16	dep
23	0.004	0.004	CD	_	24	nummod
24	)	)	NN	_	22	dep
25	.	.	.	_	16	punct

1	Reduction	reduction	NN	_	7	nsubjpass
2	of	of	IN	_	3	case
3	PTH	pth	NN	_	1	nmod
4	by	by	IN	_	5	case
5	cinacalcet	cinacalcet	NN	_	1	nmod
6	is	be	VBZ	_	7	auxpass
7	associated	associate	VBN	_	0	ROOT
8	with	with	IN	_	10	case
9	a	a	DT	_	10	det
10	decrease	decrease	NN	_	7	nmod
11	in	in	IN	_	13	case
12	darbepoetin	darbepoetin	NN	_	13	compound
13	requirement	requirement	NN	_	10	nmod
14	.	.	.	_	7	punct

1	The	the	DT	_	2	det
2	interface	interface	NN	_	10	nsubj
3	between	between	IN	_	4	case
4	bone	bone	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	bone	bone	NN	_	7	compound
7	marrow	marrow	NN	_	4	conj
8	in	in	IN	_	9	case
9	uremia	uremia	NN	_	2	nmod
10	represents	represent	VBZ	_	0	ROOT
11	a	a	DT	_	13	det
12	critical	critical	JJ	_	13	amod
13	step	step	NN	_	10	dobj
14	in	in	IN	_	18	case
15	red	red	JJ	_	18	amod
16	blood	blood	NN	_	18	compound
17	cell	cell	NN	_	18	compound
18	production	production	NN	_	13	nmod
19	which	which	WDT	_	20	det
20	merits	merit	NNS	_	22	nsubj
21	further	further	RB	_	22	advmod
22	investigation	investigation	NN	_	13	acl:relcl
23	.	.	.	_	10	punct

1	Calcium	calcium	NN	_	4	nsubj
2	does	do	VBZ	_	4	aux
3	not	not	RB	_	4	neg
4	inhibit	inhibit	VB	_	0	ROOT
5	the	the	DT	_	6	det
6	absorption	absorption	NN	_	4	dobj
7	of	of	IN	_	9	case
8	5	5	CD	_	9	nummod
9	milligrams	milligram	NNS	_	6	nmod
10	of	of	IN	_	14	case
11	nonheme	nonheme	JJ	_	14	amod
12	or	or	CC	_	11	cc
13	heme	heme	NN	_	11	conj
14	iron	iron	NN	_	9	nmod
15	at	at	IN	_	16	case
16	doses	dose	NNS	_	6	nmod
17	less	less	JJR	_	19	advmod
18	than	than	IN	_	17	mwe
19	800	800	CD	_	20	nummod
20	milligrams	milligram	NNS	_	16	dep
21	in	in	IN	_	23	case
22	nonpregnant	nonpregnant	JJ	_	23	amod
23	women	woman	NNS	_	20	nmod
24	.	.	.	_	4	punct

1	Calcium	calcium	NN	_	6	nsubj
2	is	be	VBZ	_	6	cop
3	the	the	DT	_	6	det
4	only	only	RB	_	5	advmod
5	known	known	JJ	_	6	amod
6	component	component	NN	_	0	ROOT
7	in	in	IN	_	9	case
8	the	the	DT	_	9	det
9	diet	diet	NN	_	6	nmod
10	that	that	WDT	_	12	nsubj
11	may	may	MD	_	12	aux
12	affect	affect	VB	_	6	acl:relcl
13	absorption	absorption	NN	_	12	dobj
14	of	of	IN	_	16	case
15	both	both	DT	_	16	cc:preconj
16	nonheme	nonheme	JJ	_	13	nmod
17	and	and	CC	_	16	cc
18	heme	heme	NN	_	19	compound
19	iron	iron	NN	_	16	conj
20	.	.	.	_	6	punct

1	However	however	RB	_	0	ROOT
2	,	,	,	_	1	punct
3	the	the	DT	_	4	det
4	evidence	evidence	NN	_	2	root
5	for	for	IN	_	8	case
6	a	a	DT	_	8	det
7	calcium	calcium	NN	_	8	compound
8	effect	effect	NN	_	4	nmod
9	on	on	IN	_	11	case
10	iron	iron	NN	_	11	compound
11	absorption	absorption	NN	_	8	nmod
12	mainly	mainly	RB	_	13	advmod
13	comes	come	VBZ	_	8	acl
14	from	from	IN	_	15	case
15	studies	study	NNS	_	13	nmod
16	that	that	WDT	_	19	nsubj
17	did	do	VBD	_	19	aux
18	not	not	RB	_	19	neg
19	isolate	isolate	VB	_	15	acl:relcl
20	the	the	DT	_	21	det
21	effect	effect	NN	_	19	dobj
22	of	of	IN	_	23	case
23	calcium	calcium	NN	_	21	nmod
24	from	from	IN	_	25	case
25	that	that	DT	_	21	nmod
26	of	of	IN	_	29	case
27	other	other	JJ	_	29	amod
28	dietary	dietary	JJ	_	29	amod
29	components	component	NNS	_	25	nmod
30	,	,	,	_	4	punct
31	because	because	IN	_	34	mark
32	it	it	PRP	_	34	nsubjpass
33	was	be	VBD	_	34	auxpass
34	detected	detect	VBN	_	30	root
35	in	in	IN	_	39	case
36	single	single	JJ	_	39	amod
37	-	-	:	_	39	punct
38	meal	meal	NN	_	39	compound
39	studies	study	NNS	_	34	nmod
40	.	.	.	_	34	punct

1	Our	we	PRP$	_	2	nmod:poss
2	objective	objective	NN	_	3	nsubj
3	was	be	VBD	_	0	ROOT
4	to	to	TO	_	5	mark
5	establish	establish	VB	_	3	xcomp
6	potential	potential	JJ	_	7	amod
7	effects	effect	NNS	_	5	dobj
8	of	of	IN	_	9	case
9	calcium	calcium	NN	_	7	nmod
10	on	on	IN	_	11	case
11	absorption	absorption	NN	_	7	nmod
12	of	of	IN	_	16	case
13	nonheme	nonheme	JJ	_	16	amod
14	and	and	CC	_	13	cc
15	heme	heme	NN	_	13	conj
16	iron	iron	NN	_	11	nmod
17	and	and	CC	_	16	cc
18	the	the	DT	_	20	det
19	dose	dose	NN	_	20	compound
20	response	response	NN	_	16	conj
21	for	for	IN	_	23	case
22	this	this	DT	_	23	det
23	effect	effect	NN	_	20	nmod
24	in	in	IN	_	26	case
25	the	the	DT	_	26	det
26	absence	absence	NN	_	23	nmod
27	of	of	IN	_	29	case
28	a	a	DT	_	29	det
29	meal	meal	NN	_	26	nmod
30	.	.	.	_	3	punct

1	Fifty	fifty	CD	_	9	nsubjpass
2	-	-	:	_	9	punct
3	four	four	CD	_	9	dep
4	healthy	healthy	JJ	_	9	dep
5	,	,	,	_	9	punct
6	nonpregnant	nonpregnant	JJ	_	7	amod
7	women	woman	NNS	_	9	nsubjpass
8	were	be	VBD	_	9	auxpass
9	selected	select	VBN	_	0	ROOT
10	to	to	TO	_	11	mark
11	participate	participate	VB	_	9	xcomp
12	in	in	IN	_	16	case
13	4	4	CD	_	16	nummod
14	iron	iron	NN	_	16	compound
15	absorption	absorption	NN	_	16	compound
16	studies	study	NNS	_	11	nmod
17	using	use	VBG	_	16	acl
18	iron	iron	NN	_	20	compound
19	radioactive	radioactive	JJ	_	20	amod
20	tracers	tracer	NNS	_	17	dobj
21	.	.	.	_	9	punct

1	We	we	PRP	_	2	nsubj
2	evaluated	evaluate	VBD	_	0	ROOT
3	the	the	DT	_	4	det
4	effects	effect	NNS	_	2	dobj
5	of	of	IN	_	7	case
6	calcium	calcium	NN	_	7	compound
7	doses	dose	NNS	_	4	nmod
8	between	between	IN	_	12	case
9	200	200	CD	_	12	nummod
10	and	and	CC	_	9	cc
11	1500	1500	CD	_	9	conj
12	mg	mg	NN	_	4	nmod
13	on	on	IN	_	14	case
14	absorption	absorption	NN	_	4	nmod
15	of	of	IN	_	19	case
16	5	5	CD	_	17	compound
17	mg	mg	NN	_	19	amod
18	nonheme	nonheme	JJ	_	19	amod
19	iron	iron	NN	_	14	nmod
20	(	(	RB	_	24	advmod
21	as	as	IN	_	24	case
22	ferrous	ferrous	JJ	_	24	amod
23	sulfate	sulfate	NN	_	24	compound
24	)	)	NN	_	14	nmod
25	.	.	.	_	2	punct

1	We	we	PRP	_	3	nsubj
2	also	also	RB	_	3	advmod
3	evaluated	evaluate	VBD	_	0	ROOT
4	the	the	DT	_	5	det
5	effects	effect	NNS	_	3	dobj
6	of	of	IN	_	8	case
7	calcium	calcium	NN	_	8	compound
8	doses	dose	NNS	_	5	nmod
9	between	between	IN	_	13	case
10	200	200	CD	_	13	nummod
11	and	and	CC	_	10	cc
12	800	800	CD	_	10	conj
13	mg	mg	NN	_	5	nmod
14	on	on	IN	_	15	case
15	absorption	absorption	NN	_	5	nmod
16	of	of	IN	_	20	case
17	5	5	CD	_	18	compound
18	mg	mg	NN	_	20	amod
19	heme	heme	NN	_	20	compound
20	iron	iron	NN	_	15	nmod
21	[	[	RB	_	25	advmod
22	as	as	IN	_	25	mark
23	concentrated	concentrated	JJ	_	24	amod
24	RBC	rbc	NNS	_	25	nsubj
25	(	(	VBP	_	15	acl
26	CRBC	crbc	NN	_	28	compound
27	)	)	CD	_	28	nummod
28	]	]	NN	_	25	dobj
29	.	.	.	_	3	punct

1	Calcium	calcium	NN	_	3	nsubjpass
2	was	be	VBD	_	3	auxpass
3	administered	administer	VBN	_	13	csubjpass
4	as	as	IN	_	6	case
5	calcium	calcium	NN	_	6	compound
6	chloride	chloride	NN	_	3	nmod
7	in	in	IN	_	9	case
8	all	all	DT	_	9	det
9	studies	study	NNS	_	3	nmod
10	and	and	CC	_	9	cc
11	minerals	mineral	NNS	_	9	conj
12	were	be	VBD	_	13	auxpass
13	ingested	ingest	VBN	_	0	ROOT
14	on	on	IN	_	17	case
15	an	a	DT	_	17	det
16	empty	empty	JJ	_	17	amod
17	stomach	stomach	NN	_	13	nmod
18	.	.	.	_	13	punct

1	Calcium	calcium	NN	_	2	compound
2	doses	dose	NNS	_	5	nsubj
3	1000	1000	CD	_	4	nummod
4	mg	mg	NN	_	2	dep
5	diminished	diminish	VBD	_	0	ROOT
6	nonheme	nonheme	JJ	_	8	amod
7	iron	iron	NN	_	8	compound
8	absorption	absorption	NN	_	5	dobj
9	by	by	IN	_	11	case
10	an	a	DT	_	11	det
11	average	average	NN	_	5	nmod
12	of	of	IN	_	14	case
13	49.6	49.6	CD	_	14	nummod
14	%	%	NN	_	11	nmod
15	.	.	.	_	5	punct

1	A	a	DT	_	3	det
2	calcium	calcium	NN	_	3	compound
3	dose	dose	NN	_	7	nsubj
4	of	of	IN	_	6	case
5	800	800	CD	_	6	nummod
6	mg	mg	NN	_	3	nmod
7	diminished	diminish	VBD	_	0	ROOT
8	absorption	absorption	NN	_	7	dobj
9	of	of	IN	_	13	case
10	5	5	CD	_	11	compound
11	mg	mg	NN	_	13	amod
12	heme	heme	NN	_	13	compound
13	iron	iron	NN	_	8	nmod
14	by	by	IN	_	16	case
15	37.7	37.7	CD	_	16	nummod
16	%	%	NN	_	7	nmod
17	.	.	.	_	7	punct

1	In	in	IN	_	2	case
2	conclusion	conclusion	NN	_	5	nmod
3	,	,	,	_	5	punct
4	we	we	PRP	_	5	nsubj
5	demonstrated	demonstrate	VBD	_	0	ROOT
6	an	a	DT	_	8	det
7	isolated	isolate	VBN	_	8	amod
8	effect	effect	NN	_	5	dobj
9	of	of	IN	_	11	case
10	calcium	calcium	NN	_	11	compound
11	(	(	NN	_	8	nmod
12	as	as	IN	_	14	case
13	chloride	chloride	NN	_	14	compound
14	)	)	NN	_	8	nmod
15	on	on	IN	_	16	case
16	absorption	absorption	NN	_	8	nmod
17	of	of	IN	_	19	case
18	5	5	CD	_	19	nummod
19	mg	mg	NN	_	16	nmod
20	of	of	IN	_	21	case
21	iron	iron	NN	_	19	nmod
22	provided	provide	VBN	_	8	acl
23	as	as	IN	_	25	case
24	nonheme	nonheme	JJ	_	25	amod
25	(	(	NN	_	22	nmod
26	as	as	IN	_	28	case
27	sulfate	sulfate	JJ	_	28	amod
28	)	)	NN	_	25	nmod
29	and	and	CC	_	28	cc
30	heme	heme	NN	_	28	conj
31	(	(	RB	_	35	advmod
32	as	as	IN	_	35	case
33	CRBC	crbc	NN	_	35	compound
34	)	)	CD	_	35	nummod
35	iron	iron	NN	_	28	nmod
36	.	.	.	_	5	punct

1	This	this	DT	_	2	det
2	effect	effect	NN	_	4	nsubjpass
3	was	be	VBD	_	4	auxpass
4	observed	observe	VBN	_	0	ROOT
5	at	at	IN	_	6	case
6	doses	dose	NNS	_	4	nmod
7	higher	higher	JJR	_	6	amod
8	than	than	IN	_	10	mark
9	previously	previously	RB	_	10	advmod
10	reported	report	VBN	_	7	advcl
11	from	from	IN	_	15	case
12	single	single	JJ	_	15	amod
13	-	-	:	_	15	punct
14	meal	meal	NN	_	15	compound
15	studies	study	NNS	_	10	nmod
16	,	,	,	_	4	punct
17	starting	start	VBG	_	4	xcomp
18	at	at	IN	_	21	case
19	~	~	CD	_	20	compound
20	800	800	CD	_	21	nummod
21	mg	mg	NN	_	17	nmod
22	of	of	IN	_	23	case
23	calcium	calcium	NN	_	21	nmod
24	.	.	.	_	4	punct

1	Synergistic	synergistic	JJ	_	2	amod
2	interaction	interaction	NN	_	9	nsubj
3	between	between	IN	_	4	case
4	sunitinib	sunitinib	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	docetaxel	docetaxel	NN	_	4	conj
7	is	be	VBZ	_	9	cop
8	sequence	sequence	NN	_	9	nmod:npmod
9	dependent	dependent	JJ	_	0	ROOT
10	in	in	IN	_	16	case
11	human	human	JJ	_	16	amod
12	non	non	JJ	_	16	amod
13	-	-	:	_	16	punct
14	small	small	JJ	_	16	amod
15	lung	lung	NN	_	16	compound
16	cancer	cancer	NN	_	9	nmod
17	with	with	IN	_	19	case
18	EGFR	egfr	NN	_	19	compound
19	TKIs	tki	NNS	_	16	nmod
20	-	-	:	_	9	punct
21	resistant	resistant	JJ	_	22	amod
22	mutation	mutation	NN	_	9	dep
23	.	.	.	_	9	punct

1	Previous	previous	JJ	_	2	amod
2	studies	study	NNS	_	4	nsubj
3	have	have	VBP	_	4	aux
4	demonstrated	demonstrate	VBN	_	0	ROOT
5	that	that	IN	_	7	mark
6	sunitinib	sunitinib	NN	_	7	nsubj
7	has	have	VBZ	_	4	ccomp
8	the	the	DT	_	12	det
9	anti	anti	JJ	_	12	amod
10	-	-	:	_	12	punct
11	tumor	tumor	NN	_	12	compound
12	activity	activity	NN	_	7	dobj
13	in	in	IN	_	20	case
14	human	human	JJ	_	20	amod
15	non	non	JJ	_	20	amod
16	-	-	:	_	20	punct
17	small	small	JJ	_	20	amod
18	cell	cell	NN	_	20	compound
19	lung	lung	NN	_	20	compound
20	cancer	cancer	NN	_	12	nmod
21	(	(	CD	_	23	nummod
22	NSCLC	nsclc	NN	_	23	compound
23	)	)	NN	_	20	dep
24	.	.	.	_	4	punct

1	This	this	DT	_	2	det
2	study	study	NN	_	4	nsubjpass
3	was	be	VBD	_	4	auxpass
4	aimed	aim	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	investigate	investigate	VB	_	4	xcomp
7	the	the	DT	_	8	det
8	efficacy	efficacy	NN	_	6	dobj
9	of	of	IN	_	11	case
10	single	single	JJ	_	11	amod
11	use	use	NN	_	8	nmod
12	of	of	IN	_	13	case
13	sunitinib	sunitinib	NN	_	11	nmod
14	and	and	CC	_	4	cc
15	that	that	IN	_	4	conj
16	of	of	IN	_	20	case
17	concurrent	concurrent	JJ	_	20	amod
18	or	or	CC	_	17	cc
19	sequential	sequential	JJ	_	17	conj
20	administration	administration	NN	_	15	nmod
21	of	of	IN	_	22	case
22	sunitinib	sunitinib	NN	_	20	nmod
23	and	and	CC	_	22	cc
24	docetaxel	docetaxel	NN	_	22	conj
25	in	in	IN	_	28	case
26	NSCLC	nsclc	NN	_	28	compound
27	cell	cell	NN	_	28	compound
28	lines	line	NNS	_	20	nmod
29	that	that	WDT	_	31	nsubj
30	are	be	VBP	_	31	cop
31	resistant	resistant	JJ	_	28	acl:relcl
32	to	to	TO	_	34	case
33	EGFR	egfr	NN	_	34	compound
34	TKIs	tki	NNS	_	31	nmod
35	.	.	.	_	4	punct

1	NSCLC	nsclc	NN	_	3	compound
2	cell	cell	NN	_	3	compound
3	lines	line	NNS	_	14	nsubjpass
4	with	with	IN	_	7	case
5	EGFR	egfr	NN	_	7	compound
6	T790M	t790m	NN	_	7	compound
7	mutation	mutation	NN	_	3	nmod
8	and	and	CC	_	7	cc
9	K	k	NN	_	12	compound
10	-	-	:	_	12	punct
11	ras	ras	NN	_	12	compound
12	mutation	mutation	NN	_	7	conj
13	were	be	VBD	_	14	auxpass
14	exposed	expose	VBN	_	0	ROOT
15	to	to	TO	_	17	case
16	either	either	CC	_	17	cc:preconj
17	sunitinib	sunitinib	NN	_	14	nmod
18	or	or	CC	_	17	cc
19	docetaxel	docetaxel	NN	_	17	conj
20	or	or	CC	_	17	cc
21	both	both	DT	_	17	conj
22	based	base	VBN	_	26	case
23	on	on	IN	_	26	case
24	various	various	JJ	_	26	amod
25	sequential	sequential	JJ	_	26	amod
26	administrations	administration	NNS	_	21	nmod
27	.	.	.	_	14	punct

1	After	after	IN	_	2	case
2	exposure	exposure	NN	_	8	nmod
3	,	,	,	_	8	punct
4	the	the	DT	_	6	det
5	cell	cell	NN	_	6	compound
6	viability	viability	NN	_	8	nsubjpass
7	was	be	VBD	_	8	auxpass
8	measured	measure	VBN	_	0	ROOT
9	by	by	IN	_	11	case
10	MTT	MTT	NNP	_	11	compound
11	assay	assay	NN	_	8	nmod
12	,	,	,	_	11	punct
13	cell	cell	NN	_	15	compound
14	cycle	cycle	NN	_	15	compound
15	distribution	distribution	NN	_	11	appos
16	was	be	VBD	_	17	auxpass
17	analyzed	analyze	VBN	_	28	csubjpass
18	by	by	IN	_	20	case
19	flow	flow	NN	_	20	compound
20	cytometry	cytometry	NN	_	17	nmod
21	,	,	,	_	20	punct
22	and	and	CC	_	20	cc
23	alterations	alteration	NNS	_	20	conj
24	in	in	IN	_	26	case
25	signaling	signaling	NN	_	26	compound
26	pathway	pathway	NN	_	20	nmod
27	were	be	VBD	_	28	auxpass
28	determined	determine	VBN	_	8	ccomp
29	by	by	IN	_	30	case
30	immunoblotting	immunoblotting	NN	_	28	nmod
31	.	.	.	_	8	punct

1	Sunitinib	Sunitinib	NNP	_	2	nsubj
2	exhibited	exhibit	VBD	_	0	ROOT
3	dose	dose	NN	_	2	dobj
4	-	-	:	_	3	punct
5	dependent	dependent	JJ	_	7	amod
6	growth	growth	NN	_	7	compound
7	inhibition	inhibition	NN	_	3	dep
8	in	in	IN	_	11	case
9	NSCLC	nsclc	NN	_	11	compound
10	cell	cell	NN	_	11	compound
11	lines	line	NNS	_	7	nmod
12	and	and	CC	_	7	cc
13	arrested	arrest	VBN	_	15	amod
14	cell	cell	NN	_	15	compound
15	cycle	cycle	NN	_	7	conj
16	at	at	IN	_	18	case
17	G1	g1	NN	_	18	compound
18	phase	phase	NN	_	15	nmod
19	,	,	,	_	2	punct
20	whereas	whereas	IN	_	2	dep
21	docetaxel	docetaxel	NN	_	2	dep
22	arrested	arrest	VBN	_	21	acl
23	at	at	IN	_	25	case
24	S	s	NN	_	25	compound
25	phase	phase	NN	_	22	nmod
26	.	.	.	_	2	punct

1	Although	although	IN	_	10	mark
2	single	single	JJ	_	5	amod
3	or	or	CC	_	2	cc
4	concurrent	concurrent	JJ	_	2	conj
5	use	use	NN	_	10	nsubj
6	of	of	IN	_	7	case
7	sunitinib	sunitinib	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	docetaxel	docetaxel	NN	_	7	conj
10	has	have	VBZ	_	24	advcl
11	some	some	DT	_	15	det
12	anti	anti	JJ	_	15	amod
13	-	-	:	_	15	punct
14	proliferative	proliferative	JJ	_	15	amod
15	effects	effect	NNS	_	10	dobj
16	,	,	,	_	24	punct
17	the	the	DT	_	19	det
18	sequential	sequential	JJ	_	19	amod
19	administrations	administration	NNS	_	24	nsubj
20	of	of	IN	_	22	case
21	both	both	DT	_	22	det
22	drugs	drug	NNS	_	19	nmod
23	remarkably	remarkably	RB	_	24	advmod
24	enhanced	enhance	VBD	_	0	ROOT
25	anti	anti	JJ	_	28	amod
26	-	-	:	_	28	punct
27	tumor	tumor	NN	_	28	compound
28	activity	activity	NN	_	24	dobj
29	.	.	.	_	24	punct

1	When	when	WRB	_	4	advmod
2	cells	cell	NNS	_	4	nsubjpass
3	were	be	VBD	_	4	auxpass
4	exposed	expose	VBN	_	13	advcl
5	to	to	TO	_	6	case
6	docetaxel	docetaxel	NN	_	4	nmod
7	followed	follow	VBN	_	4	dep
8	by	by	IN	_	9	case
9	sunitinib	sunitinib	NN	_	7	nmod
10	,	,	,	_	13	punct
11	synergism	synergism	NN	_	13	nsubjpass
12	was	be	VBD	_	13	auxpass
13	observed	observe	VBN	_	0	ROOT
14	.	.	.	_	13	punct

1	The	the	DT	_	3	det
2	molecular	molecular	JJ	_	3	amod
3	basis	basis	NN	_	7	nsubj
4	of	of	IN	_	6	case
5	this	this	DT	_	6	det
6	synergism	synergism	NN	_	3	nmod
7	is	be	VBZ	_	0	ROOT
8	that	that	IN	_	21	mark
9	the	the	DT	_	11	det
10	signaling	signaling	NN	_	11	compound
11	pathways	pathway	NNS	_	21	nsubjpass
12	that	that	WDT	_	15	nsubjpass
13	were	be	VBD	_	15	auxpass
14	initially	initially	RB	_	15	advmod
15	activated	activate	VBN	_	11	acl:relcl
16	by	by	IN	_	18	case
17	docetaxel	docetaxel	NN	_	18	compound
18	exposure	exposure	NN	_	15	nmod
19	were	be	VBD	_	21	auxpass
20	efficiently	efficiently	RB	_	21	advmod
21	suppressed	suppress	VBN	_	7	ccomp
22	by	by	IN	_	25	case
23	the	the	DT	_	25	det
24	subsequent	subsequent	JJ	_	25	amod
25	exposure	exposure	NN	_	21	nmod
26	to	to	TO	_	27	case
27	sunitinib	sunitinib	NN	_	25	nmod
28	.	.	.	_	7	punct

1	In	in	IN	_	2	case
2	contrast	contrast	NN	_	10	nmod
3	,	,	,	_	10	punct
4	the	the	DT	_	5	det
5	reverse	reverse	NN	_	10	nsubj
6	of	of	IN	_	9	case
7	this	this	DT	_	9	det
8	sequential	sequential	JJ	_	9	amod
9	administration	administration	NN	_	5	nmod
10	resulted	result	VBD	_	0	ROOT
11	in	in	IN	_	12	case
12	antagonism	antagonism	NN	_	10	nmod
13	,	,	,	_	12	punct
14	which	which	WDT	_	20	nsubj
15	may	may	MD	_	20	aux
16	be	be	VB	_	20	cop
17	due	due	JJ	_	20	case
18	to	to	TO	_	17	mwe
19	differential	differential	JJ	_	20	amod
20	effects	effect	NNS	_	12	acl:relcl
21	on	on	IN	_	24	case
22	cell	cell	NN	_	24	compound
23	cycle	cycle	NN	_	24	compound
24	arrest	arrest	NN	_	20	nmod
25	.	.	.	_	10	punct

1	Sunitinib	Sunitinib	NNP	_	6	nsubj
2	as	as	IN	_	5	case
3	a	a	DT	_	5	det
4	single	single	JJ	_	5	amod
5	agent	agent	NN	_	1	nmod
6	exhibits	exhibit	VBZ	_	0	ROOT
7	anti	anti	JJ	_	10	amod
8	-	-	:	_	10	punct
9	proliferative	proliferative	JJ	_	10	amod
10	effects	effect	NNS	_	6	dobj
11	in	in	FW	_	12	compound
12	vitro	vitro	FW	_	6	advmod
13	in	in	IN	_	16	case
14	NSCLC	nsclc	NN	_	16	compound
15	cell	cell	NN	_	16	compound
16	lines	line	NNS	_	6	nmod
17	with	with	IN	_	19	case
18	EGFR	egfr	NN	_	19	compound
19	T790M	t790m	NN	_	16	nmod
20	and	and	CC	_	19	cc
21	K	k	NN	_	24	compound
22	-	-	:	_	24	punct
23	ras	ras	NN	_	24	compound
24	mutations	mutation	NNS	_	19	conj
25	but	but	CC	_	6	cc
26	the	the	DT	_	28	det
27	sequential	sequential	JJ	_	28	amod
28	administration	administration	NN	_	35	nsubj
29	of	of	IN	_	30	case
30	docetaxel	docetaxel	NN	_	28	nmod
31	followed	follow	VBN	_	28	acl
32	by	by	IN	_	33	case
33	sunitinib	sunitinib	NN	_	31	nmod
34	is	be	VBZ	_	35	cop
35	superior	superior	JJ	_	6	conj
36	to	to	TO	_	37	case
37	sunitinib	sunitinib	NN	_	35	nmod
38	followed	follow	VBN	_	37	acl
39	by	by	IN	_	40	case
40	docetaxel	docetaxel	NN	_	38	nmod
41	and	and	CC	_	40	cc
42	concurrent	concurrent	JJ	_	43	amod
43	administration	administration	NN	_	40	conj
44	.	.	.	_	6	punct

1	Determinants	determinant	NNS	_	6	nsubj
2	of	of	IN	_	3	case
3	sensitivity	sensitivity	NN	_	1	nmod
4	to	to	TO	_	5	case
5	DZNep	dznep	NN	_	3	nmod
6	induced	induce	VBD	_	0	ROOT
7	apoptosis	apoptosis	NN	_	6	dobj
8	in	in	IN	_	11	case
9	multiple	multiple	JJ	_	11	amod
10	myeloma	myeloma	NN	_	11	compound
11	cells	cell	NNS	_	6	nmod
12	.	.	.	_	6	punct

1	The	the	DT	_	8	det
2	3	3	LS	_	8	dep
3	-	-	:	_	8	punct
4	Deazaneplanocin	deazaneplanocin	NN	_	8	compound
5	A	a	NN	_	8	compound
6	(	(	CD	_	8	nummod
7	DZNep	dznep	NN	_	8	compound
8	)	)	NN	_	22	nsubj
9	,	,	,	_	8	punct
10	one	one	CD	_	8	appos
11	of	of	IN	_	12	case
12	S	s	NN	_	10	nmod
13	-	-	:	_	10	punct
14	adenosylhomocysteine	adenosylhomocysteine	NN	_	19	compound
15	(	(	CD	_	19	nummod
16	AdoHcy	AdoHcy	NNP	_	19	compound
17	)	)	CD	_	19	nummod
18	hydrolase	hydrolase	NN	_	19	compound
19	inhibitors	inhibitor	NNS	_	10	dep
20	,	,	,	_	8	punct
21	has	have	VBZ	_	22	aux
22	shown	show	VBN	_	0	ROOT
23	antitumor	antitumor	NN	_	24	compound
24	activities	activity	NNS	_	22	dobj
25	in	in	IN	_	28	case
26	a	a	DT	_	28	det
27	broad	broad	JJ	_	28	amod
28	range	range	NN	_	22	nmod
29	of	of	IN	_	31	case
30	solid	solid	JJ	_	31	amod
31	tumors	tumor	NNS	_	28	nmod
32	and	and	CC	_	31	cc
33	acute	acute	JJ	_	35	amod
34	myeloid	myeloid	JJ	_	35	amod
35	leukemia	leukemia	NN	_	31	conj
36	.	.	.	_	22	punct

1	Here	here	RB	_	4	advmod
2	,	,	,	_	4	punct
3	we	we	PRP	_	4	nsubj
4	examined	examine	VBD	_	0	ROOT
5	its	its	PRP$	_	6	nmod:poss
6	effects	effect	NNS	_	4	dobj
7	on	on	IN	_	13	case
8	multiple	multiple	JJ	_	13	amod
9	myeloma	myeloma	NN	_	13	compound
10	(	(	CD	_	13	nummod
11	MM	mm	NN	_	13	compound
12	)	)	NN	_	13	compound
13	cells	cell	NNS	_	6	nmod
14	and	and	CC	_	4	cc
15	found	find	VBD	_	4	conj
16	that	that	IN	_	24	mark
17	,	,	,	_	24	punct
18	at	at	IN	_	20	case
19	500	500	CD	_	20	nummod
20	nM	nm	NN	_	24	nmod
21	,	,	,	_	24	punct
22	it	it	PRP	_	24	nsubj
23	potently	potently	RB	_	24	advmod
24	inhibited	inhibit	VBD	_	15	ccomp
25	growth	growth	NN	_	24	dobj
26	and	and	CC	_	24	cc
27	induced	induce	VBD	_	24	conj
28	apoptosis	apoptosis	NN	_	27	dobj
29	in	in	IN	_	27	nmod
30	2	2	CD	_	29	dep
31	of	of	IN	_	35	case
32	8	8	CD	_	35	nummod
33	MM	mm	NN	_	35	compound
34	cell	cell	NN	_	35	compound
35	lines	line	NNS	_	30	nmod
36	.	.	.	_	4	punct

1	RNA	rna	NN	_	11	nsubjpass
2	from	from	IN	_	3	case
3	un	un	NN	_	1	nmod
4	-	-	:	_	3	punct
5	treated	treat	VBN	_	3	dep
6	and	and	CC	_	5	cc
7	DZNep	dznep	NN	_	9	compound
8	treated	treated	JJ	_	9	amod
9	cells	cell	NNS	_	5	conj
10	was	be	VBD	_	11	auxpass
11	profiled	profile	VBN	_	30	csubjpass
12	by	by	IN	_	14	case
13	Affymetrix	Affymetrix	NNP	_	14	compound
14	HG	HG	NNP	_	11	nmod
15	-	-	:	_	14	punct
16	U133	u133	NN	_	17	compound
17	Plus	plus	NN	_	14	dep
18	2.0	2.0	CD	_	19	nummod
19	microarray	microarray	NN	_	17	dep
20	and	and	CC	_	19	cc
21	genes	gene	NNS	_	19	conj
22	with	with	IN	_	25	case
23	a	a	DT	_	25	det
24	significant	significant	JJ	_	25	amod
25	change	change	NN	_	11	nmod
26	in	in	IN	_	28	case
27	gene	gene	NN	_	28	compound
28	expression	expression	NN	_	25	nmod
29	were	be	VBD	_	30	auxpass
30	determined	determine	VBN	_	0	ROOT
31	by	by	IN	_	33	case
32	significance	significance	NN	_	33	compound
33	analysis	analysis	NN	_	30	nmod
34	of	of	IN	_	39	case
35	microarray	microarray	NN	_	39	compound
36	(	(	CD	_	39	nummod
37	SAM	SAM	NNP	_	39	compound
38	)	)	CD	_	39	nummod
39	testing	testing	NN	_	33	nmod
40	.	.	.	_	30	punct

1	ALOX5	alox5	NN	_	9	nsubj
2	was	be	VBD	_	9	cop
3	the	the	DT	_	9	det
4	most	most	RBS	_	5	advmod
5	down	down	RB	_	9	amod
6	-	-	:	_	9	punct
7	regulated	regulated	JJ	_	9	amod
8	gene	gene	NN	_	9	compound
9	(	(	NN	_	0	ROOT
10	5.8	5.8	CD	_	9	nummod
11	-	-	:	_	9	punct
12	fold	fold	JJ	_	13	amod
13	)	)	NN	_	9	dep
14	in	in	IN	_	16	case
15	sensitive	sensitive	JJ	_	16	amod
16	cells	cell	NNS	_	13	nmod
17	and	and	CC	_	13	cc
18	was	be	VBD	_	19	auxpass
19	expressed	express	VBN	_	13	conj
20	at	at	IN	_	22	case
21	low	low	JJ	_	22	amod
22	level	level	NN	_	19	nmod
23	in	in	IN	_	25	case
24	resistant	resistant	JJ	_	25	amod
25	cells	cell	NNS	_	19	nmod
26	.	.	.	_	9	punct

1	The	the	DT	_	2	det
2	results	result	NNS	_	4	nsubjpass
3	were	be	VBD	_	4	auxpass
4	corroborated	corroborate	VBN	_	0	ROOT
5	by	by	IN	_	7	case
6	quantitative	quantitative	JJ	_	7	amod
7	RT	rt	NN	_	4	nmod
8	-	-	:	_	7	punct
9	PCR	pcr	NN	_	7	dep
10	.	.	.	_	4	punct

1	Western	western	JJ	_	5	dep
2	-	-	:	_	5	punct
3	blot	blot	NN	_	4	compound
4	analysis	analysis	NN	_	5	nsubj
5	indicated	indicate	VBD	_	0	ROOT
6	ALOX5	alox5	NN	_	9	nsubjpass
7	was	be	VBD	_	9	auxpass
8	highly	highly	RB	_	9	advmod
9	expressed	express	VBN	_	5	ccomp
10	only	only	RB	_	15	advmod
11	in	in	IN	_	15	case
12	sensitive	sensitive	JJ	_	15	amod
13	cell	cell	NN	_	15	compound
14	line	line	NN	_	15	compound
15	H929	h929	NN	_	9	nmod
16	and	and	CC	_	15	cc
17	greatly	greatly	RB	_	18	advmod
18	decreased	decrease	VBN	_	15	conj
19	upon	upon	IN	_	21	case
20	DZNep	dznep	NN	_	21	compound
21	treatment	treatment	NN	_	18	nmod
22	.	.	.	_	5	punct

1	Ectopic	ectopic	JJ	_	2	amod
2	expression	expression	NN	_	5	nsubj
3	of	of	IN	_	4	case
4	ALOX5	alox5	NN	_	2	nmod
5	reduced	reduce	VBD	_	0	ROOT
6	sensitivity	sensitivity	NN	_	5	dobj
7	to	to	TO	_	8	case
8	DZNep	dznep	NN	_	6	nmod
9	in	in	IN	_	11	case
10	H929	h929	NN	_	11	compound
11	cells	cell	NNS	_	6	nmod
12	.	.	.	_	5	punct

1	Furthermore	furthermore	RB	_	13	advmod
2	,	,	,	_	13	punct
3	down	down	IN	_	5	case
4	-	-	:	_	5	punct
5	regulation	regulation	NN	_	13	nmod
6	of	of	IN	_	7	case
7	ALOX5	alox5	NN	_	5	nmod
8	by	by	IN	_	10	case
9	RNA	rna	NN	_	10	compound
10	interference	interference	NN	_	5	nmod
11	could	could	MD	_	13	aux
12	also	also	RB	_	13	advmod
13	induce	induce	VB	_	0	ROOT
14	apoptosis	apoptosis	NN	_	13	dobj
15	in	in	IN	_	16	case
16	H929	h929	NN	_	13	nmod
17	.	.	.	_	13	punct

1	Gene	gene	NN	_	3	compound
2	expression	expression	NN	_	3	compound
3	analysis	analysis	NN	_	8	nsubj
4	on	on	IN	_	7	case
5	MM	mm	NN	_	7	compound
6	patient	patient	NN	_	7	compound
7	dataset	dataset	NN	_	3	nmod
8	indicated	indicate	VBD	_	0	ROOT
9	ALOX5	alox5	NN	_	10	compound
10	expression	expression	NN	_	13	nsubj
11	was	be	VBD	_	13	cop
12	significantly	significantly	RB	_	13	advmod
13	higher	higher	JJR	_	8	ccomp
14	in	in	IN	_	16	case
15	MM	mm	NN	_	16	compound
16	patients	patient	NNS	_	13	nmod
17	compared	compare	VBN	_	21	case
18	to	to	TO	_	21	case
19	normal	normal	JJ	_	21	amod
20	plasma	plasma	NN	_	21	compound
21	cells	cell	NNS	_	13	advcl
22	.	.	.	_	8	punct

1	We	we	PRP	_	3	nsubj
2	also	also	RB	_	3	advmod
3	found	find	VBD	_	0	ROOT
4	that	that	IN	_	9	mark
5	Bcl	Bcl	NNP	_	9	nsubjpass
6	-	-	:	_	5	punct
7	2	2	CD	_	5	nummod
8	was	be	VBD	_	9	auxpass
9	overexpressed	overexpress	VBN	_	3	ccomp
10	in	in	IN	_	13	case
11	DZNep	dznep	NN	_	13	compound
12	insensitive	insensitive	JJ	_	13	amod
13	cells	cell	NNS	_	9	nmod
14	,	,	,	_	9	punct
15	and	and	CC	_	9	cc
16	cotreatment	cotreatment	NN	_	32	nsubj
17	with	with	IN	_	18	case
18	DZNep	dznep	NN	_	16	nmod
19	and	and	CC	_	18	cc
20	ABT	ABT	NNP	_	18	conj
21	-	-	:	_	20	punct
22	737	737	CD	_	20	nummod
23	,	,	,	_	20	punct
24	a	a	DT	_	29	det
25	Bcl	bcl	NN	_	29	compound
26	-	-	:	_	29	punct
27	2	2	CD	_	29	nummod
28	family	family	NN	_	29	compound
29	inhibitor	inhibitor	NN	_	20	appos
30	,	,	,	_	20	punct
31	synergistically	synergistically	RB	_	32	advmod
32	inhibited	inhibit	VBD	_	9	conj
33	growth	growth	NN	_	32	dobj
34	and	and	CC	_	32	cc
35	induced	induce	VBD	_	32	conj
36	apoptosis	apoptosis	NN	_	35	dobj
37	of	of	IN	_	41	case
38	DZNep	dznep	NN	_	41	compound
39	insensitive	insensitive	JJ	_	41	amod
40	MM	mm	NN	_	41	compound
41	cells	cell	NNS	_	36	nmod
42	.	.	.	_	3	punct

1	Taken	take	VBN	_	6	advcl
2	together	together	RB	_	1	advmod
3	,	,	,	_	6	punct
4	this	this	DT	_	5	det
5	study	study	NN	_	6	nsubj
6	shows	show	VBZ	_	0	ROOT
7	one	one	CD	_	16	nsubj
8	of	of	IN	_	9	case
9	mechanisms	mechanism	NNS	_	7	nmod
10	of	of	IN	_	13	case
11	the	the	DT	_	13	det
12	DZNep	dznep	NN	_	13	compound
13	efficacy	efficacy	NN	_	9	nmod
14	on	on	IN	_	15	case
15	MM	mm	NN	_	13	nmod
16	correlates	correlate	VBZ	_	6	ccomp
17	with	with	IN	_	19	case
18	its	its	PRP$	_	19	nmod:poss
19	ability	ability	NN	_	16	nmod
20	to	to	TO	_	21	case
21	down	down	RB	_	19	nmod
22	-	-	:	_	19	punct
23	regulate	regulate	VB	_	19	dep
24	the	the	DT	_	26	det
25	ALOX5	alox5	NN	_	26	compound
26	levels	level	NNS	_	23	dobj
27	.	.	.	_	6	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	8	nmod
3	,	,	,	_	8	punct
4	DZNep	dznep	NN	_	5	compound
5	insensitivity	insensitivity	NN	_	8	nsubjpass
6	might	might	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	associated	associate	VBN	_	0	ROOT
9	with	with	IN	_	10	case
10	overexpression	overexpression	NN	_	8	nmod
11	of	of	IN	_	12	case
12	Bcl	bcl	NN	_	10	nmod
13	-	-	:	_	12	punct
14	2	2	CD	_	12	nummod
15	,	,	,	_	8	punct
16	and	and	CC	_	8	cc
17	the	the	DT	_	18	det
18	combination	combination	NN	_	27	nsubj
19	of	of	IN	_	20	case
20	ABT	ABT	NNP	_	18	nmod
21	-	-	:	_	20	punct
22	737	737	CD	_	20	nummod
23	and	and	CC	_	20	cc
24	DZNep	dznep	NN	_	20	conj
25	could	could	MD	_	27	aux
26	synergistically	synergistically	RB	_	27	advmod
27	induced	induce	VBN	_	8	conj
28	apoptosis	apoptosis	NN	_	27	dobj
29	.	.	.	_	8	punct

1	These	these	DT	_	2	det
2	results	result	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	8	mark
5	DZNep	dznep	NN	_	8	nsubjpass
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	exploited	exploit	VBN	_	3	ccomp
9	therapeutically	therapeutically	RB	_	8	advmod
10	for	for	IN	_	12	case
11	a	a	DT	_	12	det
12	subset	subset	NN	_	8	nmod
13	of	of	IN	_	14	case
14	MM	mm	NN	_	12	nmod
15	.	.	.	_	3	punct

1	Drug	drug	NN	_	2	compound
2	interaction	interaction	NN	_	0	ROOT
3	of	of	IN	_	4	case
4	levothyroxine	levothyroxine	NN	_	2	nmod
5	with	with	IN	_	8	case
6	infant	infant	NN	_	8	compound
7	colic	colic	JJ	_	8	amod
8	drops	drop	NNS	_	2	nmod
9	.	.	.	_	2	punct

1	Infacol	Infacol	NNP	_	5	compound
2	(	(	NNP	_	5	compound
3	Forest	Forest	NNP	_	5	compound
4	Laboratories	Laboratories	NNP	_	5	compound
5	UK	UK	NNP	_	14	nsubj
6	,	,	,	_	5	punct
7	Kent	Kent	NNP	_	5	appos
8	,	,	,	_	5	punct
9	UK	UK	NNP	_	5	appos
10	)	)	CD	_	9	nummod
11	is	be	VBZ	_	14	cop
12	a	a	DT	_	14	det
13	widely	widely	RB	_	14	advmod
14	available	available	JJ	_	0	ROOT
15	over	over	IN	_	20	case
16	-	-	:	_	20	punct
17	the	the	DT	_	20	det
18	-	-	:	_	20	punct
19	counter	counter	RB	_	20	amod
20	preparation	preparation	NN	_	14	nmod
21	used	use	VBN	_	20	acl
22	to	to	TO	_	23	mark
23	relieve	relieve	VB	_	21	xcomp
24	colic	colic	JJ	_	25	amod
25	symptoms	symptom	NNS	_	23	dobj
26	in	in	IN	_	27	case
27	neonates	neonate	NNS	_	25	nmod
28	and	and	CC	_	27	cc
29	infants	infant	NNS	_	27	conj
30	.	.	.	_	14	punct

1	The	the	DT	_	3	det
2	active	active	JJ	_	3	amod
3	ingredient	ingredient	NN	_	5	nsubj
4	is	be	VBZ	_	5	cop
5	simeticone	simeticone	NN	_	0	ROOT
6	.	.	.	_	5	punct

1	No	no	DT	_	3	neg
2	drug	drug	NN	_	3	compound
3	interactions	interaction	NNS	_	7	nsubjpass
4	with	with	IN	_	5	case
5	simeticone	simeticone	NN	_	3	nmod
6	are	be	VBP	_	7	auxpass
7	documented	document	VBN	_	0	ROOT
8	in	in	IN	_	11	case
9	the	the	DT	_	11	det
10	current	current	JJ	_	11	amod
11	summary	summary	NN	_	7	nmod
12	of	of	IN	_	14	case
13	product	product	NN	_	14	compound
14	characteristics	characteristic	NNS	_	11	nmod
15	.	.	.	_	7	punct

1	The	the	DT	_	2	det
2	authors	author	NNS	_	3	nsubj
3	report	report	VBP	_	0	ROOT
4	the	the	DT	_	5	det
5	case	case	NN	_	3	dobj
6	of	of	IN	_	8	case
7	an	a	DT	_	8	det
8	infant	infant	NN	_	5	nmod
9	with	with	IN	_	12	case
10	confirmed	confirm	VBN	_	12	amod
11	congenital	congenital	JJ	_	12	amod
12	hypothyroidism	hypothyroidism	NN	_	8	nmod
13	on	on	IN	_	14	case
14	levothyroxine	levothyroxine	NN	_	12	nmod
15	who	who	WP	_	16	nsubj
16	experienced	experience	VBD	_	8	acl:relcl
17	a	a	DT	_	20	det
18	possible	possible	JJ	_	20	amod
19	drug	drug	NN	_	20	compound
20	interaction	interaction	NN	_	16	dobj
21	with	with	IN	_	22	case
22	simeticone	simeticone	NN	_	20	nmod
23	.	.	.	_	3	punct

1	Despite	despite	IN	_	4	case
2	adequate	adequate	JJ	_	4	amod
3	levothyroxine	levothyroxine	NN	_	4	compound
4	dosage	dosage	NN	_	13	nmod
5	,	,	,	_	13	punct
6	thyroid	thyroid	NN	_	11	compound
7	stimulating	stimulating	NN	_	11	compound
8	hormone	hormone	NN	_	11	compound
9	(	(	CD	_	11	nummod
10	TSH	tsh	NN	_	11	compound
11	)	)	NN	_	13	nsubj
12	was	be	VBD	_	13	cop
13	high	high	JJ	_	0	ROOT
14	,	,	,	_	13	punct
15	suggesting	suggest	VBG	_	13	xcomp
16	undertreatment	undertreatment	NN	_	15	dobj
17	.	.	.	_	13	punct

1	Questioning	question	VBG	_	2	nsubj
2	revealed	reveal	VBD	_	0	ROOT
3	the	the	DT	_	4	det
4	child	child	NN	_	6	nsubj
5	was	be	VBD	_	6	aux
6	taking	take	VBG	_	2	ccomp
7	Infacol	Infacol	NNP	_	8	nsubj
8	drops	drop	VBZ	_	6	ccomp
9	before	before	IN	_	10	mark
10	feeds	feed	VBZ	_	8	advcl
11	while	while	IN	_	13	mark
12	on	on	IN	_	13	case
13	levothyroxine	levothyroxine	NN	_	10	advcl
14	.	.	.	_	2	punct

1	The	the	DT	_	3	det
2	colic	colic	JJ	_	3	amod
3	drops	drop	NNS	_	6	nsubjpass
4	were	be	VBD	_	6	auxpass
5	immediately	immediately	RB	_	6	advmod
6	discontinued	discontinue	VBN	_	0	ROOT
7	and	and	CC	_	6	cc
8	TSH	tsh	NN	_	10	nsubj
9	promptly	promptly	RB	_	10	advmod
10	normalised	normalise	VBD	_	6	conj
11	with	with	IN	_	13	case
12	a	a	DT	_	13	det
13	reduction	reduction	NN	_	10	nmod
14	in	in	IN	_	16	case
15	thyroxine	thyroxine	NN	_	16	compound
16	requirement	requirement	NN	_	13	nmod
17	to	to	TO	_	21	case
18	an	a	DT	_	21	det
19	age	age	NN	_	21	compound
20	appropriate	appropriate	JJ	_	21	amod
21	dosage	dosage	NN	_	13	nmod
22	.	.	.	_	6	punct

1	Drug	drug	NN	_	2	compound
2	interaction	interaction	NN	_	10	nsubjpass
3	of	of	IN	_	4	case
4	thyroxine	thyroxine	NN	_	2	nmod
5	with	with	IN	_	6	case
6	simeticone	simeticone	NN	_	2	nmod
7	has	have	VBZ	_	10	aux
8	not	not	RB	_	10	neg
9	been	be	VBN	_	10	auxpass
10	reported	report	VBN	_	0	ROOT
11	previously	previously	RB	_	10	advmod
12	and	and	CC	_	10	cc
13	is	be	VBZ	_	15	auxpass
14	not	not	RB	_	15	neg
15	listed	list	VBN	_	10	conj
16	in	in	IN	_	20	case
17	the	the	DT	_	20	det
18	British	British	NNP	_	20	compound
19	National	National	NNP	_	20	compound
20	Formulary	Formulary	NNP	_	15	nmod
21	for	for	IN	_	22	case
22	Children	Children	NNP	_	15	nmod
23	.	.	.	_	10	punct

1	Clinicians	clinician	NNS	_	4	nsubj
2	and	and	CC	_	1	cc
3	parents	parent	NNS	_	1	conj
4	need	need	VBP	_	0	ROOT
5	to	to	TO	_	7	mark
6	be	be	VB	_	7	cop
7	aware	aware	JJ	_	4	xcomp
8	of	of	IN	_	10	case
9	this	this	DT	_	10	det
10	interaction	interaction	NN	_	7	nmod
11	to	to	TO	_	12	mark
12	avoid	avoid	VB	_	10	acl
13	unnecessary	unnecessary	JJ	_	14	amod
14	undertreatment	undertreatment	NN	_	12	dobj
15	and	and	CC	_	12	cc
16	prevent	prevent	VB	_	12	conj
17	potential	potential	JJ	_	22	amod
18	long	long	JJ	_	22	amod
19	-	-	:	_	22	punct
20	term	term	NN	_	22	compound
21	neurological	neurological	JJ	_	22	amod
22	sequelae	sequelae	NN	_	16	dobj
23	.	.	.	_	4	punct

1	Amphetamine	Amphetamine	NNP	_	3	compound
2	locomotor	locomotor	NN	_	3	compound
3	sensitization	sensitization	NN	_	0	ROOT
4	and	and	CC	_	3	cc
5	conditioned	condition	VBN	_	7	amod
6	place	place	NN	_	7	compound
7	preference	preference	NN	_	3	conj
8	in	in	IN	_	10	case
9	adolescent	adolescent	JJ	_	10	amod
10	male	male	NN	_	3	nmod
11	and	and	CC	_	10	cc
12	female	female	JJ	_	13	amod
13	rats	rat	NNS	_	10	conj
14	neonatally	neonatally	RB	_	15	advmod
15	treated	treat	VBN	_	10	acl
16	with	with	IN	_	17	case
17	quinpirole	quinpirole	NN	_	15	nmod
18	.	.	.	_	3	punct

1	Neonatal	neonatal	JJ	_	3	amod
2	quinpirole	quinpirole	NN	_	3	compound
3	treatment	treatment	NN	_	6	nsubjpass
4	has	have	VBZ	_	6	aux
5	been	be	VBN	_	6	auxpass
6	shown	show	VBN	_	0	ROOT
7	to	to	TO	_	8	mark
8	produce	produce	VB	_	6	xcomp
9	an	a	DT	_	10	det
10	increase	increase	NN	_	8	dobj
11	in	in	IN	_	13	case
12	dopamine	dopamine	NN	_	13	compound
13	D2	d2	NN	_	10	nmod
14	-	-	:	_	10	punct
15	like	like	IN	_	17	case
16	receptor	receptor	NN	_	17	compound
17	sensitivity	sensitivity	NN	_	10	nmod
18	that	that	WDT	_	19	nsubj
19	persists	persist	VBZ	_	17	acl:relcl
20	throughout	throughout	IN	_	25	case
21	the	the	DT	_	25	det
22	subject	subject	JJ	_	25	amod
23	'	'	''	_	25	punct
24	s	s	NNS	_	25	compound
25	lifetime	lifetime	NN	_	19	nmod
26	.	.	.	_	6	punct

1	The	the	DT	_	2	det
2	objective	objective	NN	_	3	nsubj
3	was	be	VBD	_	0	ROOT
4	to	to	TO	_	5	mark
5	analyze	analyze	VB	_	3	xcomp
6	the	the	DT	_	7	det
7	effects	effect	NNS	_	5	dobj
8	of	of	IN	_	11	case
9	neonatal	neonatal	JJ	_	11	amod
10	quinpirole	quinpirole	NN	_	11	compound
11	treatment	treatment	NN	_	7	nmod
12	on	on	IN	_	13	case
13	effects	effect	NNS	_	7	nmod
14	of	of	IN	_	15	case
15	amphetamine	amphetamine	NN	_	13	nmod
16	in	in	IN	_	18	case
17	adolescent	adolescent	JJ	_	18	amod
18	rats	rat	NNS	_	13	nmod
19	using	use	VBG	_	5	xcomp
20	locomotor	locomotor	JJ	_	21	amod
21	sensitization	sensitization	NN	_	19	dobj
22	and	and	CC	_	21	cc
23	conditioned	condition	VBN	_	26	amod
24	place	place	NN	_	26	compound
25	preference	preference	NN	_	26	compound
26	procedures	procedure	NNS	_	21	conj
27	.	.	.	_	3	punct

1	Sprague	Sprague	NNP	_	0	ROOT
2	-	-	:	_	1	punct
3	Dawley	Dawley	NNP	_	4	compound
4	rats	rat	NNS	_	6	nsubjpass
5	were	be	VBD	_	6	auxpass
6	treated	treat	VBN	_	1	dep
7	with	with	IN	_	11	case
8	quinpirole	quinpirole	NN	_	11	compound
9	(	(	NN	_	11	compound
10	1	1	CD	_	11	nummod
11	mg	mg	NN	_	6	nmod
12	/	/	:	_	11	punct
13	kg	kg	NN	_	14	compound
14	)	)	NN	_	11	dep
15	or	or	CC	_	14	cc
16	saline	saline	NN	_	14	conj
17	from	from	IN	_	19	case
18	postnatal	postnatal	JJ	_	19	amod
19	days	day	NNS	_	6	nmod
20	(	(	VBP	_	6	dep
21	P	p	NN	_	20	dobj
22	)	)	CD	_	23	compound
23	1	1	CD	_	21	nummod
24	to	to	TO	_	25	case
25	P11	p11	CD	_	20	nmod
26	and	and	CC	_	6	cc
27	raised	raise	VBD	_	6	conj
28	to	to	TO	_	29	case
29	adolescence	adolescence	NN	_	27	nmod
30	.	.	.	_	1	punct

1	For	for	IN	_	3	case
2	locomotor	locomotor	JJ	_	3	amod
3	sensitization	sensitization	NN	_	7	nmod
4	,	,	,	_	7	punct
5	subjects	subject	NNS	_	7	nsubjpass
6	were	be	VBD	_	7	auxpass
7	given	give	VBN	_	0	ROOT
8	amphetamine	amphetamine	NN	_	11	compound
9	(	(	NN	_	11	compound
10	1	1	CD	_	11	nummod
11	mg	mg	NN	_	7	iobj
12	/	/	:	_	11	punct
13	kg	kg	NN	_	14	compound
14	)	)	NN	_	11	dep
15	or	or	CC	_	14	cc
16	saline	saline	NN	_	14	conj
17	every	every	DT	_	19	det
18	second	second	JJ	_	19	amod
19	day	day	NN	_	7	nmod:tmod
20	from	from	IN	_	21	case
21	P35	p35	NN	_	7	nmod
22	to	to	TO	_	23	case
23	P47	p47	NN	_	21	nmod
24	and	and	CC	_	7	cc
25	were	be	VBD	_	26	auxpass
26	placed	place	VBN	_	7	conj
27	into	into	IN	_	30	case
28	a	a	DT	_	30	det
29	locomotor	locomotor	JJ	_	30	amod
30	arena	arena	NN	_	26	nmod
31	.	.	.	_	7	punct

1	In	in	IN	_	3	case
2	female	female	JJ	_	3	amod
3	rats	rat	NNS	_	8	nmod
4	,	,	,	_	8	punct
5	neonatal	neonatal	JJ	_	7	amod
6	quinpirole	quinpirole	NN	_	7	compound
7	treatment	treatment	NN	_	8	nsubj
8	enhanced	enhance	VBD	_	0	ROOT
9	amphetamine	amphetamine	NN	_	11	compound
10	locomotor	locomotor	NN	_	11	compound
11	sensitization	sensitization	NN	_	8	dobj
12	compared	compare	VBN	_	14	case
13	with	with	IN	_	14	case
14	quinpirole	quinpirole	NN	_	8	advcl
15	-	-	:	_	14	punct
16	free	free	JJ	_	17	amod
17	controls	control	NNS	_	14	dep
18	sensitized	sensitize	VBN	_	17	acl
19	to	to	TO	_	20	case
20	amphetamine	amphetamine	NN	_	18	nmod
21	.	.	.	_	8	punct

1	Male	male	JJ	_	2	amod
2	rats	rat	NNS	_	3	nsubj
3	demonstrated	demonstrate	VBD	_	0	ROOT
4	sensitization	sensitization	NN	_	3	dobj
5	to	to	TO	_	6	case
6	amphetamine	amphetamine	NN	_	4	nmod
7	,	,	,	_	3	punct
8	although	although	IN	_	11	mark
9	this	this	DT	_	11	nsubjpass
10	was	be	VBD	_	11	auxpass
11	muted	mute	VBN	_	3	advcl
12	compared	compare	VBN	_	15	case
13	with	with	IN	_	15	case
14	female	female	JJ	_	15	amod
15	rats	rat	NNS	_	11	advcl
16	,	,	,	_	3	punct
17	and	and	CC	_	3	cc
18	were	be	VBD	_	19	aux
19	unaffected	unaffected	JJ	_	3	conj
20	by	by	IN	_	22	case
21	neonatal	neonatal	JJ	_	22	amod
22	quinpirole	quinpirole	NN	_	19	nmod
23	.	.	.	_	3	punct

1	For	for	IN	_	4	case
2	conditioned	condition	VBN	_	4	amod
3	place	place	NN	_	4	compound
4	preference	preference	NN	_	8	nmod
5	,	,	,	_	8	punct
6	subjects	subject	NNS	_	8	nsubjpass
7	were	be	VBD	_	8	auxpass
8	conditioned	condition	VBN	_	0	ROOT
9	for	for	IN	_	12	case
10	8	8	CD	_	12	nummod
11	consecutive	consecutive	JJ	_	12	amod
12	days	day	NNS	_	8	nmod
13	(	(	VBP	_	8	dep
14	P32	p32	NN	_	17	compound
15	-	-	:	_	17	punct
16	39	39	CD	_	17	nummod
17	)	)	NN	_	13	dobj
18	with	with	IN	_	22	case
19	amphetamine	amphetamine	NN	_	22	compound
20	(	(	NN	_	22	compound
21	1	1	CD	_	22	nummod
22	mg	mg	NN	_	17	nmod
23	/	/	:	_	17	punct
24	kg	kg	NN	_	25	compound
25	)	)	NN	_	17	dep
26	or	or	CC	_	25	cc
27	saline	saline	NN	_	25	conj
28	and	and	CC	_	17	cc
29	a	a	DT	_	30	det
30	drug	drug	NN	_	17	conj
31	-	-	:	_	30	punct
32	free	free	JJ	_	34	amod
33	preference	preference	NN	_	34	compound
34	test	test	NN	_	36	nsubjpass
35	was	be	VBD	_	36	auxpass
36	conducted	conduct	VBN	_	30	dep
37	at	at	IN	_	38	case
38	P40	p40	NN	_	36	nmod
39	.	.	.	_	8	punct

1	Rats	rat	NNS	_	6	nsubj
2	treated	treat	VBN	_	1	acl
3	with	with	IN	_	5	case
4	neonatal	neonatal	JJ	_	5	amod
5	quinpirole	quinpirole	NN	_	2	nmod
6	enhanced	enhance	VBD	_	0	ROOT
7	time	time	NN	_	6	dobj
8	spent	spend	VBN	_	7	acl
9	in	in	IN	_	14	case
10	the	the	DT	_	14	det
11	amphetamine	amphetamine	NN	_	14	compound
12	-	-	:	_	14	punct
13	paired	paired	JJ	_	14	amod
14	context	context	NN	_	8	nmod
15	compared	compare	VBN	_	17	case
16	with	with	IN	_	17	case
17	quinpirole	quinpirole	NN	_	6	advcl
18	-	-	:	_	17	punct
19	free	free	JJ	_	20	amod
20	controls	control	NNS	_	17	dep
21	conditioned	condition	VBN	_	20	acl
22	with	with	IN	_	23	case
23	amphetamine	amphetamine	NN	_	21	nmod
24	,	,	,	_	6	punct
25	but	but	CC	_	6	cc
26	only	only	RB	_	28	advmod
27	female	female	JJ	_	28	amod
28	controls	control	NNS	_	32	nsubj
29	conditioned	condition	VBN	_	28	acl
30	with	with	IN	_	31	case
31	amphetamine	amphetamine	NN	_	29	nmod
32	spent	spend	VBD	_	6	conj
33	more	more	JJR	_	34	amod
34	time	time	NN	_	32	dobj
35	in	in	IN	_	37	case
36	the	the	DT	_	37	det
37	drug	drug	NN	_	32	nmod
38	-	-	:	_	32	punct
39	paired	paired	JJ	_	40	amod
40	context	context	NN	_	32	dobj
41	compared	compare	VBN	_	43	case
42	with	with	IN	_	43	case
43	saline	saline	NN	_	40	nmod
44	-	-	:	_	43	punct
45	treated	treat	VBN	_	46	amod
46	controls	control	NNS	_	43	dep
47	.	.	.	_	6	punct

1	Increased	increase	VBN	_	2	amod
2	D	d	NN	_	7	nsubj
3	-	-	:	_	2	punct
4	like	like	IN	_	6	case
5	receptor	receptor	NN	_	6	compound
6	sensitivity	sensitivity	NN	_	2	nmod
7	appears	appear	VBZ	_	0	ROOT
8	to	to	TO	_	10	mark
9	have	have	VB	_	10	aux
10	enhanced	enhance	VBN	_	7	xcomp
11	the	the	DT	_	13	det
12	behavioral	behavioral	JJ	_	13	amod
13	effects	effect	NNS	_	10	dobj
14	of	of	IN	_	15	case
15	amphetamine	amphetamine	NN	_	13	nmod
16	,	,	,	_	7	punct
17	but	but	CC	_	7	cc
18	these	these	DT	_	19	det
19	effects	effect	NNS	_	22	nsubj
20	were	be	VBD	_	22	cop
21	more	more	RBR	_	22	advmod
22	prevalent	prevalent	JJ	_	7	conj
23	in	in	IN	_	26	case
24	adolescent	adolescent	JJ	_	26	amod
25	female	female	JJ	_	26	amod
26	rats	rat	NNS	_	22	nmod
27	compared	compare	VBN	_	30	case
28	with	with	IN	_	30	case
29	male	male	JJ	_	30	amod
30	rats	rat	NNS	_	22	advcl
31	.	.	.	_	7	punct

1	Effect	effect	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	ketoconazole	ketoconazole	NN	_	1	nmod
4	-	-	:	_	1	punct
5	mediated	mediate	VBN	_	7	amod
6	CYP3A4	cyp3a4	NN	_	7	compound
7	inhibition	inhibition	NN	_	1	dep
8	on	on	IN	_	10	case
9	clinical	clinical	JJ	_	10	amod
10	pharmacokinetics	pharmacokinetic	NNS	_	7	nmod
11	of	of	IN	_	15	case
12	panobinostat	panobinostat	NN	_	15	compound
13	(	(	CD	_	15	nummod
14	LBH589	lbh589	NN	_	15	compound
15	)	)	NN	_	10	nmod
16	,	,	,	_	15	punct
17	an	a	DT	_	22	det
18	orally	orally	RB	_	19	advmod
19	active	active	JJ	_	22	amod
20	histone	histone	NN	_	22	compound
21	deacetylase	deacetylase	NN	_	22	compound
22	inhibitor	inhibitor	NN	_	15	appos
23	.	.	.	_	1	punct

1	Panobinostat	panobinostat	NN	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	partly	partly	RB	_	4	advmod
4	metabolized	metabolize	VBN	_	0	ROOT
5	by	by	IN	_	6	case
6	CYP3A4	cyp3a4	NN	_	4	nmod
7	in	in	FW	_	8	compound
8	vitro	vitro	FW	_	4	advmod
9	.	.	.	_	4	punct

1	This	this	DT	_	2	det
2	study	study	NN	_	3	nsubj
3	evaluated	evaluate	VBD	_	0	ROOT
4	the	the	DT	_	5	det
5	effect	effect	NN	_	3	dobj
6	of	of	IN	_	10	case
7	a	a	DT	_	10	det
8	potent	potent	JJ	_	10	amod
9	CYP3A	cyp3a	NN	_	10	compound
10	inhibitor	inhibitor	NN	_	5	nmod
11	,	,	,	_	10	punct
12	ketoconazole	ketoconazole	NN	_	10	appos
13	,	,	,	_	10	punct
14	on	on	IN	_	16	case
15	the	the	DT	_	16	det
16	pharmacokinetics	pharmacokinetic	NNS	_	5	nmod
17	and	and	CC	_	16	cc
18	safety	safety	NN	_	16	conj
19	of	of	IN	_	20	case
20	panobinostat	panobinostat	NN	_	16	nmod
21	.	.	.	_	3	punct

1	Patients	patient	NNS	_	2	nsubj
2	received	receive	VBD	_	0	ROOT
3	a	a	DT	_	7	det
4	single	single	JJ	_	7	amod
5	panobinostat	panobinostat	NN	_	7	compound
6	oral	oral	JJ	_	7	amod
7	dose	dose	NN	_	2	dobj
8	on	on	IN	_	9	case
9	day	day	NN	_	2	nmod
10	1	1	CD	_	9	nummod
11	,	,	,	_	2	punct
12	followed	follow	VBN	_	2	dep
13	by	by	IN	_	15	case
14	4	4	CD	_	15	nummod
15	days	day	NNS	_	12	nmod
16	wash	wash	NN	_	15	dep
17	-	-	:	_	16	punct
18	out	out	IN	_	19	case
19	period	period	NN	_	16	nmod
20	.	.	.	_	2	punct

1	On	on	IN	_	2	case
2	days	day	NNS	_	9	nmod
3	5	5	LS	_	9	dep
4	-	-	:	_	3	punct
5	9	9	CD	_	9	dep
6	,	,	,	_	9	punct
7	ketoconazole	ketoconazole	NN	_	9	nsubjpass
8	was	be	VBD	_	9	auxpass
9	administered	administer	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	On	on	IN	_	2	case
2	day	day	NN	_	10	nmod
3	8	8	CD	_	2	nummod
4	,	,	,	_	10	punct
5	a	a	DT	_	8	det
6	single	single	JJ	_	8	amod
7	panobinostat	panobinostat	NN	_	8	compound
8	dose	dose	NN	_	10	nsubj
9	was	be	VBD	_	10	cop
10	co	co	SYM	_	0	ROOT
11	-	-	:	_	10	punct
12	administered	administer	VBN	_	10	dep
13	with	with	IN	_	14	case
14	ketoconazole	ketoconazole	NN	_	12	nmod
15	.	.	.	_	10	punct

1	Panobinostat	panobinostat	NN	_	3	nsubjpass
2	was	be	VBD	_	3	auxpass
3	administered	administer	VBN	_	0	ROOT
4	as	as	IN	_	6	case
5	single	single	JJ	_	6	amod
6	agent	agent	NN	_	3	nmod
7	three	three	CD	_	8	nummod
8	times	time	NNS	_	3	nmod:tmod
9	a	a	DT	_	10	det
10	week	week	NN	_	8	nmod:npmod
11	on	on	IN	_	12	case
12	day	day	NN	_	3	nmod
13	15	15	CD	_	12	nummod
14	and	and	CC	_	12	cc
15	onward	onward	RB	_	12	conj
16	.	.	.	_	3	punct

1	In	in	IN	_	5	case
2	the	the	DT	_	5	dep
3	presence	presence	NN	_	5	dep
4	of	of	IN	_	5	case
5	ketoconazole	ketoconazole	NN	_	8	nmod
6	,	,	,	_	8	punct
7	there	there	EX	_	8	expl
8	was	be	VBD	_	0	ROOT
9	1.6	1.6	CD	_	8	nsubj
10	-	-	:	_	9	punct
11	and	and	CC	_	9	cc
12	1.8	1.8	CD	_	9	conj
13	-	-	:	_	9	punct
14	fold	fold	JJ	_	15	amod
15	increase	increase	NN	_	9	dep
16	in	in	IN	_	20	case
17	C	c	NN	_	20	compound
18	(	(	CD	_	20	nummod
19	max	max	NN	_	20	compound
20	)	)	NN	_	15	nmod
21	and	and	CC	_	15	cc
22	AUC	auc	NN	_	15	conj
23	of	of	IN	_	24	case
24	panobinostat	panobinostat	NN	_	22	nmod
25	,	,	,	_	9	punct
26	respectively	respectively	RB	_	9	advmod
27	.	.	.	_	8	punct

1	No	no	DT	_	3	neg
2	substantial	substantial	JJ	_	3	amod
3	change	change	NN	_	14	nsubjpass
4	in	in	IN	_	7	case
5	T	t	NN	_	7	compound
6	(	(	CD	_	7	nummod
7	max	max	NN	_	3	nmod
8	)	)	CD	_	7	nummod
9	or	or	CC	_	7	cc
10	half	half	NN	_	7	conj
11	-	-	:	_	3	punct
12	life	life	NN	_	3	dep
13	was	be	VBD	_	14	auxpass
14	observed	observe	VBN	_	0	ROOT
15	.	.	.	_	14	punct

1	No	no	DT	_	2	neg
2	difference	difference	NN	_	0	ROOT
3	in	in	IN	_	4	case
4	panobinostat	panobinostat	NN	_	2	nmod
5	-	-	:	_	2	punct
6	pharmacokinetics	pharmacokinetic	NNS	_	2	dep
7	between	between	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	carrying	carry	VBG	_	8	acl
10	CYP3A5	cyp3a5	NN	_	9	dobj
11	*	*	SYM	_	12	dep
12	1	1	CD	_	25	nsubjpass
13	/	/	:	_	12	punct
14	*	*	SYM	_	15	dep
15	3	3	CD	_	12	dep
16	and	and	CC	_	15	cc
17	CYP3A5	cyp3a5	NN	_	19	dep
18	*	*	SYM	_	19	dep
19	3	3	CD	_	15	conj
20	/	/	:	_	12	punct
21	*	*	SYM	_	22	dep
22	3	3	CD	_	23	nummod
23	alleles	allele	NNS	_	12	dep
24	was	be	VBD	_	25	auxpass
25	observed	observe	VBN	_	8	acl:relcl
26	.	.	.	_	2	punct

1	Most	most	JJS	_	3	nsubj
2	frequently	frequently	RB	_	3	advmod
3	reported	report	VBN	_	0	ROOT
4	adverse	adverse	JJ	_	5	amod
5	events	event	NNS	_	8	nsubj
6	were	be	VBD	_	8	cop
7	gastrointestinal	gastrointestinal	JJ	_	8	amod
8	related	related	JJ	_	3	ccomp
9	.	.	.	_	3	punct

1	Patients	patient	NNS	_	2	nsubj
2	had	have	VBD	_	0	ROOT
3	asymptomatic	asymptomatic	JJ	_	5	amod
4	hypophosphatemia	hypophosphatemia	NN	_	5	compound
5	(	(	NN	_	13	nsubj
6	64	64	CD	_	7	nummod
7	%	%	NN	_	5	dep
8	)	)	CD	_	7	nummod
9	,	,	,	_	5	punct
10	and	and	CC	_	5	cc
11	urine	urine	NN	_	12	compound
12	analysis	analysis	NN	_	5	conj
13	suggested	suggest	VBD	_	2	ccomp
14	renal	renal	JJ	_	15	amod
15	phosphate	phosphate	NN	_	16	nsubj
16	wasting	waste	VBG	_	13	ccomp
17	.	.	.	_	2	punct

1	Co	Co	NNP	_	0	ROOT
2	-	-	:	_	1	punct
3	administration	administration	NN	_	10	nsubj
4	of	of	IN	_	5	case
5	panobinostat	panobinostat	NN	_	3	nmod
6	with	with	IN	_	8	case
7	CYP3A	cyp3a	NN	_	8	compound
8	inhibitors	inhibitor	NNS	_	3	nmod
9	is	be	VBZ	_	10	cop
10	feasible	feasible	JJ	_	1	dep
11	as	as	IN	_	14	case
12	the	the	DT	_	14	det
13	observed	observe	VBN	_	14	amod
14	increase	increase	NN	_	10	nmod
15	in	in	IN	_	18	case
16	panobinostat	panobinostat	NN	_	18	compound
17	PK	pk	NN	_	18	compound
18	parameters	parameter	NNS	_	14	nmod
19	was	be	VBD	_	21	auxpass
20	not	not	RB	_	21	neg
21	considered	consider	VBN	_	10	dep
22	clinically	clinically	RB	_	23	advmod
23	relevant	relevant	JJ	_	21	xcomp
24	.	.	.	_	1	punct

1	Considering	consider	VBG	_	0	ROOT
2	the	the	DT	_	3	det
3	variability	variability	NN	_	1	dobj
4	in	in	IN	_	5	case
5	exposure	exposure	NN	_	1	nmod
6	following	follow	VBG	_	8	case
7	enzyme	enzyme	NN	_	8	compound
8	inhibition	inhibition	NN	_	5	nmod
9	and	and	CC	_	1	cc
10	the	the	DT	_	11	det
11	fact	fact	NN	_	1	conj
12	that	that	IN	_	19	mark
13	chronic	chronic	JJ	_	14	amod
14	dosing	dosing	NN	_	19	nsubjpass
15	of	of	IN	_	16	case
16	panobinostat	panobinostat	NN	_	14	nmod
17	was	be	VBD	_	19	auxpass
18	not	not	RB	_	19	neg
19	studied	study	VBN	_	11	ccomp
20	with	with	IN	_	22	case
21	CYP3A	cyp3a	NN	_	22	compound
22	inhibitors	inhibitor	NNS	_	33	nmod
23	,	,	,	_	22	punct
24	close	close	JJ	_	25	amod
25	monitoring	monitoring	NN	_	22	appos
26	of	of	IN	_	27	case
27	panobinostat	panobinostat	NN	_	25	nmod
28	-	-	:	_	22	punct
29	related	related	JJ	_	31	amod
30	adverse	adverse	JJ	_	31	amod
31	events	event	NNS	_	33	nsubj
32	is	be	VBZ	_	33	cop
33	necessary	necessary	JJ	_	19	ccomp
34	.	.	.	_	1	punct

1	Effects	effect	NNS	_	0	ROOT
2	of	of	IN	_	4	case
3	CYP	cyp	NN	_	4	compound
4	inhibitors	inhibitor	NNS	_	1	nmod
5	on	on	IN	_	1	advmod
6	precocene	precocene	NN	_	5	dep
7	I	I	PRP	_	6	dep
8	metabolism	metabolism	NN	_	7	dep
9	and	and	CC	_	8	cc
10	toxicity	toxicity	NN	_	8	conj
11	in	in	IN	_	14	case
12	rat	rat	NN	_	14	compound
13	liver	liver	NN	_	14	compound
14	slices	slice	NNS	_	7	nmod
15	.	.	.	_	1	punct

1	We	we	PRP	_	2	nsubj
2	present	present	VBP	_	0	ROOT
3	a	a	DT	_	7	det
4	comprehensive	comprehensive	JJ	_	7	amod
5	in	in	FW	_	7	amod
6	vitro	vitro	FW	_	5	dep
7	approach	approach	NN	_	2	dobj
8	to	to	TO	_	9	mark
9	assessing	assess	VBG	_	7	acl
10	metabolism	metabolism	NN	_	13	compound
11	-	-	:	_	13	punct
12	mediated	mediate	VBN	_	13	amod
13	hepatotoxicity	hepatotoxicity	NN	_	9	dobj
14	using	use	VBG	_	13	acl
15	male	male	JJ	_	16	amod
16	Sprague	sprague	NN	_	14	dobj
17	-	-	:	_	16	punct
18	Dawley	Dawley	NNP	_	21	compound
19	rat	rat	NN	_	21	compound
20	liver	liver	NN	_	21	compound
21	slices	slice	NNS	_	16	dep
22	incubated	incubate	VBN	_	21	acl
23	with	with	IN	_	27	case
24	the	the	DT	_	27	det
25	well	well	RB	_	26	advmod
26	characterized	characterize	VBN	_	27	amod
27	hepatotoxicant	hepatotoxicant	NN	_	22	nmod
28	,	,	,	_	2	punct
29	precocene	precocene	NN	_	30	compound
30	I	I	PRP	_	2	dobj
31	,	,	,	_	30	punct
32	and	and	CC	_	30	cc
33	inhibitors	inhibitor	NNS	_	30	conj
34	of	of	IN	_	40	case
35	cytochrome	cytochrome	NN	_	40	compound
36	P450	p450	NN	_	40	compound
37	(	(	CD	_	40	nummod
38	CYP	cyp	NN	_	40	compound
39	)	)	NN	_	40	compound
40	enzymes	enzyme	NNS	_	33	nmod
41	.	.	.	_	2	punct

1	This	this	DT	_	2	det
2	approach	approach	NN	_	3	nsubj
3	combines	combine	VBZ	_	0	ROOT
4	liquid	liquid	JJ	_	13	amod
5	chromatography	chromatography	NN	_	13	compound
6	mass	mass	NN	_	13	compound
7	spectrometry	spectrometry	NN	_	13	compound
8	(	(	CD	_	13	nummod
9	LC	lc	NN	_	13	compound
10	MS	ms	NN	_	13	compound
11	)	)	CD	_	13	nummod
12	detection	detection	NN	_	13	compound
13	methods	method	NNS	_	3	dobj
14	with	with	IN	_	17	case
15	multiple	multiple	JJ	_	17	amod
16	toxicity	toxicity	NN	_	17	compound
17	endpoints	endpoint	NNS	_	13	nmod
18	to	to	TO	_	19	mark
19	enable	enable	VB	_	3	advcl
20	identification	identification	NN	_	19	dobj
21	of	of	IN	_	24	case
22	critical	critical	JJ	_	24	amod
23	metabolic	metabolic	JJ	_	24	amod
24	pathways	pathway	NNS	_	20	nmod
25	for	for	IN	_	26	case
26	hepatotoxicity	hepatotoxicity	NN	_	24	nmod
27	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	incubations	incubation	NNS	_	4	nsubjpass
3	were	be	VBD	_	4	auxpass
4	performed	perform	VBN	_	0	ROOT
5	in	in	IN	_	7	case
6	the	the	DT	_	7	dep
7	absence	absence	NN	_	4	nmod
8	and	and	CC	_	7	cc
9	presence	presence	NN	_	7	conj
10	of	of	IN	_	16	case
11	the	the	DT	_	16	det
12	non	non	JJ	_	16	amod
13	-	-	:	_	16	punct
14	specific	specific	JJ	_	16	amod
15	CYP	cyp	NN	_	16	compound
16	inhibitor	inhibitor	NN	_	7	nmod
17	,	,	,	_	4	punct
18	1	1	LS	_	4	advcl
19	-	-	:	_	18	punct
20	aminobenzotriazole	aminobenzotriazole	NN	_	22	compound
21	(	(	CD	_	22	nummod
22	ABT	ABT	NNP	_	18	dep
23	)	)	CD	_	22	nummod
24	and	and	CC	_	22	cc
25	isoform	isoform	NN	_	28	compound
26	-	-	:	_	28	punct
27	specific	specific	JJ	_	28	amod
28	inhibitors	inhibitor	NNS	_	22	conj
29	.	.	.	_	4	punct

1	The	the	DT	_	3	det
2	metabolite	metabolite	NN	_	3	compound
3	profile	profile	NN	_	11	nsubj
4	of	of	IN	_	6	case
5	precocene	precocene	NN	_	6	compound
6	I	i	NN	_	3	nmod
7	in	in	IN	_	10	case
8	rat	rat	NN	_	10	compound
9	liver	liver	NN	_	10	compound
10	slices	slice	NNS	_	3	nmod
11	shares	share	VBZ	_	0	ROOT
12	some	some	DT	_	13	det
13	features	feature	NNS	_	11	dobj
14	of	of	IN	_	18	case
15	the	the	DT	_	18	det
16	in	in	FW	_	18	amod
17	vivo	vivo	FW	_	16	dep
18	profile	profile	NN	_	13	nmod
19	,	,	,	_	11	punct
20	but	but	CC	_	11	cc
21	also	also	RB	_	22	advmod
22	had	have	VBD	_	11	conj
23	a	a	DT	_	25	det
24	major	major	JJ	_	25	amod
25	difference	difference	NN	_	22	dobj
26	in	in	IN	_	34	mark
27	that	that	DT	_	34	mark
28	epoxide	epoxide	NN	_	31	compound
29	dihydrodiol	dihydrodiol	NN	_	31	compound
30	hydrolysis	hydrolysis	NN	_	31	compound
31	products	product	NNS	_	34	nsubjpass
32	were	be	VBD	_	34	auxpass
33	not	not	RB	_	34	neg
34	observed	observe	VBN	_	25	acl
35	to	to	TO	_	38	case
36	a	a	DT	_	38	det
37	measurable	measurable	JJ	_	38	amod
38	extent	extent	NN	_	34	nmod
39	.	.	.	_	11	punct

1	As	as	IN	_	2	case
2	examples	example	NNS	_	0	ROOT
3	of	of	IN	_	9	case
4	our	we	PRP$	_	9	nmod:poss
5	liver	liver	NN	_	9	compound
6	slice	slice	NN	_	9	compound
7	metabolite	metabolite	NN	_	9	compound
8	identification	identification	NN	_	9	compound
9	procedure	procedure	NN	_	2	nmod
10	,	,	,	_	2	punct
11	a	a	DT	_	14	det
12	minor	minor	JJ	_	14	amod
13	glutathione	glutathione	NN	_	14	compound
14	adduct	adduct	NN	_	10	root
15	and	and	CC	_	14	cc
16	previously	previously	RB	_	17	advmod
17	unreported	unreported	JJ	_	22	amod
18	7	7	CD	_	22	nummod
19	-	-	:	_	22	punct
20	O	o	SYM	_	22	dep
21	-	-	:	_	22	punct
22	desmethyl	desmethyl	NN	_	14	conj
23	and	and	CC	_	14	cc
24	glucuronidated	glucuronidate	VBN	_	25	amod
25	metabolites	metabolite	NNS	_	14	conj
26	of	of	IN	_	27	case
27	precocene	precocene	NN	_	25	nmod
28	I	I	PRP	_	30	nsubjpass
29	are	be	VBP	_	30	auxpass
30	reported	report	VBN	_	14	acl:relcl
31	.	.	.	_	14	punct

1	Precocene	precocene	NN	_	2	compound
2	I	i	NN	_	3	nsubj
3	induced	induce	VBD	_	0	ROOT
4	hepatocellular	hepatocellular	JJ	_	5	amod
5	necrosis	necrosis	NN	_	3	dobj
6	in	in	IN	_	8	case
7	a	a	DT	_	8	det
8	dose	dose	NN	_	3	nmod
9	-	-	:	_	3	punct
10	and	and	CC	_	3	cc
11	time	time	NN	_	14	dep
12	-	-	:	_	14	punct
13	dependent	dependent	JJ	_	14	amod
14	manner	manner	NN	_	3	conj
15	.	.	.	_	3	punct

1	ABT	ABT	NNP	_	2	nsubj
2	decreased	decrease	VBD	_	0	ROOT
3	the	the	DT	_	4	det
4	toxicity	toxicity	NN	_	2	dobj
5	of	of	IN	_	7	case
6	precocene	precocene	NN	_	7	compound
7	I	i	NN	_	4	nmod
8	,	,	,	_	2	punct
9	increased	increase	VBD	_	10	amod
10	exposure	exposure	NN	_	2	conj
11	to	to	TO	_	13	case
12	parent	parent	NN	_	13	compound
13	compound	compound	NN	_	10	nmod
14	,	,	,	_	2	punct
15	and	and	CC	_	2	cc
16	decreased	decrease	VBD	_	2	conj
17	metabolite	metabolite	NN	_	18	compound
18	levels	level	NNS	_	16	dobj
19	in	in	IN	_	24	case
20	a	a	DT	_	24	det
21	dose	dose	NN	_	24	compound
22	-	-	:	_	24	punct
23	dependent	dependent	JJ	_	24	amod
24	manner	manner	NN	_	16	nmod
25	.	.	.	_	2	punct

1	Of	of	IN	_	3	case
2	the	the	DT	_	3	det
3	isoform	isoform	NN	_	0	ROOT
4	-	-	:	_	7	punct
5	specific	specific	JJ	_	7	amod
6	CYP	cyp	NN	_	7	compound
7	inhibitors	inhibitor	NNS	_	3	dep
8	tested	test	VBN	_	7	acl
9	for	for	IN	_	11	case
10	an	a	DT	_	11	det
11	effect	effect	NN	_	8	nmod
12	on	on	IN	_	17	case
13	the	the	DT	_	17	det
14	precocene	precocene	NN	_	17	compound
15	I	I	PRP	_	17	compound
16	metabolite	metabolite	NN	_	17	compound
17	profile	profile	NN	_	11	nmod
18	,	,	,	_	7	punct
19	only	only	RB	_	20	advmod
20	tranylcypromine	tranylcypromine	NN	_	23	nsubj
21	was	be	VBD	_	23	cop
22	noticeably	noticeably	RB	_	23	advmod
23	effective	effective	JJ	_	7	acl:relcl
24	,	,	,	_	23	punct
25	indicating	indicate	VBG	_	23	xcomp
26	a	a	DT	_	27	det
27	role	role	NN	_	25	dobj
28	of	of	IN	_	30	case
29	CYPs	cyp	NNS	_	30	compound
30	2A6	2a6	NN	_	27	nmod
31	,	,	,	_	30	punct
32	2C9	2c9	NN	_	30	conj
33	,	,	,	_	30	punct
34	2Cl9	2cl9	NN	_	30	conj
35	,	,	,	_	30	punct
36	and	and	CC	_	30	cc
37	2E1	2e1	NN	_	30	conj
38	.	.	.	_	3	punct

1	With	with	IN	_	2	case
2	respect	respect	NN	_	17	nmod
3	to	to	TO	_	4	case
4	toxicity	toxicity	NN	_	2	nmod
5	,	,	,	_	17	punct
6	the	the	DT	_	7	det
7	order	order	NN	_	17	nsubj
8	of	of	IN	_	11	case
9	CYP	cyp	NN	_	11	compound
10	inhibitor	inhibitor	NN	_	11	compound
11	effectiveness	effectiveness	NN	_	7	nmod
12	was	be	VBD	_	17	cop
13	ABT	ABT	NNP	_	17	compound
14	>	>	JJR	_	17	advmod
15	diethyldithiocarbamate	diethyldithiocarbamate	NN	_	17	compound
16	~	~	NN	_	17	compound
17	tranylcypromine	tranylcypromine	NN	_	0	ROOT
18	>	>	JJR	_	19	amod
19	ketoconazole	ketoconazole	NN	_	17	dobj
20	.	.	.	_	17	punct

1	Furafylline	furafylline	NN	_	4	nsubj
2	and	and	CC	_	1	cc
3	sulfaphenazole	sulfaphenazole	NN	_	1	conj
4	had	have	VBD	_	0	ROOT
5	no	no	DT	_	6	neg
6	effect	effect	NN	_	4	dobj
7	,	,	,	_	4	punct
8	while	while	IN	_	10	mark
9	quinidine	quinidine	NN	_	10	nsubj
10	appeared	appear	VBD	_	4	advcl
11	to	to	TO	_	12	mark
12	augment	augment	VB	_	10	xcomp
13	precocene	precocene	NN	_	15	compound
14	I	I	PRP	_	15	compound
15	toxicity	toxicity	NN	_	12	dobj
16	.	.	.	_	4	punct

1	These	these	DT	_	2	det
2	results	result	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	10	mark
5	rat	rat	NN	_	7	compound
6	liver	liver	NN	_	7	compound
7	slices	slice	NNS	_	10	nsubj
8	do	do	VBP	_	10	aux
9	not	not	RB	_	10	neg
10	reproduce	reproduce	VB	_	3	ccomp
11	the	the	DT	_	15	det
12	reported	report	VBN	_	15	amod
13	in	in	FW	_	15	amod
14	vivo	vivo	FW	_	13	dep
15	biotransformation	biotransformation	NN	_	10	dobj
16	of	of	IN	_	17	case
17	precocene	precocene	NN	_	15	nmod
18	I	i	CD	_	17	nummod
19	and	and	CC	_	10	cc
20	therefore	therefore	RB	_	26	advmod
21	may	may	MD	_	26	aux
22	not	not	RB	_	26	neg
23	be	be	VB	_	26	cop
24	an	a	DT	_	26	det
25	appropriate	appropriate	JJ	_	26	amod
26	model	model	NN	_	10	conj
27	for	for	IN	_	30	case
28	precocene	precocene	NN	_	30	compound
29	I	I	PRP	_	30	compound
30	metabolism	metabolism	NN	_	26	nmod
31	.	.	.	_	3	punct

1	However	however	RB	_	5	advmod
2	,	,	,	_	5	punct
3	these	these	DT	_	4	det
4	results	result	NNS	_	5	nsubj
5	provide	provide	VBP	_	0	ROOT
6	an	a	DT	_	7	det
7	example	example	NN	_	5	dobj
8	of	of	IN	_	12	case
9	how	how	WRB	_	10	advmod
10	small	small	JJ	_	12	amod
11	molecule	molecule	NN	_	12	compound
12	manipulation	manipulation	NN	_	7	nmod
13	of	of	IN	_	15	case
14	CYP	cyp	NN	_	15	compound
15	activity	activity	NN	_	12	nmod
16	in	in	IN	_	20	case
17	an	a	DT	_	20	det
18	in	in	FW	_	20	amod
19	vitro	vitro	FW	_	18	dep
20	model	model	NN	_	5	nmod
21	can	can	MD	_	23	aux
22	be	be	VB	_	23	auxpass
23	used	use	VBN	_	5	dep
24	to	to	TO	_	25	mark
25	confirm	confirm	VB	_	23	xcomp
26	metabolism	metabolism	NN	_	25	dobj
27	-	-	:	_	26	punct
28	mediated	mediate	VBN	_	29	amod
29	toxicity	toxicity	NN	_	26	dep
30	.	.	.	_	5	punct

1	Glycosidic	glycosidic	JJ	_	2	amod
2	enzymes	enzyme	NNS	_	3	nsubj
3	enhance	enhance	VBP	_	0	ROOT
4	retinal	retinal	JJ	_	5	amod
5	transduction	transduction	NN	_	3	dobj
6	following	follow	VBG	_	8	case
7	intravitreal	intravitreal	JJ	_	8	amod
8	delivery	delivery	NN	_	5	nmod
9	of	of	IN	_	10	case
10	AAV2	aav2	NN	_	8	nmod
11	.	.	.	_	3	punct

1	To	to	TO	_	2	mark
2	determine	determine	VB	_	0	ROOT
3	whether	whether	IN	_	13	mark
4	the	the	DT	_	5	det
5	co	co	NN	_	13	nsubj
6	-	-	:	_	5	punct
7	injection	injection	NN	_	5	dep
8	of	of	IN	_	12	case
9	extracellular	extracellular	JJ	_	12	amod
10	matrix	matrix	NN	_	12	compound
11	degrading	degrading	JJ	_	12	amod
12	enzymes	enzyme	NNS	_	7	nmod
13	improves	improve	VBZ	_	2	ccomp
14	retinal	retinal	JJ	_	15	amod
15	transduction	transduction	NN	_	13	dobj
16	following	follow	VBG	_	18	case
17	intravitreal	intravitreal	JJ	_	18	amod
18	delivery	delivery	NN	_	15	nmod
19	of	of	IN	_	20	case
20	adeno	adeno	NN	_	18	nmod
21	-	-	:	_	18	punct
22	associated	associated	JJ	_	23	amod
23	virus	virus	NN	_	18	dep
24	-	-	:	_	23	punct
25	2	2	CD	_	26	compound
26	(	(	CD	_	28	nummod
27	AAV2	aav2	NN	_	28	compound
28	)	)	NN	_	23	dep
29	.	.	.	_	2	punct

1	AAV2	aav2	NN	_	5	nsubj
2	containing	contain	VBG	_	1	acl
3	cDNA	cdna	NN	_	4	compound
4	encoding	encoding	NN	_	2	dobj
5	enhanced	enhance	VBD	_	0	ROOT
6	green	green	JJ	_	8	amod
7	fluorescent	fluorescent	JJ	_	8	amod
8	protein	protein	NN	_	5	dobj
9	(	(	CD	_	8	nummod
10	GFP	gfp	NN	_	11	compound
11	)	)	NN	_	8	dep
12	,	,	,	_	5	punct
13	under	under	IN	_	15	case
14	the	the	DT	_	15	det
15	control	control	NN	_	5	nmod
16	of	of	IN	_	21	case
17	a	a	DT	_	21	det
18	chicken	chicken	NN	_	21	compound
19	-	-	:	_	21	punct
20	actin	actin	NN	_	21	compound
21	promoter	promoter	NN	_	15	nmod
22	,	,	,	_	5	punct
23	was	be	VBD	_	24	auxpass
24	delivered	deliver	VBN	_	5	dep
25	by	by	IN	_	27	case
26	intravitreal	intravitreal	JJ	_	27	amod
27	injection	injection	NN	_	24	nmod
28	to	to	TO	_	30	case
29	adult	adult	JJ	_	30	amod
30	mice	mouse	NNS	_	27	nmod
31	in	in	IN	_	32	case
32	conjunction	conjunction	NN	_	24	nmod
33	with	with	IN	_	34	case
34	enzymes	enzyme	NNS	_	32	nmod
35	including	include	VBG	_	36	case
36	collagenase	collagenase	NN	_	34	nmod
37	,	,	,	_	36	punct
38	hyaluronan	hyaluronan	NN	_	39	compound
39	lyase	lyase	NN	_	36	conj
40	,	,	,	_	36	punct
41	heparinase	heparinase	NN	_	36	conj
42	III	iii	CD	_	41	nummod
43	,	,	,	_	36	punct
44	or	or	CC	_	36	cc
45	chondroitin	chondroitin	NN	_	47	compound
46	ABC	ABC	NNP	_	47	compound
47	lyase	lyase	NN	_	36	conj
48	.	.	.	_	5	punct

1	Two	two	CD	_	2	nummod
2	weeks	week	NNS	_	3	nmod:npmod
3	later	later	RB	_	8	advmod
4	,	,	,	_	8	punct
5	retinal	retinal	JJ	_	6	amod
6	flatmounts	flatmount	NNS	_	8	nsubjpass
7	were	be	VBD	_	8	auxpass
8	examined	examine	VBN	_	0	ROOT
9	for	for	IN	_	11	case
10	GFP	gfp	NN	_	11	compound
11	expression	expression	NN	_	8	nmod
12	using	use	VBG	_	11	acl
13	confocal	confocal	JJ	_	14	amod
14	microscopy	microscopy	NN	_	12	dobj
15	.	.	.	_	8	punct

1	Without	without	IN	_	3	case
2	the	the	DT	_	3	det
3	addition	addition	NN	_	9	nmod
4	of	of	IN	_	5	case
5	enzymes	enzyme	NNS	_	3	nmod
6	,	,	,	_	9	punct
7	transduction	transduction	NN	_	9	nsubjpass
8	was	be	VBD	_	9	auxpass
9	limited	limit	VBN	_	0	ROOT
10	to	to	TO	_	12	case
11	occasional	occasional	JJ	_	12	amod
12	cells	cell	NNS	_	9	nmod
13	in	in	IN	_	18	case
14	the	the	DT	_	18	det
15	retinal	retinal	JJ	_	18	amod
16	ganglion	ganglion	NN	_	18	compound
17	cell	cell	NN	_	18	compound
18	layer	layer	NN	_	12	nmod
19	.	.	.	_	9	punct

1	The	the	DT	_	2	det
2	addition	addition	NN	_	11	nsubj
3	of	of	IN	_	4	case
4	heparinase	heparinase	NN	_	2	nmod
5	III	iii	CD	_	4	nummod
6	or	or	CC	_	4	cc
7	chondroitin	chondroitin	NN	_	9	compound
8	ABC	ABC	NNP	_	9	compound
9	lyase	lyase	NN	_	4	conj
10	greatly	greatly	RB	_	11	advmod
11	enhanced	enhance	VBD	_	0	ROOT
12	transduction	transduction	NN	_	11	dobj
13	of	of	IN	_	18	case
14	the	the	DT	_	18	det
15	retinal	retinal	JJ	_	18	amod
16	ganglion	ganglion	NN	_	18	compound
17	cell	cell	NN	_	18	compound
18	layer	layer	NN	_	12	nmod
19	and	and	CC	_	11	cc
20	increased	increase	VBD	_	11	conj
21	the	the	DT	_	22	det
22	depth	depth	NN	_	20	dobj
23	of	of	IN	_	24	case
24	transduction	transduction	NN	_	22	nmod
25	into	into	IN	_	28	case
26	the	the	DT	_	28	det
27	outer	outer	JJ	_	28	amod
28	retina	retina	NN	_	20	nmod
29	.	.	.	_	11	punct

1	Hyaluronan	hyaluronan	NN	_	2	compound
2	lyase	lyase	NN	_	3	nsubj
3	had	have	VBD	_	0	ROOT
4	a	a	DT	_	6	det
5	limited	limited	JJ	_	6	amod
6	effect	effect	NN	_	3	dobj
7	and	and	CC	_	3	cc
8	collagenase	collagenase	NN	_	10	nsubj
9	was	be	VBD	_	10	cop
10	ineffective	ineffective	JJ	_	3	conj
11	.	.	.	_	3	punct

1	Electroretinograms	electroretinograms	NN	_	2	nsubj
2	survived	survive	VBD	_	0	ROOT
3	with	with	IN	_	5	case
4	higher	higher	JJR	_	5	amod
5	concentrations	concentration	NNS	_	2	nmod
6	of	of	IN	_	7	case
7	heparinase	heparinase	NN	_	5	nmod
8	III	iii	CD	_	7	nummod
9	and	and	CC	_	7	cc
10	chondroitin	chondroitin	NN	_	12	compound
11	ABC	ABC	NNP	_	12	compound
12	lyase	lyase	NN	_	7	conj
13	than	than	IN	_	15	mark
14	were	be	VBD	_	15	auxpass
15	required	require	VBN	_	5	dep
16	for	for	IN	_	19	case
17	optimal	optimal	JJ	_	19	amod
18	retinal	retinal	JJ	_	19	amod
19	transduction	transduction	NN	_	15	nmod
20	.	.	.	_	2	punct

1	AAV2	aav2	NN	_	7	nsubjpass
2	-	-	:	_	1	punct
3	mediated	mediate	VBN	_	5	amod
4	retinal	retinal	JJ	_	5	amod
5	transduction	transduction	NN	_	1	dep
6	is	be	VBZ	_	7	auxpass
7	improved	improve	VBN	_	0	ROOT
8	by	by	IN	_	9	case
9	co	co	NN	_	7	nmod
10	-	-	:	_	9	punct
11	injection	injection	NN	_	9	dep
12	of	of	IN	_	13	case
13	heparinase	heparinase	NN	_	11	nmod
14	III	iii	CD	_	13	nummod
15	or	or	CC	_	13	cc
16	chondroitin	chondroitin	NN	_	18	compound
17	ABC	ABC	NNP	_	18	compound
18	lyase	lyase	NN	_	13	conj
19	.	.	.	_	7	punct

1	Improved	improve	VBN	_	3	amod
2	transduction	transduction	NN	_	3	compound
3	efficiency	efficiency	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	allow	allow	VB	_	0	ROOT
6	intravitreal	intravitreal	JJ	_	7	amod
7	injection	injection	NN	_	5	dobj
8	to	to	TO	_	9	mark
9	become	become	VB	_	5	xcomp
10	the	the	DT	_	12	det
11	preferred	preferred	JJ	_	12	amod
12	route	route	NN	_	9	xcomp
13	for	for	IN	_	14	mark
14	delivering	deliver	VBG	_	12	acl
15	gene	gene	NN	_	16	compound
16	therapy	therapy	NN	_	14	dobj
17	to	to	TO	_	23	case
18	both	both	CC	_	23	cc:preconj
19	the	the	DT	_	23	det
20	inner	inner	JJ	_	23	amod
21	and	and	CC	_	20	cc
22	outer	outer	JJ	_	20	conj
23	retina	retina	NN	_	14	nmod
24	.	.	.	_	5	punct

1	Ticagrelor	Ticagrelor	NNP	_	3	compound
2	(	(	CD	_	3	nummod
3	Brilinta	Brilinta	NNP	_	0	ROOT
4	)	)	CD	_	3	nummod
5	--	--	:	_	3	punct
6	better	better	JJR	_	3	dep
7	than	than	IN	_	8	case
8	clopidogrel	clopidogrel	NN	_	6	nmod
9	(	(	CD	_	10	nummod
10	Plavix	Plavix	NNP	_	8	dep
11	)	)	CD	_	10	nummod

1	The	the	DT	_	2	det
2	FDA	FDA	NNP	_	4	nsubj
3	has	have	VBZ	_	4	aux
4	approved	approve	VBN	_	0	ROOT
5	ticagrelor	ticagrelor	JJ	_	7	amod
6	(	(	NN	_	7	compound
7	Brilinta	brilinta	NN	_	4	dobj
8	-	-	:	_	7	punct
9	AstraZeneca	AstraZeneca	NNP	_	10	compound
10	)	)	NNP	_	7	dep
11	,	,	,	_	10	punct
12	an	a	DT	_	15	det
13	oral	oral	JJ	_	15	amod
14	antiplatelet	antiplatelet	JJ	_	15	amod
15	drug	drug	NN	_	10	appos
16	,	,	,	_	10	punct
17	for	for	IN	_	18	case
18	use	use	NN	_	10	nmod
19	with	with	IN	_	23	case
20	low	low	JJ	_	23	amod
21	-	-	:	_	23	punct
22	dose	dose	NN	_	23	compound
23	aspirin	aspirin	NN	_	18	nmod
24	to	to	TO	_	25	mark
25	reduce	reduce	VB	_	18	acl
26	the	the	DT	_	27	det
27	rate	rate	NN	_	25	dobj
28	of	of	IN	_	31	case
29	thrombotic	thrombotic	JJ	_	31	amod
30	cardiovascular	cardiovascular	JJ	_	31	amod
31	events	event	NNS	_	27	nmod
32	in	in	IN	_	33	case
33	patients	patient	NNS	_	31	nmod
34	with	with	IN	_	37	case
35	acute	acute	JJ	_	37	amod
36	coronary	coronary	JJ	_	37	amod
37	syndrome	syndrome	NN	_	33	nmod
38	(	(	CD	_	40	nummod
39	ACS	acs	NN	_	40	compound
40	)	)	NN	_	37	dep
41	.	.	.	_	4	punct

1	It	it	PRP	_	3	nsubj
2	will	will	MD	_	3	aux
3	compete	compete	VB	_	0	ROOT
4	with	with	IN	_	8	case
5	clopidogrel	clopidogrel	NN	_	8	compound
6	(	(	CD	_	8	nummod
7	Plavix	Plavix	NNP	_	8	compound
8	)	)	NN	_	3	nmod
9	and	and	CC	_	8	cc
10	prasugrel	prasugrel	NN	_	13	compound
11	(	(	CD	_	13	nummod
12	Effient	effient	JJ	_	13	amod
13	)	)	NN	_	8	conj
14	for	for	IN	_	16	case
15	such	such	JJ	_	16	amod
16	use	use	NN	_	3	nmod
17	.	.	.	_	3	punct

1	Clopidogrel	Clopidogrel	NNP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	expected	expect	VBN	_	0	ROOT
4	to	to	TO	_	5	mark
5	become	become	VB	_	3	xcomp
6	available	available	JJ	_	5	xcomp
7	generically	generically	RB	_	5	advmod
8	in	in	IN	_	10	case
9	the	the	DT	_	10	det
10	US	US	NNP	_	7	nmod
11	within	within	IN	_	15	case
12	the	the	DT	_	15	det
13	next	next	JJ	_	15	amod
14	few	few	JJ	_	15	amod
15	months	month	NNS	_	5	nmod
16	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	role	role	NN	_	0	ROOT
3	of	of	IN	_	7	case
4	p27	p27	NN	_	7	compound
5	(	(	CD	_	7	nummod
6	Kip1	kip1	NN	_	7	compound
7	)	)	NN	_	2	nmod
8	in	in	IN	_	9	case
9	dasatinib	dasatinib	NN	_	2	nmod
10	-	-	:	_	2	punct
11	enhanced	enhance	VBN	_	13	amod
12	paclitaxel	paclitaxel	NN	_	13	compound
13	cytotoxicity	cytotoxicity	NN	_	2	dep
14	in	in	IN	_	18	case
15	human	human	JJ	_	18	amod
16	ovarian	ovarian	JJ	_	18	amod
17	cancer	cancer	NN	_	18	compound
18	cells	cell	NNS	_	13	nmod
19	.	.	.	_	2	punct

1	Less	less	RBR	_	3	advmod
2	than	than	IN	_	1	mwe
3	50	50	CD	_	4	nummod
4	%	%	NN	_	8	nsubj
5	of	of	IN	_	7	case
6	ovarian	ovarian	JJ	_	7	amod
7	cancers	cancer	NNS	_	4	nmod
8	respond	respond	VBP	_	0	ROOT
9	to	to	TO	_	10	case
10	paclitaxel	paclitaxel	NN	_	8	nmod
11	.	.	.	_	8	punct

1	Effective	effective	JJ	_	2	amod
2	strategies	strategy	NNS	_	4	nsubjpass
3	are	be	VBP	_	4	auxpass
4	needed	need	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	enhance	enhance	VB	_	4	xcomp
7	paclitaxel	paclitaxel	NN	_	8	compound
8	sensitivity	sensitivity	NN	_	6	dobj
9	.	.	.	_	4	punct

1	A	a	DT	_	2	det
2	library	library	NN	_	6	nsubj
3	of	of	IN	_	5	case
4	silencing	silencing	NN	_	5	compound
5	RNAs	rna	NNS	_	2	nmod
6	(	(	VBP	_	0	ROOT
7	siRNAs	sirna	NNS	_	10	nsubjpass
8	)	)	CD	_	7	nummod
9	was	be	VBD	_	10	auxpass
10	used	use	VBN	_	6	ccomp
11	to	to	TO	_	12	mark
12	identify	identify	VB	_	10	xcomp
13	kinases	kinase	NNS	_	12	dobj
14	that	that	WDT	_	15	nsubj
15	regulate	regulate	VBP	_	13	acl:relcl
16	paclitaxel	paclitaxel	NN	_	17	compound
17	sensitivity	sensitivity	NN	_	15	dobj
18	in	in	IN	_	23	case
19	human	human	JJ	_	23	amod
20	ovarian	ovarian	JJ	_	23	amod
21	cancer	cancer	NN	_	23	compound
22	SKOv3	skov3	NN	_	23	compound
23	cells	cell	NNS	_	17	nmod
24	.	.	.	_	6	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	18	nsubjpass
3	of	of	IN	_	4	case
4	dasatinib	dasatinib	NN	_	2	nmod
5	,	,	,	_	4	punct
6	an	a	DT	_	7	det
7	inhibitor	inhibitor	NN	_	4	appos
8	of	of	IN	_	12	case
9	Src	src	NN	_	12	compound
10	and	and	CC	_	9	cc
11	Abl	abl	NN	_	9	conj
12	kinases	kinase	NNS	_	7	nmod
13	,	,	,	_	4	punct
14	on	on	IN	_	16	case
15	paclitaxel	paclitaxel	NN	_	16	compound
16	sensitivity	sensitivity	NN	_	2	nmod
17	was	be	VBD	_	18	auxpass
18	measured	measure	VBN	_	0	ROOT
19	in	in	IN	_	22	case
20	ovarian	ovarian	JJ	_	22	amod
21	cancer	cancer	NN	_	22	compound
22	cells	cell	NNS	_	18	nmod
23	and	and	CC	_	22	cc
24	HEY	hey	NN	_	25	compound
25	xenografts	xenograft	NNS	_	22	conj
26	.	.	.	_	18	punct

1	The	the	DT	_	2	det
2	roles	role	NNS	_	23	nsubjpass
3	of	of	IN	_	7	case
4	p27	p27	NN	_	7	compound
5	(	(	CD	_	7	nummod
6	Kip1	kip1	NN	_	7	compound
7	)	)	NN	_	2	nmod
8	,	,	,	_	7	punct
9	Bcl	bcl	NN	_	11	dep
10	-	-	:	_	11	punct
11	2	2	CD	_	7	conj
12	,	,	,	_	7	punct
13	and	and	CC	_	7	cc
14	Cdk1	cdk1	NN	_	7	conj
15	in	in	IN	_	16	case
16	apoptosis	apoptosis	NN	_	2	nmod
17	induced	induce	VBN	_	16	acl
18	by	by	IN	_	19	case
19	dasatinib	dasatinib	NN	_	17	nmod
20	and	and	CC	_	19	cc
21	paclitaxel	paclitaxel	NN	_	19	conj
22	were	be	VBD	_	23	auxpass
23	assessed	assess	VBN	_	0	ROOT
24	using	use	VBG	_	23	xcomp
25	a	a	DT	_	28	det
26	terminal	terminal	JJ	_	28	amod
27	deoxynucleotidyl	deoxynucleotidyl	NN	_	28	compound
28	transferase	transferase	NN	_	24	dobj
29	-	-	:	_	28	punct
30	mediated	mediate	VBN	_	32	amod
31	dUTP	dutp	NN	_	32	compound
32	nick	nick	NN	_	28	dep
33	-	-	:	_	28	punct
34	end	end	NN	_	39	compound
35	labeling	labeling	NN	_	39	compound
36	(	(	CD	_	39	nummod
37	TUNEL	tunel	NN	_	39	compound
38	)	)	NN	_	39	compound
39	assay	assay	NN	_	28	dep
40	,	,	,	_	28	punct
41	siRNA	sirna	NN	_	42	compound
42	knockdown	knockdown	NN	_	28	appos
43	of	of	IN	_	45	case
44	gene	gene	NN	_	45	compound
45	expression	expression	NN	_	42	nmod
46	,	,	,	_	28	punct
47	transfection	transfection	NN	_	28	conj
48	with	with	IN	_	49	case
49	Bcl	bcl	NN	_	47	nmod
50	-	-	:	_	49	punct
51	2	2	CD	_	49	nummod
52	and	and	CC	_	49	cc
53	Cdk1	cdk1	NN	_	55	compound
54	expression	expression	NN	_	55	compound
55	vectors	vector	NNS	_	49	conj
56	,	,	,	_	28	punct
57	and	and	CC	_	28	cc
58	flow	flow	NN	_	59	compound
59	cytometry	cytometry	NN	_	28	conj
60	.	.	.	_	23	punct

1	All	all	DT	_	3	det
2	statistical	statistical	JJ	_	3	amod
3	tests	test	NNS	_	5	nsubj
4	were	be	VBD	_	5	cop
5	two	two	CD	_	0	ROOT
6	-	-	:	_	5	punct
7	sided	side	VBD	_	5	dep
8	.	.	.	_	5	punct

1	Src	src	NN	_	2	compound
2	family	family	NN	_	7	nsubjpass
3	and	and	CC	_	2	cc
4	Abl	abl	NN	_	5	compound
5	kinases	kinase	NNS	_	2	conj
6	were	be	VBD	_	7	auxpass
7	identified	identify	VBN	_	0	ROOT
8	as	as	IN	_	9	case
9	modulators	modulator	NNS	_	7	nmod
10	of	of	IN	_	12	case
11	paclitaxel	paclitaxel	NN	_	12	compound
12	sensitivity	sensitivity	NN	_	9	nmod
13	in	in	IN	_	15	case
14	SKOv3	skov3	NN	_	15	compound
15	cells	cell	NNS	_	12	nmod
16	.	.	.	_	7	punct

1	The	the	DT	_	3	det
2	siRNA	sirna	NN	_	3	compound
3	knockdown	knockdown	NN	_	11	nsubj
4	of	of	IN	_	5	case
5	Src	src	NN	_	3	nmod
6	,	,	,	_	5	punct
7	Fyn	fyn	NN	_	5	conj
8	,	,	,	_	5	punct
9	or	or	CC	_	5	cc
10	Abl1	abl1	NN	_	5	conj
11	enhanced	enhance	VBD	_	0	ROOT
12	paclitaxel	paclitaxel	NN	_	11	dobj
13	-	-	:	_	12	punct
14	mediated	mediate	VBN	_	16	amod
15	growth	growth	NN	_	16	compound
16	inhibition	inhibition	NN	_	12	dep
17	in	in	IN	_	20	case
18	ovarian	ovarian	JJ	_	20	amod
19	cancer	cancer	NN	_	20	compound
20	cells	cell	NNS	_	16	nmod
21	compared	compare	VBN	_	25	case
22	with	with	IN	_	25	case
23	a	a	DT	_	25	det
24	control	control	NN	_	25	compound
25	siRNA	siRNA	NNP	_	16	nmod
26	.	.	.	_	11	punct

1	HEY	hey	NN	_	2	compound
2	cells	cell	NNS	_	8	nsubj
3	treated	treat	VBN	_	2	acl
4	with	with	IN	_	5	case
5	dasatinib	dasatinib	NN	_	3	nmod
6	plus	plus	CC	_	5	cc
7	paclitaxel	paclitaxel	NN	_	5	conj
8	formed	form	VBD	_	0	ROOT
9	fewer	fewer	JJR	_	10	amod
10	colonies	colony	NNS	_	8	dobj
11	than	than	IN	_	12	dep
12	did	do	VBD	_	10	dep
13	cells	cell	NNS	_	12	nsubj
14	treated	treat	VBN	_	13	acl
15	with	with	IN	_	17	case
16	either	either	CC	_	17	det
17	agent	agent	NN	_	14	nmod
18	alone	alone	RB	_	17	advmod
19	.	.	.	_	8	punct

1	Treatment	treatment	NN	_	12	nsubj
2	of	of	IN	_	4	case
3	HEY	hey	NN	_	4	compound
4	xenograft	xenograft	NN	_	1	nmod
5	-	-	:	_	1	punct
6	bearing	bear	VBG	_	1	acl
7	mice	mouse	NNS	_	6	dobj
8	with	with	IN	_	9	case
9	dasatinib	dasatinib	NN	_	6	nmod
10	plus	plus	CC	_	9	cc
11	paclitaxel	paclitaxel	NN	_	9	conj
12	inhibited	inhibit	VBD	_	0	ROOT
13	tumor	tumor	NN	_	14	compound
14	growth	growth	NN	_	12	dobj
15	more	more	JJR	_	12	advmod
16	than	than	IN	_	17	case
17	treatment	treatment	NN	_	15	nmod
18	with	with	IN	_	20	case
19	either	either	CC	_	20	det
20	agent	agent	NN	_	17	nmod
21	alone	alone	RB	_	20	advmod
22	(	(	RB	_	25	advmod
23	average	average	JJ	_	25	amod
24	tumor	tumor	NN	_	25	compound
25	volume	volume	NN	_	17	dep
26	per	per	IN	_	27	case
27	mouse	mouse	NN	_	25	nmod
28	,	,	,	_	27	punct
29	dasatinib	dasatinib	NN	_	27	conj
30	+	+	CC	_	27	cc
31	paclitaxel	paclitaxel	NN	_	27	conj
32	vs	vs	CC	_	31	cc
33	paclitaxel	paclitaxel	NN	_	31	conj
34	:	:	:	_	12	punct
35	0.28	0.28	CD	_	39	compound
36	vs	vs	CC	_	39	dep
37	.	.	.	_	39	punct
38	0.81	0.81	CD	_	39	nummod
39	cm3	cm3	NN	_	12	dep
40	,	,	,	_	39	punct
41	difference	difference	NN	_	39	appos
42	=	=	JJ	_	41	amod
43	0.53	0.53	CD	_	44	nummod
44	cm3	cm3	NN	_	42	dep
45	,	,	,	_	39	punct
46	95	95	CD	_	47	compound
47	%	%	NN	_	52	amod
48	confidence	confidence	NN	_	52	compound
49	interval	interval	NN	_	52	compound
50	[	[	CD	_	52	nummod
51	CI	ci	NN	_	52	compound
52	]	]	NN	_	39	appos
53	=	=	JJ	_	52	amod
54	0.44	0.44	CD	_	56	compound
55	to	to	TO	_	56	dep
56	0.62	0.62	CD	_	57	nummod
57	cm3	cm3	NN	_	53	dep
58	,	,	,	_	39	punct
59	P	p	NN	_	60	nsubj
60	=	=	JJ	_	39	acl:relcl
61	.	.	.	_	60	punct
62	014	014	CD	_	63	nummod
63	)	)	NN	_	60	dep
64	;	;	:	_	12	punct

1	dasatinib	dasatinib	NN	_	0	ROOT
2	+	+	CC	_	1	cc
3	paclitaxel	paclitaxel	NN	_	1	conj
4	vs	vs	CC	_	1	dep
5	.	.	.	_	1	punct

1	dasatinib	dasatinib	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	0.28	0.28	CD	_	4	nummod
4	vs	vs	CC	_	1	dep
5	.	.	.	_	1	punct

1	0.55	0.55	CD	_	2	nummod
2	cm3	cm3	NN	_	0	ROOT
3	,	,	,	_	2	punct
4	difference	difference	NN	_	2	appos
5	=	=	JJ	_	4	amod
6	0.27	0.27	CD	_	7	nummod
7	cm3	cm3	NN	_	5	dep
8	,	,	,	_	2	punct
9	95	95	CD	_	10	compound
10	%	%	NN	_	11	amod
11	CI	ci	NN	_	2	appos
12	=	=	JJ	_	11	amod
13	0.21	0.21	CD	_	15	compound
14	to	to	TO	_	15	dep
15	0.33	0.33	CD	_	16	nummod
16	cm3	cm3	NN	_	12	dep
17	,	,	,	_	2	punct
18	P	p	NN	_	19	nsubj
19	=	=	JJ	_	2	acl:relcl
20	.	.	.	_	19	punct
21	035	035	CD	_	22	nummod
22	)	)	NN	_	19	dep
23	.	.	.	_	2	punct

1	Combined	combined	JJ	_	2	amod
2	treatment	treatment	NN	_	3	nsubj
3	induced	induce	VBD	_	0	ROOT
4	more	more	RBR	_	5	amod
5	TUNEL	tunel	NN	_	3	dobj
6	-	-	:	_	5	punct
7	positive	positive	JJ	_	9	amod
8	apoptotic	apoptotic	JJ	_	9	amod
9	cells	cell	NNS	_	5	dep
10	than	than	IN	_	11	dep
11	did	do	VBD	_	5	dep
12	either	either	DT	_	13	det
13	agent	agent	NN	_	11	nsubj
14	alone	alone	RB	_	13	advmod
15	.	.	.	_	3	punct

1	The	the	DT	_	3	det
2	siRNA	sirna	NN	_	3	compound
3	knockdown	knockdown	NN	_	9	nsubj
4	of	of	IN	_	8	case
5	p27	p27	NN	_	8	compound
6	(	(	CD	_	8	nummod
7	Kip1	kip1	NN	_	8	compound
8	)	)	NN	_	3	nmod
9	decreased	decrease	VBD	_	0	ROOT
10	dasatinib	dasatinib	NN	_	9	dobj
11	-	-	:	_	10	punct
12	and	and	CC	_	10	cc
13	paclitaxel	paclitaxel	NN	_	10	conj
14	-	-	:	_	10	punct
15	induced	induced	JJ	_	16	amod
16	apoptosis	apoptosis	NN	_	10	dep
17	compared	compare	VBN	_	22	case
18	with	with	IN	_	22	case
19	a	a	DT	_	22	det
20	negative	negative	JJ	_	22	amod
21	control	control	NN	_	22	compound
22	siRNA	sirna	NN	_	16	nmod
23	(	(	CD	_	22	nummod
24	sub	sub	SYM	_	22	dep
25	-	-	:	_	22	punct
26	G1	g1	NN	_	27	compound
27	fraction	fraction	NN	_	22	dep
28	,	,	,	_	22	punct
29	control	control	NN	_	30	compound
30	siRNA	siRNA	NNP	_	22	appos
31	vs	vs	CC	_	30	cc
32	.	.	.	_	30	punct
33	p27	p27	NN	_	35	compound
34	(	(	CD	_	35	nummod
35	Kip1	kip1	NN	_	30	dep
36	)	)	CD	_	37	nummod
37	siRNA	sirna	NN	_	35	dep
38	:	:	:	_	35	punct
39	42.5	42.5	CD	_	40	nummod
40	%	%	NN	_	35	dep
41	vs	vs	CC	_	40	advmod
42	.	.	.	_	9	punct
43	20.1	20.1	CD	_	44	nummod
44	%	%	NN	_	9	dep
45	,	,	,	_	44	punct
46	difference	difference	NN	_	44	appos
47	=	=	JJ	_	46	amod
48	22.4	22.4	CD	_	49	nummod
49	%	%	NN	_	47	dep
50	,	,	,	_	44	punct
51	95	95	CD	_	52	nummod
52	%	%	NN	_	62	dep
53	CI	ci	NN	_	62	dep
54	=	=	JJ	_	62	dep
55	20.1	20.1	CD	_	62	dep
56	%	%	NN	_	62	dep
57	to	to	TO	_	59	case
58	24.7	24.7	CD	_	59	nummod
59	%	%	NN	_	56	nmod
60	,	,	,	_	62	punct
61	P	p	NN	_	62	nsubj
62	=	=	JJ	_	44	dep
63	.	.	.	_	44	punct
64	017	017	CD	_	65	nummod
65	)	)	NN	_	44	dep
66	.	.	.	_	9	punct

1	Studies	study	NNS	_	14	nsubj
2	with	with	IN	_	4	case
3	forced	force	VBN	_	4	amod
4	expression	expression	NN	_	1	nmod
5	and	and	CC	_	4	cc
6	siRNA	sirna	NN	_	7	compound
7	knockdown	knockdown	NN	_	4	conj
8	of	of	IN	_	9	case
9	Bcl	bcl	NN	_	7	nmod
10	-	-	:	_	4	punct
11	2	2	CD	_	4	dep
12	and	and	CC	_	11	cc
13	Cdk1	cdk1	NN	_	11	conj
14	suggest	suggest	VBP	_	0	ROOT
15	that	that	IN	_	14	dobj
16	dasatinib	dasatinib	NN	_	15	dep
17	-	-	:	_	16	punct
18	mediated	mediated	JJ	_	19	amod
19	induction	induction	NN	_	25	nsubj
20	of	of	IN	_	24	case
21	p27	p27	NN	_	24	compound
22	(	(	CD	_	24	nummod
23	Kip1	kip1	NN	_	24	compound
24	)	)	NN	_	19	nmod
25	enhanced	enhance	VBD	_	16	dep
26	paclitaxel	paclitaxel	NN	_	25	dobj
27	-	-	:	_	26	punct
28	induced	induced	JJ	_	29	amod
29	apoptosis	apoptosis	NN	_	26	dep
30	by	by	IN	_	32	mark
31	negatively	negatively	RB	_	32	advmod
32	regulating	regulate	VBG	_	29	acl
33	Bcl	Bcl	NNP	_	38	compound
34	-	-	:	_	33	punct
35	2	2	CD	_	33	nummod
36	and	and	CC	_	33	cc
37	Cdk1	cdk1	NN	_	33	conj
38	expression	expression	NN	_	32	dobj
39	.	.	.	_	14	punct

1	Inhibition	inhibition	NN	_	13	nsubj
2	of	of	IN	_	4	case
3	Src	src	NN	_	4	compound
4	family	family	NN	_	1	nmod
5	and	and	CC	_	4	cc
6	Abl	abl	NN	_	7	compound
7	kinases	kinase	NNS	_	4	conj
8	with	with	IN	_	10	case
9	either	either	CC	_	10	cc:preconj
10	siRNAs	sirnas	NN	_	1	nmod
11	or	or	CC	_	10	cc
12	dasatinib	dasatinib	NN	_	10	conj
13	enhances	enhance	VBZ	_	0	ROOT
14	paclitaxel	paclitaxel	NN	_	15	compound
15	sensitivity	sensitivity	NN	_	13	dobj
16	of	of	IN	_	19	case
17	ovarian	ovarian	JJ	_	19	amod
18	cancer	cancer	NN	_	19	compound
19	cells	cell	NNS	_	15	nmod
20	through	through	IN	_	23	case
21	p27	p27	NN	_	23	compound
22	(	(	CD	_	23	nummod
23	Kip1	kip1	NN	_	13	nmod
24	)	)	SYM	_	27	dep
25	-	-	:	_	27	punct
26	mediated	mediate	VBN	_	27	amod
27	suppression	suppression	NN	_	23	dep
28	of	of	IN	_	29	case
29	Bcl	bcl	NN	_	27	nmod
30	-	-	:	_	27	punct
31	2	2	CD	_	34	nummod
32	and	and	CC	_	31	cc
33	Cdk1	cdk1	NN	_	31	conj
34	expression	expression	NN	_	27	dep
35	.	.	.	_	13	punct

1	Influence	influence	NN	_	6	nsubj
2	of	of	IN	_	3	case
3	piperine	piperine	NN	_	1	nmod
4	on	on	IN	_	5	case
5	ibuprofen	ibuprofen	NN	_	1	nmod
6	induced	induce	VBD	_	0	ROOT
7	antinociception	antinociception	NN	_	6	dobj
8	and	and	CC	_	7	cc
9	its	its	PRP$	_	10	nmod:poss
10	pharmacokinetics	pharmacokinetic	NNS	_	7	conj
11	.	.	.	_	6	punct

1	Piperine	Piperine	NNP	_	3	compound
2	(	(	CD	_	3	nummod
3	CAS	CAS	NNP	_	0	ROOT
4	94	94	CD	_	3	nummod
5	-	-	:	_	3	punct
6	62	62	CD	_	3	dep
7	-	-	:	_	3	punct
8	2	2	CD	_	9	compound
9	)	)	CD	_	3	dep
10	,	,	,	_	3	punct
11	an	a	DT	_	12	det
12	alkaloid	alkaloid	NN	_	3	appos
13	obtained	obtain	VBN	_	12	acl
14	from	from	IN	_	16	case
15	Piper	Piper	NNP	_	16	compound
16	nigrum	nigrum	NNP	_	13	nmod
17	and	and	CC	_	16	cc
18	P	p	NN	_	16	conj
19	.	.	.	_	3	punct

1	longum	longum	NN	_	6	nsubj
2	,	,	,	_	6	punct
3	is	be	VBZ	_	6	cop
4	a	a	DT	_	6	det
5	known	known	JJ	_	6	amod
6	inhibitor	inhibitor	NN	_	0	ROOT
7	of	of	IN	_	9	case
8	various	various	JJ	_	9	amod
9	enzymes	enzyme	NNS	_	6	nmod
10	(	(	VBP	_	6	acl
11	CYP	cyp	NN	_	12	compound
12	isozymes	isozyme	NNS	_	13	nsubj
13	)	)	VBP	_	10	ccomp
14	responsible	responsible	JJ	_	13	xcomp
15	for	for	IN	_	16	case
16	biotransformation	biotransformation	NN	_	14	nmod
17	of	of	IN	_	18	case
18	drugs	drug	NNS	_	16	nmod
19	.	.	.	_	6	punct

1	By	by	IN	_	2	mark
2	inhibiting	inhibit	VBG	_	9	advcl
3	the	the	DT	_	4	det
4	metabolism	metabolism	NN	_	2	dobj
5	of	of	IN	_	6	case
6	drugs	drug	NNS	_	4	nmod
7	,	,	,	_	9	punct
8	piperine	piperine	NN	_	9	nsubj
9	improves	improve	VBZ	_	0	ROOT
10	the	the	DT	_	11	det
11	bioavailability	bioavailability	NN	_	9	dobj
12	of	of	IN	_	13	case
13	drugs	drug	NNS	_	11	nmod
14	.	.	.	_	9	punct

1	In	in	IN	_	4	case
2	the	the	DT	_	4	det
3	present	present	JJ	_	4	amod
4	study	study	NN	_	0	ROOT
5	piperine	piperine	NN	_	4	dep
6	(	(	CD	_	7	compound
7	10	10	CD	_	8	nummod
8	mg	mg	NN	_	13	nsubj
9	/	/	:	_	8	punct
10	kg	kg	NN	_	11	compound
11	)	)	NN	_	8	dep
12	significantly	significantly	RB	_	13	advmod
13	increased	increase	VBD	_	5	acl:relcl
14	the	the	DT	_	15	det
15	dose	dose	NN	_	13	dobj
16	-	-	:	_	15	punct
17	dependent	dependent	JJ	_	19	amod
18	antinociceptive	antinociceptive	JJ	_	19	amod
19	activity	activity	NN	_	15	dep
20	of	of	IN	_	21	case
21	ibuprofen	ibuprofen	NN	_	19	nmod
22	evaluated	evaluate	VBN	_	19	acl
23	by	by	IN	_	26	case
24	both	both	CC	_	26	cc:preconj
25	acetic	acetic	JJ	_	26	amod
26	acid	acid	NN	_	22	nmod
27	writhing	writhe	VBG	_	30	compound
28	and	and	CC	_	27	cc
29	formalin	formalin	NN	_	27	conj
30	test	test	NN	_	26	dep
31	,	,	,	_	13	punct
32	when	when	WRB	_	35	advmod
33	it	it	PRP	_	35	nsubjpass
34	was	be	VBD	_	35	auxpass
35	administered	administer	VBN	_	13	advcl
36	with	with	IN	_	37	case
37	ibuprofen	ibuprofen	NN	_	35	nmod
38	.	.	.	_	4	punct

1	Ibuprofen	ibuprofen	NN	_	3	compound
2	plasma	plasma	NN	_	3	compound
3	concentration	concentration	NN	_	6	nsubjpass
4	was	be	VBD	_	6	auxpass
5	also	also	RB	_	6	advmod
6	increased	increase	VBN	_	0	ROOT
7	when	when	WRB	_	10	advmod
8	it	it	PRP	_	10	nsubjpass
9	was	be	VBD	_	10	auxpass
10	administered	administer	VBN	_	6	advcl
11	with	with	IN	_	12	case
12	piperine	piperine	NN	_	10	nmod
13	.	.	.	_	6	punct

1	The	the	DT	_	4	det
2	synergistic	synergistic	JJ	_	4	amod
3	antinociception	antinociception	NN	_	4	compound
4	activity	activity	NN	_	13	nsubjpass
5	of	of	IN	_	6	case
6	ibuprofen	ibuprofen	NN	_	4	nmod
7	when	when	WRB	_	8	advmod
8	administered	administer	VBN	_	4	acl:relcl
9	with	with	IN	_	10	case
10	piperine	piperine	NN	_	8	nmod
11	can	can	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	attributed	attribute	VBN	_	0	ROOT
14	to	to	TO	_	17	case
15	increased	increase	VBN	_	17	amod
16	plasma	plasma	NN	_	17	compound
17	concentration	concentration	NN	_	13	nmod
18	of	of	IN	_	19	case
19	ibuprofen	ibuprofen	NN	_	17	nmod
20	.	.	.	_	13	punct

1	From	from	IN	_	3	case
2	this	this	DT	_	3	det
3	study	study	NN	_	7	nmod
4	it	it	PRP	_	7	nsubjpass
5	can	can	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	concluded	conclude	VBN	_	0	ROOT
8	that	that	IN	_	12	mark
9	piperine	piperine	NN	_	12	nsubjpass
10	can	can	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	used	use	VBN	_	7	ccomp
13	as	as	IN	_	15	case
14	a	a	DT	_	15	det
15	bioenhancer	bioenhancer	NN	_	12	nmod
16	along	along	IN	_	18	case
17	with	with	IN	_	18	case
18	ibuprofen	ibuprofen	NN	_	15	nmod
19	.	.	.	_	7	punct

1	Prevention	Prevention	NNP	_	0	ROOT
2	of	of	IN	_	4	case
3	emergence	emergence	NN	_	4	compound
4	agitation	agitation	NN	_	1	nmod
5	in	in	IN	_	7	case
6	seven	seven	CD	_	7	nummod
7	children	child	NNS	_	1	nmod
8	receiving	receive	VBG	_	7	acl
9	low	low	JJ	_	12	amod
10	-	-	:	_	12	punct
11	dose	dose	NN	_	12	compound
12	ketamine	ketamine	NN	_	8	dobj
13	and	and	CC	_	12	cc
14	propofol	propofol	NN	_	17	compound
15	total	total	JJ	_	17	amod
16	intravenous	intravenous	JJ	_	17	amod
17	anesthesia	anesthesia	NN	_	12	conj
18	.	.	.	_	1	punct

1	Emergence	emergence	NN	_	5	compound
2	agitation	agitation	NN	_	5	compound
3	(	(	CD	_	5	nummod
4	EA	ea	NN	_	5	compound
5	)	)	NN	_	11	nsubj
6	can	can	MD	_	11	aux
7	be	be	VB	_	11	cop
8	a	a	DT	_	11	det
9	distressing	distressing	JJ	_	11	amod
10	side	side	NN	_	11	compound
11	effect	effect	NN	_	0	ROOT
12	of	of	IN	_	14	case
13	pediatric	pediatric	JJ	_	14	amod
14	anesthesia	anesthesia	NN	_	11	nmod
15	.	.	.	_	11	punct

1	We	we	PRP	_	3	nsubj
2	retrospectively	retrospectively	RB	_	3	advmod
3	reviewed	review	VBD	_	0	ROOT
4	the	the	DT	_	5	det
5	records	record	NNS	_	3	dobj
6	of	of	IN	_	10	case
7	7	7	CD	_	10	nummod
8	pediatric	pediatric	JJ	_	10	amod
9	oncology	oncology	NN	_	10	compound
10	patients	patient	NNS	_	5	nmod
11	who	who	WP	_	12	nsubj
12	received	receive	VBD	_	10	acl:relcl
13	low	low	JJ	_	16	amod
14	-	-	:	_	16	punct
15	dose	dose	NN	_	16	compound
16	ketamine	ketamine	NN	_	12	dobj
17	in	in	IN	_	18	case
18	conjunction	conjunction	NN	_	12	nmod
19	with	with	IN	_	20	case
20	propofol	propofol	NN	_	18	nmod
21	for	for	IN	_	24	case
22	total	total	JJ	_	24	amod
23	intravenous	intravenous	JJ	_	24	amod
24	anesthesia	anesthesia	NN	_	12	nmod
25	(	(	CD	_	26	nummod
26	TIVA	tiva	NN	_	24	dep
27	)	)	CD	_	26	nummod
28	repeatedly	repeatedly	RB	_	26	advmod
29	for	for	IN	_	31	case
30	radiation	radiation	NN	_	31	compound
31	therapy	therapy	NN	_	26	nmod
32	.	.	.	_	3	punct

1	EA	ea	NN	_	2	compound
2	signs	sign	NNS	_	4	nsubjpass
3	were	be	VBD	_	4	auxpass
4	observed	observe	VBN	_	0	ROOT
5	in	in	IN	_	8	case
6	all	all	DT	_	8	det
7	7	7	CD	_	8	nummod
8	patients	patient	NNS	_	4	nmod
9	in	in	IN	_	10	case
10	association	association	NN	_	8	nmod
11	with	with	IN	_	13	case
12	propofol	propofol	NN	_	13	compound
13	TIVA	tiva	NN	_	10	nmod
14	but	but	CC	_	4	cc
15	did	do	VBD	_	17	aux
16	not	not	RB	_	17	neg
17	recur	recur	VB	_	4	conj
18	in	in	IN	_	17	nmod
19	any	any	DT	_	18	dep
20	of	of	IN	_	24	case
21	123	123	CD	_	24	nummod
22	subsequent	subsequent	JJ	_	24	amod
23	anesthetics	anesthetic	NNS	_	24	compound
24	sessions	session	NNS	_	19	nmod
25	during	during	IN	_	26	case
26	which	which	WDT	_	32	nmod
27	low	low	JJ	_	30	amod
28	-	-	:	_	30	punct
29	dose	dose	NN	_	30	compound
30	ketamine	ketamine	NN	_	32	nsubjpass
31	was	be	VBD	_	32	auxpass
32	added	add	VBN	_	24	acl:relcl
33	to	to	TO	_	34	case
34	propofol	propofol	NN	_	32	nmod
35	.	.	.	_	4	punct

1	Based	base	VBN	_	4	case
2	on	on	IN	_	4	case
3	this	this	DT	_	4	det
4	experience	experience	NN	_	7	advcl
5	,	,	,	_	7	punct
6	we	we	PRP	_	7	nsubj
7	suggest	suggest	VBP	_	0	ROOT
8	that	that	IN	_	13	mark
9	low	low	JJ	_	12	amod
10	-	-	:	_	12	punct
11	dose	dose	NN	_	12	compound
12	ketamine	ketamine	NN	_	13	nsubj
13	added	add	VBD	_	7	ccomp
14	to	to	TO	_	15	case
15	propofol	propofol	NN	_	13	nmod
16	may	may	MD	_	18	aux
17	be	be	VB	_	18	auxpass
18	associated	associate	VBN	_	13	ccomp
19	with	with	IN	_	20	case
20	prevention	prevention	NN	_	18	nmod
21	of	of	IN	_	22	case
22	EA	ea	NN	_	20	nmod
23	in	in	IN	_	24	case
24	children	child	NNS	_	20	nmod
25	with	with	IN	_	27	case
26	a	a	DT	_	27	det
27	history	history	NN	_	24	nmod
28	of	of	IN	_	29	case
29	EA	ea	NN	_	27	nmod
30	with	with	IN	_	32	case
31	propofol	propofol	NN	_	32	compound
32	TIVA	tiva	NN	_	29	nmod
33	.	.	.	_	7	punct

1	[	[	NN	_	2	compound
2	Efficacy	efficacy	NN	_	0	ROOT
3	of	of	IN	_	6	case
4	fixed	fix	VBN	_	6	amod
5	combination	combination	NN	_	6	compound
6	amlodipine	amlodipine	NN	_	2	nmod
7	/	/	:	_	2	punct
8	valsartan	valsartan	NN	_	2	dep
9	in	in	IN	_	11	case
10	hospitalized	hospitalize	VBN	_	11	amod
11	patients	patient	NNS	_	8	nmod
12	with	with	IN	_	15	case
13	hypertensive	hypertensive	JJ	_	15	amod
14	disease	disease	NN	_	15	compound
15	]	]	NN	_	11	nmod

1	Efficacy	efficacy	NN	_	11	nsubjpass
2	and	and	CC	_	1	cc
3	tolerability	tolerability	NN	_	1	conj
4	of	of	IN	_	6	case
5	fixed	fix	VBN	_	6	amod
6	amlodipine	amlodipine	NN	_	1	nmod
7	/	/	:	_	6	punct
8	valsartan	valsartan	NN	_	9	compound
9	combination	combination	NN	_	6	dep
10	was	be	VBD	_	11	auxpass
11	studied	study	VBN	_	0	ROOT
12	in	in	IN	_	14	case
13	86	86	CD	_	14	nummod
14	patients	patient	NNS	_	11	nmod
15	with	with	IN	_	17	case
16	hypertensive	hypertensive	JJ	_	17	amod
17	disease	disease	NN	_	14	nmod
18	hospitalized	hospitalize	VBN	_	14	acl
19	in	in	IN	_	20	case
20	departments	department	NNS	_	18	nmod
21	of	of	IN	_	24	case
22	general	general	JJ	_	24	amod
23	internal	internal	JJ	_	24	amod
24	medicine	medicine	NN	_	20	nmod
25	or	or	CC	_	24	cc
26	cardiology	cardiology	NN	_	24	conj
27	.	.	.	_	11	punct

1	All	all	DT	_	2	det
2	patients	patient	NNS	_	3	nsubj
3	had	have	VBD	_	0	ROOT
4	indications	indication	NNS	_	3	dobj
5	for	for	IN	_	7	case
6	antihypertensive	antihypertensive	JJ	_	7	amod
7	therapy	therapy	NN	_	4	nmod
8	and	and	CC	_	3	cc
9	were	be	VBD	_	10	auxpass
10	randomized	randomize	VBN	_	3	conj
11	either	either	CC	_	15	dep
12	to	to	TO	_	15	case
13	fixed	fix	VBN	_	15	amod
14	combination	combination	NN	_	15	compound
15	amlodipine	amlodipine	NN	_	10	nmod
16	/	/	:	_	15	punct
17	valsartan	valsartan	NN	_	19	compound
18	(	(	NN	_	19	compound
19	n	n	NN	_	20	nsubj
20	=	=	JJ	_	15	dep
21	43	43	CD	_	22	nummod
22	)	)	CD	_	20	dobj
23	or	or	CC	_	15	cc
24	to	to	TO	_	25	case
25	therapy	therapy	NN	_	15	conj
26	which	which	WDT	_	27	nsubj
27	corresponded	correspond	VBD	_	25	acl:relcl
28	to	to	TO	_	33	case
29	the	the	DT	_	33	det
30	hospital	hospital	NN	_	33	compound
31	formulary	formulary	NN	_	33	compound
32	(	(	CD	_	33	nummod
33	n	n	NN	_	27	nmod
34	=	=	JJ	_	27	xcomp
35	43	43	CD	_	36	nummod
36	)	)	NN	_	34	dep
37	.	.	.	_	3	punct

1	Correction	correction	NN	_	6	nsubjpass
2	of	of	IN	_	4	case
3	antihypertensive	antihypertensive	JJ	_	4	amod
4	therapy	therapy	NN	_	1	nmod
5	was	be	VBD	_	6	auxpass
6	performed	perform	VBN	_	0	ROOT
7	by	by	IN	_	8	mark
8	treating	treat	VBG	_	6	advcl
9	physician	physician	NN	_	8	dobj
10	at	at	IN	_	12	case
11	daily	daily	JJ	_	12	amod
12	rounds	round	NNS	_	8	nmod
13	.	.	.	_	6	punct

1	Self	self	NN	_	3	compound
2	-	-	:	_	3	punct
3	control	control	NN	_	11	nsubjpass
4	of	of	IN	_	6	case
5	blood	blood	NN	_	6	compound
6	pressure	pressure	NN	_	3	nmod
7	(	(	CD	_	9	nummod
8	BP	bp	NN	_	9	compound
9	)	)	NN	_	6	dep
10	was	be	VBD	_	11	auxpass
11	performed	perform	VBN	_	0	ROOT
12	by	by	IN	_	13	case
13	patients	patient	NNS	_	11	nmod
14	with	with	IN	_	16	case
15	the	the	DT	_	16	det
16	use	use	NN	_	13	nmod
17	of	of	IN	_	19	case
18	UA767PC	ua767pc	NN	_	19	compound
19	apparatus	apparatus	NN	_	16	nmod
20	.	.	.	_	11	punct

1	Results	result	NNS	_	0	ROOT
2	of	of	IN	_	4	case
3	BP	bp	NN	_	4	compound
4	self	self	NN	_	1	nmod
5	-	-	:	_	1	punct
6	control	control	NN	_	8	nsubjpass
7	were	be	VBD	_	8	auxpass
8	compared	compare	VBN	_	1	dep
9	with	with	IN	_	11	case
10	clinical	clinical	JJ	_	11	amod
11	measurements	measurement	NNS	_	8	nmod
12	in	in	IN	_	15	mark
13	order	order	NN	_	12	mwe
14	to	to	TO	_	15	mark
15	detect	detect	VB	_	11	acl
16	concealed	conceal	VBN	_	17	amod
17	inefficacy	inefficacy	NN	_	15	dobj
18	of	of	IN	_	19	case
19	treatment	treatment	NN	_	17	nmod
20	.	.	.	_	1	punct

1	Results	result	NNS	_	0	ROOT
2	.	.	.	_	1	punct

1	Rate	rate	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	achievement	achievement	NN	_	1	nmod
4	of	of	IN	_	6	case
5	target	target	NN	_	6	compound
6	BP	bp	NN	_	3	nmod
7	with	with	IN	_	10	case
8	fixed	fix	VBN	_	10	amod
9	combination	combination	NN	_	10	compound
10	amlodipine	amlodipine	NN	_	1	nmod
11	/	/	:	_	10	punct
12	valsartan	valsartan	NN	_	18	nsubj
13	(	(	CD	_	14	compound
14	93	93	CD	_	15	nummod
15	%	%	NN	_	12	dep
16	)	)	CD	_	15	nummod
17	was	be	VBD	_	18	cop
18	comparable	comparable	JJ	_	10	acl:relcl
19	with	with	IN	_	20	case
20	that	that	DT	_	18	nmod
21	on	on	IN	_	24	case
22	traditional	traditional	JJ	_	24	amod
23	therapy	therapy	NN	_	24	compound
24	(	(	NN	_	20	nmod
25	90	90	CD	_	26	nummod
26	%	%	NN	_	24	dep
27	)	)	CD	_	26	nummod
28	.	.	.	_	1	punct

1	But	but	CC	_	15	cc
2	the	the	DT	_	3	det
3	use	use	NN	_	15	nsubjpass
4	of	of	IN	_	7	case
5	fixed	fix	VBN	_	7	amod
6	combination	combination	NN	_	7	compound
7	amlodipine	amlodipine	NN	_	3	nmod
8	/	/	:	_	7	punct
9	valsartan	valsartan	NN	_	7	dep
10	compared	compare	VBN	_	13	case
11	with	with	IN	_	13	case
12	traditional	traditional	JJ	_	13	amod
13	therapy	therapy	NN	_	3	nmod
14	was	be	VBD	_	15	auxpass
15	associated	associate	VBN	_	0	ROOT
16	with	with	IN	_	18	case
17	lower	lower	JJR	_	18	dep
18	clinical	clinical	JJ	_	15	nmod
19	and	and	CC	_	18	cc
20	self	self	NN	_	18	conj
21	measured	measure	VBD	_	18	dep
22	BP	BP	NNP	_	21	dobj
23	,	,	,	_	22	punct
24	quicker	quicker	JJR	_	25	amod
25	achievement	achievement	NN	_	22	appos
26	of	of	IN	_	28	case
27	target	target	NN	_	28	compound
28	BP	bp	NN	_	25	nmod
29	(	(	CD	_	30	compound
30	5.8	5.8	CD	_	28	nummod
31	+	+	CC	_	28	cc
32	/	/	:	_	28	punct
33	-	-	:	_	53	punct
34	2.3	2.3	CD	_	53	dep
35	and	and	CC	_	34	cc
36	9.2	9.2	CD	_	34	conj
37	+	+	CC	_	34	cc
38	/	/	:	_	53	punct
39	-	-	:	_	53	punct
40	1.8	1.8	CD	_	41	nummod
41	days	day	NNS	_	53	nsubj
42	,	,	,	_	53	punct
43	respectively	respectively	RB	_	53	advmod
44	,	,	,	_	53	punct
45	0.05	0.05	CD	_	46	nummod
46	)	)	NN	_	53	nsubj
47	,	,	,	_	46	punct
48	lesser	lesser	JJR	_	49	amod
49	number	number	NN	_	46	appos
50	of	of	IN	_	52	case
51	antihypertensive	antihypertensive	JJ	_	52	amod
52	drugs	drug	NNS	_	49	nmod
53	(	(	VBP	_	28	dep
54	2.5	2.5	CD	_	53	dobj
55	+	+	CC	_	54	cc
56	/	/	:	_	54	punct
57	-	-	:	_	56	punct
58	0.6	0.6	CD	_	57	root
59	and	and	CC	_	58	cc
60	3.0	3.0	CD	_	58	conj
61	+	+	CC	_	58	cc
62	/	/	:	_	58	conj
63	-	-	:	_	62	punct
64	0.9	0.9	CD	_	65	nummod
65	days	day	NNS	_	63	root
66	,	,	,	_	65	punct
67	respectively	respectively	RB	_	68	advmod
68	)	)	CD	_	66	root
69	,	,	,	_	68	punct
70	lower	lower	JJR	_	71	amod
71	rate	rate	NN	_	69	root
72	of	of	IN	_	74	case
73	concealed	conceal	VBN	_	74	amod
74	inefficacy	inefficacy	NN	_	71	nmod
75	of	of	IN	_	76	case
76	treatment	treatment	NN	_	74	nmod
77	(	(	CD	_	78	nummod
78	12	12	CD	_	81	nummod
79	and	and	CC	_	78	cc
80	31	31	CD	_	78	conj
81	%	%	NN	_	76	dep
82	,	,	,	_	81	punct
83	respectively	respectively	RB	_	81	advmod
84	,	,	,	_	81	punct
85	0.05	0.05	CD	_	86	nummod
86	)	)	NN	_	81	appos
87	.	.	.	_	71	punct

1	Conclusions	conclusion	NNS	_	0	ROOT
2	.	.	.	_	1	punct

1	We	we	PRP	_	3	nsubj
2	have	have	VBP	_	3	aux
3	demonstrated	demonstrate	VBN	_	0	ROOT
4	appropriateness	appropriateness	NN	_	13	dep
5	of	of	IN	_	7	case
6	inhospital	inhospital	JJ	_	7	amod
7	administration	administration	NN	_	4	nmod
8	of	of	IN	_	10	case
9	fixed	fix	VBN	_	10	amod
10	amlodipine	amlodipine	NN	_	7	nmod
11	/	/	:	_	13	punct
12	valsartan	valsartan	NN	_	13	compound
13	combination	combination	NN	_	3	ccomp
14	as	as	IN	_	16	case
15	an	a	DT	_	16	det
16	approach	approach	NN	_	13	nmod
17	allowing	allow	VBG	_	16	acl
18	to	to	TO	_	19	mark
19	achieve	achieve	VB	_	17	xcomp
20	target	target	NN	_	21	compound
21	BP	bp	NN	_	19	dobj
22	in	in	IN	_	24	case
23	shorter	shorter	JJR	_	24	amod
24	time	time	NN	_	19	nmod
25	,	,	,	_	13	punct
26	with	with	IN	_	28	case
27	the	the	DT	_	28	det
28	use	use	NN	_	13	nmod
29	of	of	IN	_	32	case
30	fewer	fewer	JJR	_	32	amod
31	antihypertensive	antihypertensive	JJ	_	32	amod
32	drugs	drug	NNS	_	28	nmod
33	,	,	,	_	13	punct
34	and	and	CC	_	13	cc
35	diminishing	diminish	VBG	_	13	conj
36	concealed	conceal	VBN	_	37	amod
37	inefficacy	inefficacy	NN	_	35	dobj
38	of	of	IN	_	39	case
39	treatment	treatment	NN	_	37	nmod
40	.	.	.	_	3	punct

1	Antitumor	antitumor	JJ	_	2	amod
2	effects	effect	NNS	_	0	ROOT
3	of	of	IN	_	4	case
4	CRM197	crm197	NN	_	2	nmod
5	,	,	,	_	4	punct
6	a	a	DT	_	8	det
7	specific	specific	JJ	_	8	amod
8	inhibitor	inhibitor	NN	_	4	appos
9	of	of	IN	_	10	case
10	HB	hb	NN	_	8	nmod
11	-	-	:	_	8	punct
12	EGF	egf	NN	_	8	dep
13	,	,	,	_	4	punct
14	in	in	IN	_	20	case
15	T	t	NN	_	20	compound
16	-	-	:	_	20	punct
17	cell	cell	NN	_	20	compound
18	acute	acute	JJ	_	20	amod
19	lymphoblastic	lymphoblastic	JJ	_	20	amod
20	leukemia	leukemia	NN	_	2	nmod
21	.	.	.	_	2	punct

1	The	the	DT	_	3	det
2	therapeutic	therapeutic	JJ	_	3	amod
3	outcome	outcome	NN	_	16	nsubj
4	for	for	IN	_	12	case
5	T	t	NN	_	12	compound
6	-	-	:	_	12	punct
7	cell	cell	NN	_	12	compound
8	acute	acute	JJ	_	12	amod
9	lymphoblastic	lymphoblastic	JJ	_	12	amod
10	leukemia	leukemia	NN	_	12	compound
11	(	(	NN	_	12	compound
12	T	t	NN	_	3	nmod
13	-	-	:	_	12	punct
14	ALL	all	NN	_	15	compound
15	)	)	NN	_	12	dep
16	remains	remain	VBZ	_	0	ROOT
17	poor	poor	JJ	_	16	xcomp
18	;	;	:	_	16	punct

1	thus	thus	RB	_	9	advmod
2	,	,	,	_	9	punct
3	novel	novel	JJ	_	9	dep
4	,	,	,	_	9	punct
5	targeted	target	VBN	_	6	amod
6	therapies	therapy	NNS	_	9	nsubjpass
7	are	be	VBP	_	9	auxpass
8	urgently	urgently	RB	_	9	advmod
9	needed	need	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	Recently	recently	RB	_	4	advmod
2	,	,	,	_	4	punct
3	we	we	PRP	_	4	nsubj
4	showed	show	VBD	_	0	ROOT
5	that	that	IN	_	32	mark
6	heparin	heparin	NN	_	11	compound
7	-	-	:	_	11	punct
8	binding	bind	VBG	_	11	amod
9	epidermal	epidermal	JJ	_	11	amod
10	growth	growth	NN	_	11	compound
11	factor	factor	NN	_	32	nsubj
12	-	-	:	_	11	punct
13	like	like	IN	_	15	case
14	growth	growth	NN	_	15	compound
15	factor	factor	NN	_	11	nmod
16	(	(	CD	_	17	nummod
17	HB	hb	NN	_	15	dep
18	-	-	:	_	17	punct
19	EGF	egf	NN	_	20	compound
20	)	)	NN	_	17	dep
21	,	,	,	_	15	punct
22	a	a	DT	_	23	det
23	member	member	NN	_	15	appos
24	of	of	IN	_	27	case
25	the	the	DT	_	27	det
26	EGF	egf	NN	_	27	compound
27	family	family	NN	_	23	nmod
28	,	,	,	_	15	punct
29	is	be	VBZ	_	32	cop
30	a	a	DT	_	32	det
31	promising	promising	JJ	_	32	amod
32	target	target	NN	_	4	ccomp
33	for	for	IN	_	35	case
34	the	the	DT	_	35	det
35	treatment	treatment	NN	_	32	nmod
36	of	of	IN	_	38	case
37	various	various	JJ	_	38	amod
38	types	type	NNS	_	35	nmod
39	of	of	IN	_	40	case
40	cancer	cancer	NN	_	38	nmod
41	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	aim	aim	NN	_	7	nsubj
3	of	of	IN	_	6	case
4	the	the	DT	_	6	det
5	present	present	JJ	_	6	amod
6	study	study	NN	_	2	nmod
7	was	be	VBD	_	0	ROOT
8	to	to	TO	_	9	mark
9	investigate	investigate	VB	_	7	xcomp
10	whether	whether	IN	_	17	mark
11	HB	hb	NN	_	13	compound
12	-	-	:	_	13	punct
13	EGF	egf	NN	_	17	nsubj
14	is	be	VBZ	_	17	cop
15	a	a	DT	_	17	det
16	therapeutic	therapeutic	JJ	_	17	amod
17	target	target	NN	_	9	ccomp
18	for	for	IN	_	21	case
19	T	t	NN	_	21	compound
20	-	-	:	_	21	punct
21	ALL	all	NN	_	17	nmod
22	,	,	,	_	9	punct
23	and	and	CC	_	9	cc
24	to	to	TO	_	26	mark
25	further	further	RB	_	26	advmod
26	elucidate	elucidate	VB	_	9	conj
27	the	the	DT	_	29	det
28	antitumor	antitumor	JJ	_	29	amod
29	effects	effect	NNS	_	26	dobj
30	of	of	IN	_	33	case
31	a	a	DT	_	33	det
32	specific	specific	JJ	_	33	amod
33	inhibitor	inhibitor	NN	_	29	nmod
34	of	of	IN	_	35	case
35	HB	hb	NN	_	33	nmod
36	-	-	:	_	35	punct
37	EGF	egf	NN	_	35	dep
38	,	,	,	_	35	punct
39	cross	cross	NN	_	35	appos
40	-	-	:	_	29	punct
41	reacting	react	VBG	_	29	acl
42	material	material	NN	_	41	dobj
43	197	197	CD	_	44	compound
44	(	(	CD	_	46	nummod
45	CRM197	crm197	NN	_	46	compound
46	)	)	NN	_	42	dep
47	.	.	.	_	7	punct

1	We	we	PRP	_	2	nsubj
2	elucidated	elucidate	VBD	_	0	ROOT
3	the	the	DT	_	4	det
4	expression	expression	NN	_	2	dobj
5	of	of	IN	_	6	case
6	HB	hb	NN	_	4	nmod
7	-	-	:	_	6	punct
8	EGF	egf	NN	_	6	dep
9	in	in	IN	_	14	case
10	T	t	NN	_	14	compound
11	-	-	:	_	14	punct
12	ALL	all	NN	_	14	compound
13	cell	cell	NN	_	14	compound
14	lines	line	NNS	_	8	nmod
15	,	,	,	_	6	punct
16	and	and	CC	_	2	cc
17	evaluated	evaluate	VBD	_	2	conj
18	the	the	DT	_	19	det
19	effect	effect	NN	_	17	dobj
20	of	of	IN	_	21	case
21	CRM197	crm197	NN	_	19	nmod
22	on	on	IN	_	24	case
23	these	these	DT	_	24	det
24	cells	cell	NNS	_	19	nmod
25	alone	alone	RB	_	26	advmod
26	or	or	CC	_	24	advmod
27	in	in	IN	_	28	case
28	combination	combination	NN	_	26	conj
29	with	with	IN	_	31	case
30	anticancer	anticancer	JJ	_	31	amod
31	agent	agent	NN	_	28	nmod
32	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	expression	expression	NN	_	9	nsubjpass
3	of	of	IN	_	4	case
4	EGFR	egfr	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	EGFR	egfr	NN	_	4	conj
7	ligands	ligand	NNS	_	4	dep
8	was	be	VBD	_	9	auxpass
9	determined	determine	VBN	_	0	ROOT
10	by	by	IN	_	12	case
11	flow	flow	NN	_	12	compound
12	cytometry	cytometry	NN	_	9	nmod
13	,	,	,	_	12	punct
14	RT	rt	NN	_	16	compound
15	-	-	:	_	16	punct
16	PCR	pcr	NN	_	12	conj
17	and	and	CC	_	12	cc
18	real	real	JJ	_	20	amod
19	-	-	:	_	20	punct
20	time	time	NN	_	12	conj
21	quantitative	quantitative	JJ	_	22	amod
22	PCR	pcr	NN	_	20	dep
23	.	.	.	_	9	punct

1	Induction	induction	NN	_	5	nsubjpass
2	of	of	IN	_	3	case
3	apoptosis	apoptosis	NN	_	1	nmod
4	was	be	VBD	_	5	auxpass
5	assessed	assess	VBN	_	0	ROOT
6	by	by	IN	_	8	case
7	TUNEL	tunel	NN	_	8	compound
8	assay	assay	NN	_	5	nmod
9	.	.	.	_	5	punct

1	HB	hb	SYM	_	6	dep
2	-	-	:	_	6	punct
3	EGF	egf	NN	_	6	nsubjpass
4	was	be	VBD	_	6	auxpass
5	strongly	strongly	RB	_	6	advmod
6	expressed	express	VBN	_	0	ROOT
7	by	by	IN	_	12	case
8	T	t	NN	_	12	compound
9	-	-	:	_	12	punct
10	ALL	all	NN	_	12	compound
11	cell	cell	NN	_	12	compound
12	lines	line	NNS	_	6	nmod
13	,	,	,	_	6	punct
14	and	and	CC	_	6	cc
15	the	the	DT	_	16	det
16	expression	expression	NN	_	25	nsubjpass
17	of	of	IN	_	19	case
18	both	both	DT	_	19	cc:preconj
19	HB	hb	NN	_	16	nmod
20	-	-	:	_	19	punct
21	EGF	egf	NN	_	19	dep
22	and	and	CC	_	21	cc
23	EGFR	egfr	NN	_	21	conj
24	was	be	VBD	_	25	auxpass
25	enhanced	enhance	VBN	_	6	conj
26	by	by	IN	_	27	case
27	doxorubicin	doxorubicin	NN	_	25	nmod
28	.	.	.	_	6	punct

1	CRM197	crm197	NN	_	2	nsubj
2	induced	induce	VBD	_	0	ROOT
3	apoptosis	apoptosis	NN	_	2	dobj
4	,	,	,	_	2	punct
5	and	and	CC	_	2	cc
6	furthermore	furthermore	RB	_	14	advmod
7	,	,	,	_	14	punct
8	the	the	DT	_	9	det
9	combination	combination	NN	_	14	nsubj
10	of	of	IN	_	11	case
11	CRM197	crm197	NN	_	9	nmod
12	plus	plus	CC	_	11	cc
13	doxorubicin	doxorubicin	NN	_	11	conj
14	enhanced	enhance	VBD	_	2	conj
15	cytotoxicity	cytotoxicity	NN	_	14	dobj
16	in	in	IN	_	22	case
17	a	a	DT	_	22	det
18	T	t	NN	_	22	compound
19	-	-	:	_	22	punct
20	ALL	all	NN	_	22	compound
21	cell	cell	NN	_	22	compound
22	line	line	NN	_	14	nmod
23	.	.	.	_	2	punct

1	These	these	DT	_	2	det
2	results	result	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	12	mark
5	HB	hb	NN	_	7	compound
6	-	-	:	_	7	punct
7	EGF	egf	NN	_	12	nsubj
8	is	be	VBZ	_	12	cop
9	a	a	DT	_	12	det
10	promising	promising	JJ	_	12	amod
11	therapeutic	therapeutic	JJ	_	12	amod
12	target	target	NN	_	3	ccomp
13	for	for	IN	_	16	case
14	T	t	NN	_	16	compound
15	-	-	:	_	16	punct
16	ALL	all	NN	_	12	nmod
17	.	.	.	_	3	punct

1	Distinct	distinct	JJ	_	3	amod
2	synergistic	synergistic	JJ	_	3	amod
3	action	action	NN	_	0	ROOT
4	of	of	IN	_	5	case
5	piperacillin	piperacillin	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	methylglyoxal	methylglyoxal	NN	_	5	conj
8	against	against	IN	_	10	case
9	Pseudomonas	pseudomonas	FW	_	10	compound
10	aeruginosa	aeruginosa	FW	_	3	nmod
11	.	.	.	_	3	punct

1	The	the	DT	_	4	det
2	dicarbonyl	dicarbonyl	NN	_	4	compound
3	compound	compound	NN	_	4	compound
4	methylglyoxal	methylglyoxal	NN	_	8	nsubj
5	is	be	VBZ	_	8	cop
6	a	a	DT	_	8	det
7	natural	natural	JJ	_	8	amod
8	constituent	constituent	NN	_	0	ROOT
9	of	of	IN	_	11	case
10	Manuka	Manuka	NNP	_	11	compound
11	honey	honey	NN	_	8	nmod
12	produced	produce	VBD	_	8	acl
13	from	from	IN	_	15	case
14	Manuka	Manuka	NNP	_	15	compound
15	flowers	flower	NNS	_	12	nmod
16	in	in	IN	_	18	case
17	New	New	NNP	_	18	compound
18	Zealand	Zealand	NNP	_	15	nmod
19	.	.	.	_	8	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	known	know	VBN	_	0	ROOT
4	to	to	TO	_	5	mark
5	possess	possess	VB	_	3	xcomp
6	both	both	CC	_	7	cc:preconj
7	anticancer	anticancer	JJ	_	10	amod
8	and	and	CC	_	7	cc
9	antibacterial	antibacterial	JJ	_	7	conj
10	activity	activity	NN	_	5	dobj
11	.	.	.	_	3	punct

1	Such	such	JJ	_	2	amod
2	observations	observation	NNS	_	3	nsubj
3	prompted	prompt	VBD	_	0	ROOT
4	to	to	TO	_	5	mark
5	investigate	investigate	VB	_	3	xcomp
6	the	the	DT	_	7	det
7	ability	ability	NN	_	5	dobj
8	of	of	IN	_	9	case
9	methylglyoxal	methylglyoxal	NN	_	7	nmod
10	as	as	IN	_	13	case
11	a	a	DT	_	13	det
12	potent	potent	JJ	_	13	amod
13	drug	drug	NN	_	7	nmod
14	against	against	IN	_	18	case
15	multidrug	multidrug	JJ	_	18	amod
16	resistant	resistant	JJ	_	18	amod
17	Pseudomonas	pseudomonas	FW	_	18	compound
18	aeruginosa	aeruginosa	FW	_	13	nmod
19	.	.	.	_	3	punct

1	A	a	DT	_	2	det
2	total	total	NN	_	0	ROOT
3	of	of	IN	_	6	case
4	12	12	CD	_	6	nummod
5	test	test	NN	_	6	compound
6	P	p	NN	_	2	nmod
7	.	.	.	_	2	punct

1	aeruginosa	aeruginosa	FW	_	2	compound
2	strains	strain	NNS	_	8	nsubjpass
3	isolated	isolate	VBN	_	2	acl
4	from	from	IN	_	6	case
5	various	various	JJ	_	6	amod
6	hospitals	hospital	NNS	_	3	nmod
7	were	be	VBD	_	8	auxpass
8	tested	test	VBN	_	0	ROOT
9	for	for	IN	_	11	case
10	their	they	PRP$	_	11	nmod:poss
11	resistances	resistance	NNS	_	8	nmod
12	against	against	IN	_	14	case
13	many	many	JJ	_	14	amod
14	antibiotics	antibiotic	NNS	_	11	nmod
15	,	,	,	_	14	punct
16	most	most	JJS	_	20	nsubjpass
17	of	of	IN	_	18	case
18	which	which	WDT	_	16	nmod
19	are	be	VBP	_	20	auxpass
20	applied	apply	VBN	_	14	acl:relcl
21	in	in	IN	_	23	case
22	the	the	DT	_	23	det
23	treatment	treatment	NN	_	20	nmod
24	of	of	IN	_	25	case
25	P	p	NN	_	23	nmod
26	.	.	.	_	8	punct

1	aeruginosa	aeruginosa	FW	_	2	compound
2	infections	infection	NNS	_	0	ROOT
3	.	.	.	_	2	punct

1	Results	result	NNS	_	2	nsubj
2	revealed	reveal	VBD	_	0	ROOT
3	that	that	IN	_	7	mark
4	the	the	DT	_	5	det
5	strains	strain	NNS	_	7	nsubj
6	were	be	VBD	_	7	cop
7	resistant	resistant	JJ	_	2	ccomp
8	to	to	TO	_	10	case
9	many	many	JJ	_	10	amod
10	drugs	drug	NNS	_	7	nmod
11	at	at	IN	_	13	case
12	high	high	JJ	_	13	amod
13	levels	level	NNS	_	7	nmod
14	,	,	,	_	7	punct
15	only	only	RB	_	16	advmod
16	piperacillin	piperacillin	NN	_	23	nsubj
17	,	,	,	_	16	punct
18	carbenicillin	carbenicillin	NN	_	16	conj
19	,	,	,	_	16	punct
20	amikacin	amikacin	NN	_	16	conj
21	and	and	CC	_	16	cc
22	ciprofloxacin	ciprofloxacin	NN	_	16	conj
23	showed	show	VBD	_	7	ccomp
24	resistances	resistance	NNS	_	23	dobj
25	at	at	IN	_	28	case
26	comparatively	comparatively	RB	_	27	advmod
27	lower	lower	JJR	_	28	amod
28	levels	level	NNS	_	23	nmod
29	.	.	.	_	2	punct

1	Following	follow	VBG	_	3	case
2	multiple	multiple	JJ	_	3	amod
3	experimentations	experimentation	NNS	_	6	nmod
4	it	it	PRP	_	6	nsubjpass
5	was	be	VBD	_	6	auxpass
6	observed	observe	VBN	_	0	ROOT
7	that	that	IN	_	11	mark
8	methylglyoxal	methylglyoxal	NN	_	11	nsubj
9	was	be	VBD	_	11	cop
10	also	also	RB	_	11	advmod
11	antimicrobic	antimicrobic	JJ	_	6	ccomp
12	against	against	IN	_	15	case
13	all	all	PDT	_	15	det:predet
14	the	the	DT	_	15	det
15	strains	strain	NNS	_	11	nmod
16	at	at	IN	_	18	case
17	comparable	comparable	JJ	_	18	amod
18	levels	level	NNS	_	11	nmod
19	.	.	.	_	6	punct

1	Distinct	distinct	JJ	_	5	amod
2	and	and	CC	_	1	cc
3	statistically	statistically	RB	_	4	advmod
4	significant	significant	JJ	_	1	conj
5	synergism	synergism	NN	_	7	nsubjpass
6	was	be	VBD	_	7	auxpass
7	observed	observe	VBN	_	0	ROOT
8	between	between	IN	_	9	case
9	methylglyoxal	methylglyoxal	JJ	_	7	nmod
10	and	and	CC	_	9	cc
11	piperacillin	piperacillin	NN	_	9	conj
12	by	by	IN	_	15	case
13	disc	disc	NN	_	15	compound
14	diffusion	diffusion	NN	_	15	compound
15	tests	test	NNS	_	7	nmod
16	when	when	WRB	_	17	advmod
17	compared	compare	VBN	_	7	advcl
18	with	with	IN	_	21	case
19	their	they	PRP$	_	21	nmod:poss
20	individual	individual	JJ	_	21	amod
21	effects	effect	NNS	_	17	nmod
22	.	.	.	_	7	punct

1	The	the	DT	_	5	det
2	fractional	fractional	JJ	_	5	amod
3	inhibitory	inhibitory	JJ	_	5	amod
4	concentration	concentration	NN	_	5	compound
5	index	index	NN	_	15	nsubj
6	of	of	IN	_	8	case
7	this	this	DT	_	8	det
8	combination	combination	NN	_	5	nmod
9	evaluated	evaluate	VBN	_	8	acl
10	by	by	IN	_	12	case
11	checkerboard	checkerboard	NN	_	12	compound
12	analysis	analysis	NN	_	9	nmod
13	,	,	,	_	5	punct
14	was	be	VBD	_	15	cop
15	0.5	0.5	CD	_	0	ROOT
16	,	,	,	_	15	punct
17	which	which	WDT	_	18	nsubj
18	confirmed	confirm	VBD	_	15	acl:relcl
19	synergism	synergism	NN	_	18	dobj
20	between	between	IN	_	22	case
21	the	the	DT	_	22	det
22	pair	pair	NN	_	19	nmod
23	.	.	.	_	15	punct

1	Synergism	synergism	NN	_	4	nsubjpass
2	was	be	VBD	_	4	auxpass
3	also	also	RB	_	4	advmod
4	noted	note	VBN	_	0	ROOT
5	when	when	WRB	_	8	advmod
6	methylglyoxal	methylglyoxal	NN	_	8	nsubjpass
7	was	be	VBD	_	8	auxpass
8	combined	combine	VBN	_	4	advcl
9	with	with	IN	_	10	case
10	carbenicillin	carbenicillin	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	amikacin	amikacin	NN	_	10	conj
13	.	.	.	_	4	punct

1	Implanon	implanon	NN	_	2	compound
2	failure	failure	NN	_	0	ROOT
3	in	in	IN	_	8	case
4	an	a	DT	_	8	det
5	HIV	hiv	NN	_	8	compound
6	-	-	:	_	8	punct
7	positive	positive	JJ	_	8	amod
8	woman	woman	NN	_	2	nmod
9	on	on	IN	_	11	case
10	antiretroviral	antiretroviral	JJ	_	11	amod
11	therapy	therapy	NN	_	8	nmod
12	resulting	result	VBG	_	11	acl
13	in	in	IN	_	16	case
14	two	two	CD	_	16	nummod
15	ectopic	ectopic	JJ	_	16	amod
16	pregnancies	pregnancy	NNS	_	12	nmod
17	.	.	.	_	2	punct

1	Since	since	IN	_	3	case
2	its	its	PRP$	_	3	nmod:poss
3	introduction	introduction	NN	_	8	nmod
4	in	in	IN	_	5	case
5	1999	1999	CD	_	3	nmod
6	,	,	,	_	8	punct
7	Implanon	implanon	NN	_	8	nsubj
8	remains	remain	VBZ	_	0	ROOT
9	one	one	CD	_	8	xcomp
10	of	of	IN	_	14	case
11	the	the	DT	_	14	det
12	preferred	preferred	JJ	_	14	amod
13	contraceptive	contraceptive	JJ	_	14	amod
14	choices	choice	NNS	_	9	nmod
15	for	for	IN	_	17	case
16	many	many	JJ	_	17	amod
17	women	woman	NNS	_	14	nmod
18	as	as	IN	_	20	mark
19	it	it	PRP	_	20	nsubj
20	offers	offer	VBZ	_	8	advcl
21	a	a	DT	_	24	det
22	highly	highly	RB	_	23	advmod
23	effective	effective	JJ	_	24	amod
24	means	means	NNS	_	20	dobj
25	of	of	IN	_	29	case
26	long	long	JJ	_	29	amod
27	-	-	:	_	29	punct
28	term	term	NN	_	29	compound
29	contraception	contraception	NN	_	24	nmod
30	for	for	IN	_	32	case
31	three	three	CD	_	32	nummod
32	years	year	NNS	_	29	nmod
33	that	that	WDT	_	36	nsubj
34	does	do	VBZ	_	36	aux
35	not	not	RB	_	36	neg
36	rely	rely	VB	_	24	acl:relcl
37	on	on	IN	_	38	case
38	adherence	adherence	NN	_	36	nmod
39	.	.	.	_	8	punct

1	Like	like	IN	_	4	case
2	all	all	DT	_	4	det
3	hormonal	hormonal	JJ	_	4	amod
4	contraceptives	contraceptive	NNS	_	13	nmod
5	,	,	,	_	13	punct
6	certain	certain	JJ	_	8	amod
7	hepatic	hepatic	JJ	_	8	amod
8	enzyme	enzyme	NN	_	13	nsubj
9	-	-	:	_	13	punct
10	inducing	induce	VBG	_	13	csubj
11	drugs	drug	NNS	_	10	dobj
12	may	may	MD	_	13	aux
13	reduce	reduce	VB	_	0	ROOT
14	its	its	PRP$	_	15	nmod:poss
15	efficacy	efficacy	NN	_	13	dobj
16	.	.	.	_	13	punct

1	We	we	PRP	_	2	nsubj
2	present	present	VBP	_	0	ROOT
3	an	a	DT	_	5	det
4	interesting	interesting	JJ	_	5	amod
5	case	case	NN	_	2	dobj
6	of	of	IN	_	11	case
7	an	a	DT	_	11	det
8	HIV	hiv	NN	_	11	compound
9	-	-	:	_	11	punct
10	positive	positive	JJ	_	11	amod
11	woman	woman	NN	_	5	nmod
12	on	on	IN	_	14	case
13	antiretroviral	antiretroviral	JJ	_	14	amod
14	therapy	therapy	NN	_	11	nmod
15	having	have	VBG	_	11	acl
16	tubal	tubal	JJ	_	17	amod
17	pregnancies	pregnancy	NNS	_	15	dobj
18	on	on	IN	_	21	case
19	two	two	CD	_	21	nummod
20	separate	separate	JJ	_	21	amod
21	occasions	occasion	NNS	_	15	nmod
22	with	with	IN	_	23	case
23	Implanon	implanon	NN	_	21	nmod
24	in	in	IN	_	25	case
25	place	place	NN	_	21	nmod
26	.	.	.	_	2	punct

1	Tamoxifen	tamoxifen	NN	_	5	compound
2	and	and	CC	_	1	cc
3	CYP	cyp	NN	_	1	conj
4	2D6	2d6	NN	_	5	compound
5	inhibitors	inhibitor	NNS	_	0	ROOT
6	:	:	:	_	5	punct
7	caution	caution	NN	_	5	dep
8	.	.	.	_	5	punct

1	Tamoxifen	tamoxifen	NN	_	11	nsubj
2	,	,	,	_	1	punct
3	an	a	DT	_	5	det
4	estrogen	estrogen	NN	_	5	compound
5	antagonist	antagonist	NN	_	1	appos
6	,	,	,	_	1	punct
7	is	be	VBZ	_	11	cop
8	the	the	DT	_	11	det
9	standard	standard	JJ	_	11	amod
10	hormone	hormone	NN	_	11	compound
11	treatment	treatment	NN	_	0	ROOT
12	for	for	IN	_	14	case
13	breast	breast	NN	_	14	compound
14	cancer	cancer	NN	_	11	nmod
15	.	.	.	_	11	punct

1	It	it	PRP	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	extensively	extensively	RB	_	4	advmod
4	transformed	transform	VBN	_	0	ROOT
5	into	into	IN	_	8	case
6	its	its	PRP$	_	8	nmod:poss
7	active	active	JJ	_	8	amod
8	metabolites	metabolite	NNS	_	4	nmod
9	by	by	IN	_	14	case
10	the	the	DT	_	14	det
11	cytochrome	cytochrome	NN	_	14	compound
12	P450	p450	NN	_	14	compound
13	enzyme	enzyme	NN	_	14	compound
14	system	system	NN	_	4	nmod
15	,	,	,	_	4	punct
16	especially	especially	RB	_	18	advmod
17	into	into	IN	_	18	case
18	endoxifen	endoxifen	NN	_	4	nmod
19	by	by	IN	_	22	case
20	isoenzyme	isoenzyme	NN	_	22	compound
21	CYP	cyp	NN	_	22	compound
22	2D6	2d6	NN	_	18	nmod
23	.	.	.	_	4	punct

1	Co	Co	NNP	_	11	nsubj
2	-	-	:	_	1	punct
3	administration	administration	NN	_	1	dep
4	of	of	IN	_	5	case
5	tamoxifen	tamoxifen	NN	_	3	nmod
6	with	with	IN	_	10	case
7	isoenzyme	isoenzyme	NN	_	10	compound
8	CYP	cyp	NN	_	10	compound
9	2D6	2d6	NN	_	10	compound
10	inhibitors	inhibitor	NNS	_	3	nmod
11	reduces	reduce	VBZ	_	0	ROOT
12	this	this	DT	_	13	det
13	metabolism	metabolism	NN	_	11	dobj
14	.	.	.	_	11	punct

1	Selective	selective	JJ	_	8	amod
2	serotonin	serotonin	NN	_	8	compound
3	reuptake	reuptake	NN	_	8	compound
4	inhibitor	inhibitor	NN	_	8	compound
5	(	(	NN	_	8	compound
6	SSRI	ssri	NN	_	8	compound
7	)	)	CD	_	8	nummod
8	antidepressants	antidepressant	NNS	_	9	nsubj
9	inhibit	inhibit	VBP	_	0	ROOT
10	isoenzyme	isoenzyme	NN	_	12	compound
11	CYP	cyp	NN	_	12	compound
12	2D6	2d6	NN	_	9	dobj
13	.	.	.	_	9	punct

1	Paroxetine	Paroxetine	NNP	_	4	nsubj
2	and	and	CC	_	1	cc
3	fluoxetine	fluoxetine	NN	_	1	conj
4	reduce	reduce	VB	_	0	ROOT
5	the	the	DT	_	7	det
6	plasma	plasma	NN	_	7	compound
7	concentration	concentration	NN	_	4	dobj
8	of	of	IN	_	9	case
9	endoxifen	endoxifen	NN	_	7	nmod
10	by	by	IN	_	13	case
11	about	about	IN	_	12	advmod
12	50	50	CD	_	13	nummod
13	%	%	NN	_	4	nmod
14	.	.	.	_	4	punct

1	Two	two	CD	_	3	nummod
2	epidemiological	epidemiological	JJ	_	3	amod
3	studies	study	NNS	_	9	nsubj
4	involving	involve	VBG	_	3	acl
5	about	about	IN	_	6	advmod
6	3700	3700	CD	_	7	nummod
7	women	woman	NNS	_	4	dobj
8	have	have	VBP	_	9	aux
9	shown	show	VBN	_	0	ROOT
10	a	a	DT	_	11	det
11	link	link	NN	_	9	dobj
12	between	between	IN	_	14	case
13	the	the	DT	_	14	det
14	use	use	NN	_	11	nmod
15	of	of	IN	_	17	case
16	SSRI	SSRI	NNP	_	17	compound
17	antidepressants	antidepressant	NNS	_	14	nmod
18	and	and	CC	_	14	cc
19	an	a	DT	_	21	det
20	increased	increase	VBN	_	21	amod
21	frequency	frequency	NN	_	14	conj
22	of	of	IN	_	25	case
23	breast	breast	NN	_	25	compound
24	cancer	cancer	NN	_	25	compound
25	recurrence	recurrence	NN	_	21	nmod
26	.	.	.	_	9	punct

1	Other	other	JJ	_	2	amod
2	studies	study	NNS	_	13	nsubj
3	,	,	,	_	2	punct
4	with	with	IN	_	7	case
5	a	a	DT	_	7	det
6	lower	lower	JJR	_	7	amod
7	level	level	NN	_	2	nmod
8	of	of	IN	_	9	case
9	evidence	evidence	NN	_	7	nmod
10	,	,	,	_	2	punct
11	were	be	VBD	_	13	cop
12	less	less	RBR	_	13	advmod
13	convincing	convincing	JJ	_	0	ROOT
14	.	.	.	_	13	punct

1	Studies	study	NNS	_	8	nsubj
2	of	of	IN	_	7	case
3	other	other	JJ	_	7	amod
4	isoenzyme	isoenzyme	NN	_	7	compound
5	CYP	cyp	NN	_	7	compound
6	2D6	2d6	NN	_	7	compound
7	inhibitors	inhibitor	NNS	_	1	nmod
8	showed	show	VBD	_	0	ROOT
9	no	no	DT	_	10	neg
10	increase	increase	NN	_	8	dobj
11	in	in	IN	_	13	case
12	the	the	DT	_	13	det
13	risk	risk	NN	_	10	nmod
14	of	of	IN	_	17	case
15	breast	breast	NN	_	17	compound
16	cancer	cancer	NN	_	17	compound
17	recurrence	recurrence	NN	_	13	nmod
18	,	,	,	_	8	punct
19	but	but	CC	_	8	cc
20	they	they	PRP	_	21	nsubj
21	lacked	lack	VBD	_	8	conj
22	statistical	statistical	JJ	_	23	amod
23	power	power	NN	_	21	dobj
24	.	.	.	_	8	punct

1	It	it	PRP	_	3	nsubj
2	is	be	VBZ	_	3	cop
3	better	better	JJR	_	0	ROOT
4	to	to	TO	_	5	mark
5	avoid	avoid	VB	_	3	xcomp
6	prescribing	prescribe	VBG	_	5	xcomp
7	isoenzyme	isoenzyme	NN	_	10	compound
8	CYP	cyp	NN	_	10	compound
9	2D6	2d6	NN	_	10	compound
10	inhibitors	inhibitor	NNS	_	6	dobj
11	to	to	TO	_	12	case
12	women	woman	NNS	_	6	nmod
13	treated	treat	VBN	_	12	acl
14	with	with	IN	_	15	case
15	tamoxifen	tamoxifen	NN	_	13	nmod
16	for	for	IN	_	18	case
17	breast	breast	NN	_	18	compound
18	cancer	cancer	NN	_	15	nmod
19	,	,	,	_	3	punct
20	especially	especially	RB	_	22	advmod
21	SSRI	SSRI	NNP	_	22	compound
22	antidepressants	antidepressant	NNS	_	3	dep
23	such	such	JJ	_	25	case
24	as	as	IN	_	23	mwe
25	paroxetine	paroxetine	NN	_	22	nmod
26	and	and	CC	_	25	cc
27	fluoxetine	fluoxetine	NN	_	25	conj
28	.	.	.	_	3	punct

1	Depression	depression	NN	_	5	nsubj
2	does	do	VBZ	_	5	aux
3	not	not	RB	_	5	neg
4	always	always	RB	_	5	advmod
5	require	require	VB	_	0	ROOT
6	antidepressant	antidepressant	JJ	_	8	amod
7	drug	drug	NN	_	8	compound
8	therapy	therapy	NN	_	5	dobj
9	,	,	,	_	5	punct
10	and	and	CC	_	5	cc
11	antidepressants	antidepressant	NNS	_	12	nsubj
12	have	have	VBP	_	5	conj
13	no	no	DT	_	16	neg
14	proven	proven	JJ	_	16	amod
15	preventive	preventive	JJ	_	16	amod
16	impact	impact	NN	_	12	dobj
17	on	on	IN	_	19	case
18	hot	hot	JJ	_	19	amod
19	flushes	flush	NNS	_	16	nmod
20	linked	link	VBN	_	19	acl
21	to	to	TO	_	23	case
22	the	the	DT	_	23	det
23	menopause	menopause	NN	_	20	nmod
24	.	.	.	_	5	punct

1	If	if	IN	_	9	mark
2	in	in	IN	_	4	case
3	certain	certain	JJ	_	4	amod
4	cases	case	NNS	_	9	nmod
5	,	,	,	_	9	punct
6	an	a	DT	_	7	det
7	antidepressant	antidepressant	JJ	_	9	nsubjpass
8	is	be	VBZ	_	9	auxpass
9	considered	consider	VBN	_	15	advcl
10	necessary	necessary	JJ	_	9	xcomp
11	,	,	,	_	15	punct
12	it	it	PRP	_	15	nsubj
13	may	may	MD	_	15	aux
14	be	be	VB	_	15	cop
15	advisable	advisable	JJ	_	0	ROOT
16	to	to	TO	_	17	mark
17	replace	replace	VB	_	15	xcomp
18	tamoxifen	tamoxifen	NN	_	17	dobj
19	with	with	IN	_	20	case
20	anastrozole	anastrozole	NN	_	17	nmod
21	.	.	.	_	15	punct

1	Phase	phase	NN	_	3	compound
2	I	i	CD	_	3	nummod
3	trial	trial	NN	_	0	ROOT
4	of	of	IN	_	5	case
5	lenalidomide	lenalidomide	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	CCI	cci	NN	_	5	conj
8	-	-	:	_	3	punct
9	779	779	CD	_	3	dep
10	in	in	IN	_	11	case
11	patients	patient	NNS	_	9	nmod
12	with	with	IN	_	15	case
13	relapsed	relapse	VBN	_	15	amod
14	multiple	multiple	JJ	_	15	amod
15	myeloma	myeloma	NN	_	11	nmod
16	:	:	:	_	3	punct
17	evidence	evidence	NN	_	3	dep
18	for	for	IN	_	19	case
19	lenalidomide	lenalidomide	NN	_	17	nmod
20	-	-	:	_	19	punct
21	CCI	cci	SYM	_	24	dep
22	-	-	:	_	24	punct
23	779	779	CD	_	24	nummod
24	interaction	interaction	NN	_	19	dep
25	via	via	IN	_	26	case
26	P	p	NN	_	24	nmod
27	-	-	:	_	26	punct
28	glycoprotein	glycoprotein	NN	_	26	dep
29	.	.	.	_	3	punct

1	Multiple	multiple	JJ	_	5	amod
2	myeloma	myeloma	NN	_	5	compound
3	(	(	CD	_	5	nummod
4	MM	mm	NN	_	5	compound
5	)	)	NN	_	12	nsubj
6	is	be	VBZ	_	12	cop
7	an	a	DT	_	12	det
8	incurable	incurable	JJ	_	12	amod
9	plasma	plasma	NN	_	12	compound
10	-	-	:	_	12	punct
11	cell	cell	NN	_	12	compound
12	neoplasm	neoplasm	NN	_	0	ROOT
13	for	for	IN	_	14	case
14	which	which	WDT	_	17	nmod
15	most	most	RBS	_	16	amod
16	treatments	treatment	NNS	_	17	nsubj
17	involve	involve	VBP	_	12	acl:relcl
18	a	a	DT	_	20	det
19	therapeutic	therapeutic	JJ	_	20	amod
20	agent	agent	NN	_	17	dobj
21	combined	combine	VBN	_	20	acl
22	with	with	IN	_	23	case
23	dexamethasone	dexamethasone	NN	_	21	nmod
24	.	.	.	_	12	punct

1	The	the	DT	_	3	det
2	preclinical	preclinical	JJ	_	3	amod
3	combination	combination	NN	_	0	ROOT
4	of	of	IN	_	5	case
5	lenalidomide	lenalidomide	NN	_	3	nmod
6	with	with	IN	_	10	case
7	the	the	DT	_	10	det
8	mTOR	mtor	NN	_	10	compound
9	inhibitor	inhibitor	NN	_	10	compound
10	CCI	cci	NN	_	3	nmod
11	-	-	:	_	10	punct
12	779	779	CD	_	14	nsubj
13	has	have	VBZ	_	14	aux
14	displayed	display	VBN	_	10	acl:relcl
15	synergy	synergy	NN	_	14	dobj
16	in	in	FW	_	17	compound
17	vitro	vitro	FW	_	15	advmod
18	and	and	CC	_	14	cc
19	represents	represent	VBZ	_	14	conj
20	a	a	DT	_	22	det
21	novel	novel	JJ	_	22	amod
22	combination	combination	NN	_	19	dobj
23	in	in	IN	_	24	case
24	MM	mm	NN	_	22	nmod
25	.	.	.	_	3	punct

1	In	in	FW	_	4	amod
2	vivo	vivo	FW	_	1	dep
3	CYP3A	cyp3a	NN	_	4	compound
4	activity	activity	NN	_	7	nsubj
5	is	be	VBZ	_	7	cop
6	significantly	significantly	RB	_	7	advmod
7	lower	lower	JJR	_	0	ROOT
8	in	in	IN	_	9	case
9	cyclosporine	cyclosporine	NN	_	7	nmod
10	-	-	:	_	9	punct
11	treated	treat	VBN	_	9	acl
12	as	as	IN	_	13	mark
13	compared	compare	VBN	_	11	advcl
14	with	with	IN	_	15	case
15	tacrolimus	tacrolimus	NN	_	13	nmod
16	-	-	:	_	15	punct
17	treated	treat	VBN	_	20	amod
18	renal	renal	JJ	_	20	amod
19	allograft	allograft	NN	_	20	compound
20	recipients	recipient	NNS	_	15	dep
21	.	.	.	_	7	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	5	nsubj
4	have	have	VBP	_	5	aux
5	identified	identify	VBN	_	0	ROOT
6	cyclosporine	cyclosporine	NN	_	5	dobj
7	and	and	CC	_	6	cc
8	tacrolimus	tacrolimus	NN	_	6	conj
9	as	as	IN	_	11	case
10	CYP3A	cyp3a	NN	_	11	compound
11	inhibitors	inhibitor	NNS	_	5	nmod
12	.	.	.	_	5	punct

1	In	in	IN	_	4	case
2	the	the	DT	_	4	det
3	current	current	JJ	_	4	amod
4	study	study	NN	_	11	nmod
5	in	in	IN	_	8	case
6	renal	renal	JJ	_	8	amod
7	allograft	allograft	NN	_	8	compound
8	recipients	recipient	NNS	_	4	nmod
9	,	,	,	_	11	punct
10	we	we	PRP	_	11	nsubj
11	used	use	VBD	_	0	ROOT
12	intravenously	intravenously	RB	_	13	advmod
13	and	and	CC	_	15	advmod
14	orally	orally	RB	_	13	advmod
15	administered	administer	VBN	_	11	dep
16	midazolam	midazolam	NN	_	15	dobj
17	as	as	IN	_	20	case
18	a	a	DT	_	20	det
19	drug	drug	NN	_	20	compound
20	probe	probe	NN	_	15	nmod
21	to	to	TO	_	22	mark
22	assess	assess	VB	_	15	advcl
23	whether	whether	IN	_	26	mark
24	the	the	DT	_	25	det
25	study	study	NN	_	26	nsubj
26	drugs	drug	NNS	_	22	ccomp
27	at	at	IN	_	28	case
28	doses	dose	NNS	_	26	nmod
29	that	that	WDT	_	32	nsubjpass
30	are	be	VBP	_	32	auxpass
31	generally	generally	RB	_	32	advmod
32	used	use	VBN	_	28	acl:relcl
33	in	in	IN	_	35	case
34	clinical	clinical	JJ	_	35	amod
35	practice	practice	NN	_	32	nmod
36	have	have	VBP	_	15	dep
37	differential	differential	JJ	_	38	amod
38	effects	effect	NNS	_	36	dobj
39	on	on	IN	_	42	case
40	in	in	FW	_	42	amod
41	vivo	vivo	FW	_	40	dep
42	hepatic	hepatic	JJ	_	36	nmod
43	and	and	CC	_	42	cc
44	first	first	JJ	_	42	conj
45	-	-	:	_	46	punct
46	pass	pass	VB	_	42	dep
47	CYP3A	cyp3a	NN	_	48	compound
48	activities	activity	NNS	_	46	dobj
49	.	.	.	_	11	punct

1	Systemic	systemic	JJ	_	6	amod
2	and	and	CC	_	1	cc
3	apparent	apparent	JJ	_	1	conj
4	oral	oral	JJ	_	6	amod
5	midazolam	midazolam	NN	_	6	compound
6	clearance	clearance	NN	_	9	nsubj
7	were	be	VBD	_	9	cop
8	24	24	CD	_	9	nummod
9	%	%	NN	_	0	ROOT
10	(	(	CD	_	11	compound
11	269	269	CD	_	12	nummod
12	73	73	CD	_	9	dep
13	vs	vs	CC	_	12	advmod
14	.	.	.	_	9	punct
15	354	354	CD	_	17	nummod
16	102	102	CD	_	17	nummod
17	ml	ml	NN	_	9	dep
18	/	/	:	_	17	punct
19	min	min	NN	_	17	dep
20	,	,	,	_	17	punct
21	P	p	NN	_	22	nsubj
22	=	=	JJ	_	17	acl:relcl
23	0.022	0.022	CD	_	24	nummod
24	)	)	NN	_	22	dobj
25	and	and	CC	_	24	cc
26	31	31	CD	_	27	nummod
27	%	%	NN	_	24	conj
28	(	(	CD	_	29	compound
29	479	479	CD	_	30	nummod
30	190	190	CD	_	27	dep
31	vs	vs	CC	_	30	advmod
32	.	.	.	_	9	punct
33	688	688	CD	_	34	compound
34	265	265	CD	_	35	nummod
35	ml	ml	NN	_	9	dep
36	/	/	:	_	35	punct
37	min	min	NN	_	35	dep
38	,	,	,	_	35	punct
39	P	p	NN	_	40	nsubj
40	=	=	JJ	_	35	dep
41	0.013	0.013	CD	_	42	nummod
42	)	)	NN	_	40	dobj
43	,	,	,	_	35	punct
44	respectively	respectively	RB	_	35	advmod
45	,	,	,	_	35	punct
46	lower	lower	JJR	_	35	amod
47	in	in	IN	_	48	case
48	cyclosporine	cyclosporine	NN	_	46	nmod
49	-	-	:	_	35	punct
50	treated	treat	VBN	_	51	amod
51	patients	patient	NNS	_	35	dep
52	(	(	CD	_	53	nummod
53	n	n	NN	_	51	dep
54	=	=	JJ	_	53	amod
55	20	20	CD	_	56	nummod
56	)	)	NN	_	54	dep
57	than	than	IN	_	60	case
58	in	in	IN	_	60	case
59	matched	match	VBN	_	60	amod
60	tacrolimus	tacrolimus	NN	_	51	nmod
61	-	-	:	_	35	punct
62	treated	treat	VBN	_	63	amod
63	patients	patient	NNS	_	35	dep
64	(	(	CD	_	65	nummod
65	n	n	NN	_	66	nsubj
66	=	=	JJ	_	63	acl:relcl
67	20	20	CD	_	68	nummod
68	)	)	NN	_	66	dobj
69	.	.	.	_	9	punct

1	The	the	DT	_	5	det
2	latter	latter	JJ	_	5	amod
3	displayed	display	VBN	_	5	amod
4	midazolam	midazolam	NN	_	5	compound
5	clearances	clearance	NNS	_	0	ROOT
6	similar	similar	JJ	_	5	amod
7	to	to	TO	_	8	case
8	those	those	DT	_	6	nmod
9	in	in	IN	_	12	case
10	two	two	CD	_	12	nummod
11	larger	larger	JJR	_	12	amod
12	cohorts	cohort	NNS	_	8	nmod
13	of	of	IN	_	15	case
14	nonmatched	nonmatched	JJ	_	15	amod
15	tacrolimus	tacrolimus	NN	_	12	nmod
16	-	-	:	_	12	punct
17	treated	treat	VBN	_	18	amod
18	patients	patient	NNS	_	12	dep
19	(	(	CD	_	20	nummod
20	n	n	NN	_	18	dep
21	=	=	JJ	_	20	amod
22	58	58	CD	_	21	dep
23	and	and	CC	_	18	cc
24	n	n	NN	_	25	nsubj
25	=	=	JJ	_	18	conj
26	80	80	CD	_	27	nummod
27	)	)	NN	_	25	dobj
28	and	and	CC	_	18	cc
29	to	to	TO	_	30	case
30	those	those	DT	_	18	conj
31	receiving	receive	VBG	_	30	acl
32	a	a	DT	_	34	det
33	calcineurin	calcineurin	NN	_	34	compound
34	inhibitor	inhibitor	NN	_	31	dobj
35	-	-	:	_	34	punct
36	free	free	JJ	_	39	amod
37	regimen	regimen	NN	_	39	compound
38	(	(	NN	_	39	compound
39	n	n	NN	_	40	nsubj
40	=	=	JJ	_	34	dep
41	6	6	CD	_	42	nummod
42	)	)	NN	_	40	dobj
43	.	.	.	_	5	punct

1	This	this	DT	_	2	nsubj
2	implies	imply	VBZ	_	0	ROOT
3	that	that	IN	_	15	mark
4	in	in	FW	_	6	amod
5	vivo	vivo	FW	_	4	dep
6	hepatic	hepatic	JJ	_	15	nsubj
7	and	and	CC	_	6	cc
8	first	first	JJ	_	6	conj
9	-	-	:	_	6	punct
10	pass	pass	VB	_	6	dep
11	CYP3A	cyp3a	NN	_	12	compound
12	activities	activity	NNS	_	10	dobj
13	are	be	VBP	_	15	cop
14	significantly	significantly	RB	_	15	advmod
15	lower	lower	JJR	_	2	ccomp
16	in	in	IN	_	17	case
17	patients	patient	NNS	_	15	nmod
18	receiving	receive	VBG	_	17	acl
19	cyclosporine	cyclosporine	NN	_	18	dobj
20	than	than	IN	_	22	case
21	in	in	IN	_	22	case
22	those	those	DT	_	15	nmod
23	receiving	receive	VBG	_	22	acl
24	tacrolimus	tacrolimus	NN	_	23	dobj
25	,	,	,	_	15	punct
26	indicating	indicate	VBG	_	15	xcomp
27	that	that	IN	_	41	mark
28	,	,	,	_	41	punct
29	at	at	IN	_	31	case
30	the	the	DT	_	31	det
31	doses	dose	NNS	_	41	nmod
32	generally	generally	RB	_	33	advmod
33	used	use	VBN	_	31	acl
34	in	in	IN	_	36	case
35	clinical	clinical	JJ	_	36	amod
36	practice	practice	NN	_	33	nmod
37	,	,	,	_	41	punct
38	cyclosporine	cyclosporine	NN	_	41	nsubj
39	is	be	VBZ	_	41	cop
40	the	the	DT	_	41	det
41	stronger	stronger	JJR	_	26	ccomp
42	of	of	IN	_	44	case
43	the	the	DT	_	44	det
44	two	two	CD	_	41	nmod
45	with	with	IN	_	46	case
46	respect	respect	NN	_	41	nmod
47	to	to	TO	_	49	case
48	CYP3A	cyp3a	NN	_	49	compound
49	inhibition	inhibition	NN	_	46	nmod
50	.	.	.	_	2	punct

1	This	this	DT	_	2	det
2	observation	observation	NN	_	3	nsubj
3	has	have	VBZ	_	0	ROOT
4	important	important	JJ	_	5	amod
5	implications	implication	NNS	_	3	dobj
6	in	in	IN	_	8	case
7	the	the	DT	_	8	det
8	context	context	NN	_	5	nmod
9	of	of	IN	_	10	case
10	drug	drug	NN	_	8	nmod
11	-	-	:	_	10	punct
12	drug	drug	NN	_	13	compound
13	interactions	interaction	NNS	_	10	dep
14	in	in	IN	_	16	case
15	transplant	transplant	NN	_	16	compound
16	recipients	recipient	NNS	_	10	nmod
17	.	.	.	_	3	punct

1	[	[	NN	_	2	compound
2	Influence	influence	NN	_	0	ROOT
3	of	of	IN	_	4	case
4	hemantane	hemantane	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	doxycycline	doxycycline	NN	_	4	conj
7	on	on	IN	_	8	case
8	MPTP	mptp	NN	_	2	nmod
9	-	-	:	_	2	punct
10	evoked	evoke	VBN	_	12	amod
11	behavior	behavior	NN	_	12	compound
12	violations	violation	NNS	_	2	dep
13	in	in	IN	_	14	case
14	C57BL	c57bl	NN	_	12	nmod
15	/	/	:	_	2	punct
16	6	6	CD	_	17	nummod
17	mice	mouse	NNS	_	18	nmod:npmod
18	]	]	RB	_	2	advmod
19	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	0	ROOT
3	of	of	IN	_	8	case
4	anti	anti	JJ	_	8	amod
5	-	-	:	_	8	punct
6	parkinsonian	parkinsonian	JJ	_	8	amod
7	drug	drug	NN	_	8	compound
8	hemantane	hemantane	NN	_	2	nmod
9	[	[	CD	_	10	nummod
10	(	(	NN	_	8	dep
11	2	2	CD	_	10	nummod
12	-	-	:	_	8	punct
13	adamantyl	adamantyl	NN	_	15	compound
14	)	)	NN	_	15	compound
15	hexamethylenimine	hexamethylenimine	NN	_	8	dep
16	]	]	CD	_	18	compound
17	(	(	CD	_	18	compound
18	10	10	CD	_	19	nummod
19	mg	mg	NN	_	15	dep
20	/	/	:	_	19	punct
21	kg	kg	NN	_	19	dep
22	,	,	,	_	19	punct
23	p	p	NN	_	19	appos
24	.	.	.	_	2	punct
25	o	o	NN	_	2	dep
26	.	.	.	_	25	punct
27	)	)	SYM	_	2	dep

1	and	and	CC	_	11	cc
2	/	/	:	_	9	punct
3	or	or	CC	_	9	cc
4	antibiotic	antibiotic	JJ	_	9	amod
5	drug	drug	NN	_	9	compound
6	doxycycline	doxycycline	NN	_	9	compound
7	(	(	NN	_	9	compound
8	100	100	CD	_	9	nummod
9	mg	mg	NN	_	11	dep
10	/	/	:	_	9	punct
11	kg	kg	NN	_	0	ROOT
12	,	,	,	_	11	punct
13	p	p	NN	_	15	compound
14	.	.	.	_	15	punct
15	o	o	NN	_	11	parataxis
16	.	.	.	_	15	punct
17	)	)	NN	_	15	conj
18	,	,	,	_	15	punct
19	as	as	RB	_	15	cc
20	well	well	RB	_	19	mwe
21	as	as	IN	_	19	mwe
22	that	that	DT	_	15	conj
23	of	of	IN	_	24	case
24	neurotoxin	neurotoxin	NN	_	22	nmod
25	1	1	CD	_	24	nummod
26	-	-	:	_	24	punct
27	methyl	methyl	NN	_	24	dep
28	-	-	:	_	24	punct
29	4	4	LS	_	24	dep
30	-	-	:	_	31	punct
31	phenyl	phenyl	NN	_	29	root
32	-	-	:	_	31	punct
33	1,2,3,4	1,2,3,4	CD	_	31	dep
34	-	-	:	_	31	punct
35	tetrahydropyridine	tetrahydropyridine	NN	_	43	compound
36	(	(	CD	_	43	nummod
37	MPTP	mptp	NN	_	43	compound
38	)	)	NN	_	43	compound
39	(	(	CD	_	43	nummod
40	4	4	CD	_	43	nummod
41	x	x	NN	_	43	compound
42	20	20	CD	_	43	nummod
43	mg	mg	NN	_	31	dep
44	/	/	:	_	43	punct
45	kg	kg	NN	_	43	dep
46	,	,	,	_	43	punct
47	i	i	FW	_	49	compound
48	.	.	.	_	49	punct
49	p	p	NN	_	43	advmod
50	.	.	.	_	31	punct
51	)	)	SYM	_	31	punct

1	were	be	VBD	_	2	auxpass
2	studied	study	VBN	_	0	ROOT
3	in	in	IN	_	7	case
4	elevated	elevated	JJ	_	7	amod
5	plus	plus	CC	_	4	cc
6	maze	maze	NN	_	4	conj
7	test	test	NN	_	2	nmod
8	on	on	IN	_	9	case
9	C57BL	c57bl	NN	_	7	nmod
10	/	/	:	_	7	punct
11	6	6	CD	_	12	nummod
12	mice	mouse	NNS	_	7	dep
13	.	.	.	_	2	punct

1	On	on	IN	_	3	case
2	second	second	JJ	_	3	amod
3	day	day	NN	_	8	nmod
4	after	after	IN	_	5	case
5	injection	injection	NN	_	3	nmod
6	,	,	,	_	8	punct
7	MPTP	mptp	NN	_	8	nsubj
8	decreased	decrease	VBD	_	0	ROOT
9	the	the	DT	_	10	det
10	locomot	locomot	NN	_	8	dobj
11	or	or	CC	_	10	cc
12	activity	activity	NN	_	10	conj
13	in	in	IN	_	14	case
14	comparison	comparison	NN	_	8	nmod
15	to	to	TO	_	16	case
16	saline	saline	NN	_	14	nmod
17	.	.	.	_	8	punct

1	Acute	acute	JJ	_	2	amod
2	administration	administration	NN	_	7	nsubj
3	of	of	IN	_	4	case
4	hemantane	hemantane	NN	_	2	nmod
5	or	or	CC	_	4	cc
6	doxycycline	doxycycline	NN	_	4	conj
7	failed	fail	VBD	_	0	ROOT
8	to	to	TO	_	9	mark
9	influence	influence	VB	_	7	xcomp
10	locomotion	locomotion	NN	_	9	dobj
11	in	in	IN	_	12	case
12	mice	mouse	NNS	_	10	nmod
13	,	,	,	_	7	punct
14	while	while	IN	_	17	mark
15	their	they	PRP$	_	16	nmod:poss
16	combination	combination	NN	_	17	nsubj
17	normalized	normalize	VBD	_	7	advcl
18	motor	motor	NN	_	19	compound
19	activity	activity	NN	_	17	dobj
20	.	.	.	_	7	punct

1	The	the	DT	_	2	det
2	results	result	NNS	_	4	nsubj
3	obtained	obtain	VBN	_	2	acl
4	confirm	confirm	VBP	_	0	ROOT
5	the	the	DT	_	6	det
6	role	role	NN	_	4	dobj
7	of	of	IN	_	9	case
8	inflammatory	inflammatory	JJ	_	9	amod
9	processes	process	NNS	_	6	nmod
10	in	in	IN	_	11	case
11	parkinsonism	parkinsonism	NN	_	6	nmod
12	and	and	CC	_	4	cc
13	suggest	suggest	VBP	_	4	conj
14	expediency	expediency	NN	_	13	dobj
15	of	of	IN	_	17	case
16	combined	combined	JJ	_	17	amod
17	pharmacotherapy	pharmacotherapy	NN	_	14	nmod
18	of	of	IN	_	20	case
19	neurodegenerative	neurodegenerative	JJ	_	20	amod
20	diseases	disease	NNS	_	17	nmod
21	.	.	.	_	4	punct

1	Exposure	exposure	NN	_	0	ROOT
2	to	to	TO	_	4	case
3	oral	oral	JJ	_	4	amod
4	S	s	NN	_	1	nmod
5	-	-	:	_	1	punct
6	ketamine	ketamine	NN	_	8	nsubjpass
7	is	be	VBZ	_	8	auxpass
8	unaffected	unaffected	JJ	_	1	dep
9	by	by	IN	_	10	case
10	itraconazole	itraconazole	NN	_	8	nmod
11	but	but	CC	_	8	cc
12	greatly	greatly	RB	_	13	advmod
13	increased	increase	VBN	_	8	conj
14	by	by	IN	_	15	case
15	ticlopidine	ticlopidine	NN	_	13	nmod
16	.	.	.	_	1	punct

1	This	this	DT	_	2	det
2	study	study	NN	_	3	nsubj
3	examined	examine	VBN	_	0	ROOT
4	drug	drug	NN	_	7	compound
5	-	-	:	_	7	punct
6	drug	drug	NN	_	7	compound
7	interactions	interaction	NNS	_	3	dobj
8	of	of	IN	_	10	case
9	oral	oral	JJ	_	10	amod
10	S	s	NN	_	7	nmod
11	-	-	:	_	7	punct
12	ketamine	ketamine	NN	_	7	dep
13	with	with	IN	_	22	case
14	the	the	DT	_	22	det
15	cytochrome	cytochrome	NN	_	22	compound
16	P450	p450	NN	_	22	compound
17	(	(	CD	_	22	nummod
18	CYP	cyp	NN	_	22	compound
19	)	)	CD	_	22	nummod
20	2B6	2b6	NN	_	22	compound
21	inhibitor	inhibitor	NN	_	22	compound
22	ticlopidine	ticlopidine	NN	_	12	nmod
23	and	and	CC	_	22	cc
24	the	the	DT	_	27	det
25	CYP3A	cyp3a	NN	_	27	compound
26	inhibitor	inhibitor	NN	_	27	compound
27	itraconazole	itraconazole	NN	_	22	conj
28	.	.	.	_	3	punct

1	In	in	IN	_	0	ROOT
2	this	this	DT	_	1	dep
3	randomized	randomize	VBN	_	2	dep
4	,	,	,	_	3	punct
5	blinded	blind	VBN	_	4	root
6	,	,	,	_	5	punct
7	crossover	crossover	NN	_	8	compound
8	study	study	NN	_	6	root
9	,	,	,	_	8	punct
10	11	11	CD	_	12	nummod
11	healthy	healthy	JJ	_	12	amod
12	volunteers	volunteer	NNS	_	13	nsubj
13	ingested	ingest	VBD	_	8	acl:relcl
14	0.2	0.2	CD	_	15	nummod
15	mg	mg	NN	_	13	dobj
16	/	/	:	_	15	punct
17	kg	kg	NN	_	18	compound
18	S	s	NN	_	15	dep
19	-	-	:	_	15	punct
20	ketamine	ketamine	NN	_	15	dep
21	after	after	IN	_	22	case
22	pretreatments	pretreatment	NNS	_	20	nmod
23	with	with	IN	_	26	case
24	oral	oral	JJ	_	26	amod
25	ticlopidine	ticlopidine	NN	_	26	compound
26	(	(	NN	_	22	nmod
27	250	250	CD	_	28	nummod
28	mg	mg	NN	_	26	dep
29	twice	twice	RB	_	31	advmod
30	daily	daily	JJ	_	31	amod
31	)	)	NN	_	28	dep
32	,	,	,	_	31	punct
33	itraconazole	itraconazole	NN	_	36	compound
34	(	(	NN	_	36	compound
35	200	200	CD	_	36	nummod
36	mg	mg	NN	_	31	appos
37	once	once	RB	_	39	advmod
38	daily	daily	JJ	_	39	amod
39	)	)	NN	_	36	dep
40	,	,	,	_	39	punct
41	or	or	CC	_	39	cc
42	placebo	placebo	NN	_	39	conj
43	in	in	IN	_	44	case
44	6	6	CD	_	42	nmod
45	-	-	:	_	31	punct
46	day	day	NN	_	48	compound
47	treatment	treatment	NN	_	48	compound
48	periods	period	NNS	_	31	dep
49	at	at	IN	_	50	case
50	intervals	interval	NNS	_	48	nmod
51	of	of	IN	_	53	case
52	4	4	CD	_	53	nummod
53	weeks	week	NNS	_	50	nmod
54	.	.	.	_	8	punct

1	Ticlopidine	ticlopidine	NN	_	2	compound
2	treatment	treatment	NN	_	3	nsubj
3	increased	increase	VBD	_	0	ROOT
4	the	the	DT	_	6	det
5	mean	mean	JJ	_	6	amod
6	area	area	NN	_	3	dobj
7	under	under	IN	_	10	case
8	the	the	DT	_	10	det
9	plasma	plasma	NN	_	10	compound
10	concentration	concentration	NN	_	3	nmod
11	-	-	:	_	3	punct
12	time	time	NN	_	13	compound
13	curve	curve	NN	_	14	nsubj
14	extrapolated	extrapolate	VBD	_	3	parataxis
15	to	to	TO	_	19	case
16	infinity	infinity	NN	_	19	compound
17	(	(	CD	_	19	nummod
18	AUC	auc	NN	_	19	compound
19	(	(	NN	_	14	nmod
20	0	0	CD	_	19	nummod
21	-	-	:	_	19	punct
22	)	)	CD	_	23	nummod
23	)	)	NN	_	19	dep
24	of	of	IN	_	26	case
25	oral	oral	JJ	_	26	amod
26	ketamine	ketamine	NN	_	23	nmod
27	by	by	IN	_	28	case
28	2.4	2.4	CD	_	23	nmod
29	-	-	:	_	28	punct
30	fold	fold	NN	_	28	dep
31	,	,	,	_	14	punct
32	whereas	whereas	IN	_	14	dep
33	itraconazole	itraconazole	NN	_	34	compound
34	treatment	treatment	NN	_	37	nsubj
35	did	do	VBD	_	37	aux
36	not	not	RB	_	37	neg
37	increase	increase	VB	_	14	parataxis
38	the	the	DT	_	39	det
39	exposure	exposure	NN	_	37	dobj
40	to	to	TO	_	41	case
41	S	s	NN	_	39	nmod
42	-	-	:	_	41	punct
43	ketamine	ketamine	NN	_	41	dep
44	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	ratio	ratio	NN	_	0	ROOT
3	of	of	IN	_	5	case
4	norketamine	norketamine	NN	_	5	compound
5	AUC	auc	NN	_	2	nmod
6	(	(	CD	_	7	compound
7	0	0	CD	_	5	nummod
8	-	-	:	_	5	punct
9	)	)	CD	_	5	nummod
10	to	to	TO	_	11	mark
11	ketamine	ketamine	VB	_	2	acl
12	AUC	auc	NN	_	13	compound
13	(	(	NN	_	11	dobj
14	0	0	CD	_	13	nummod
15	-	-	:	_	2	punct
16	)	)	CD	_	19	nsubjpass
17	was	be	VBD	_	19	auxpass
18	significantly	significantly	RB	_	19	advmod
19	decreased	decrease	VBN	_	2	dep
20	in	in	IN	_	25	case
21	the	the	DT	_	25	det
22	ticlopidine	ticlopidine	NN	_	25	compound
23	(	(	CD	_	25	nummod
24	P	p	NN	_	25	compound
25	&amp	&amp	NN	_	19	nmod
26	;	;	:	_	19	punct
27	lt	lt	NN	_	19	dep
28	;	;	:	_	27	punct
29	0.001	0.001	CD	_	30	nummod
30	)	)	NN	_	34	nsubj
31	and	and	CC	_	30	cc
32	itraconazole	itraconazole	NN	_	33	compound
33	phases	phase	NNS	_	30	conj
34	(	(	VBP	_	27	dep
35	P	p	NN	_	36	nsubj
36	=	=	JJ	_	34	ccomp
37	0.006	0.006	CD	_	38	nummod
38	)	)	CD	_	36	dobj
39	as	as	IN	_	40	mark
40	compared	compare	VBN	_	36	advcl
41	to	to	TO	_	42	case
42	placebo	placebo	NN	_	40	nmod
43	.	.	.	_	2	punct

1	In	in	IN	_	6	case
2	the	the	DT	_	6	det
3	ticlopidine	ticlopidine	NN	_	6	compound
4	and	and	CC	_	3	cc
5	itraconazole	itraconazole	NN	_	3	conj
6	phases	phase	NNS	_	16	nmod
7	,	,	,	_	16	punct
8	the	the	DT	_	9	det
9	areas	area	NNS	_	16	nsubj
10	under	under	IN	_	12	case
11	the	the	DT	_	12	det
12	effect	effect	NN	_	9	nmod
13	-	-	:	_	16	punct
14	time	time	NN	_	15	compound
15	curves	curve	NNS	_	16	nsubj
16	(	(	VBP	_	0	ROOT
17	self	self	NN	_	19	dep
18	-	-	:	_	19	punct
19	reported	report	VBN	_	23	amod
20	drowsiness	drowsiness	NN	_	23	compound
21	and	and	CC	_	20	cc
22	performance	performance	NN	_	20	conj
23	)	)	NN	_	26	nsubj
24	were	be	VBD	_	26	cop
25	significantly	significantly	RB	_	26	advmod
26	higher	higher	JJR	_	16	ccomp
27	than	than	IN	_	28	case
28	those	those	DT	_	26	nmod
29	in	in	IN	_	35	case
30	the	the	DT	_	35	det
31	placebo	placebo	NN	_	35	compound
32	phase	phase	NN	_	35	compound
33	(	(	CD	_	35	nummod
34	P	p	NN	_	35	compound
35	&lt	&lt	NN	_	28	nmod
36	;	;	:	_	16	punct
37	0.05	0.05	CD	_	38	nummod
38	)	)	CD	_	16	parataxis
39	.	.	.	_	16	punct

1	The	the	DT	_	2	det
2	findings	finding	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	13	mark
5	the	the	DT	_	6	det
6	dosage	dosage	NN	_	13	nsubjpass
7	of	of	IN	_	8	case
8	S	s	NN	_	6	nmod
9	-	-	:	_	10	punct
10	ketamine	ketamine	NN	_	13	nsubjpass
11	should	should	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	reduced	reduce	VBN	_	3	ccomp
14	in	in	IN	_	15	case
15	patients	patient	NNS	_	13	nmod
16	receiving	receive	VBG	_	15	acl
17	ticlopidine	ticlopidine	NN	_	16	dobj
18	.	.	.	_	3	punct

1	Interaction	interaction	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	celecoxib	celecoxib	NN	_	1	nmod
4	with	with	IN	_	11	case
5	different	different	JJ	_	11	amod
6	anti	anti	JJ	_	11	dep
7	-	-	:	_	11	punct
8	cancer	cancer	NN	_	9	compound
9	drugs	drug	NNS	_	11	nsubj
10	is	be	VBZ	_	11	cop
11	antagonistic	antagonistic	JJ	_	1	nmod
12	in	in	IN	_	13	case
13	breast	breast	NN	_	11	nmod
14	but	but	CC	_	13	cc
15	not	not	RB	_	19	neg
16	in	in	IN	_	19	case
17	other	other	JJ	_	19	amod
18	cancer	cancer	NN	_	19	compound
19	cells	cell	NNS	_	13	conj
20	.	.	.	_	1	punct

1	Celecoxib	Celecoxib	NNP	_	12	nsubjpass
2	,	,	,	_	1	punct
3	an	a	DT	_	4	det
4	inhibitor	inhibitor	NN	_	1	appos
5	of	of	IN	_	6	case
6	cyclooxygenase	cyclooxygenase	NN	_	4	nmod
7	-	-	:	_	1	punct
8	2	2	CD	_	1	dep
9	,	,	,	_	1	punct
10	is	be	VBZ	_	12	aux
11	being	be	VBG	_	12	auxpass
12	investigated	investigate	VBN	_	0	ROOT
13	for	for	IN	_	14	case
14	enhancement	enhancement	NN	_	12	nmod
15	of	of	IN	_	17	case
16	chemotherapy	chemotherapy	NN	_	17	compound
17	efficacy	efficacy	NN	_	14	nmod
18	in	in	IN	_	21	case
19	cancer	cancer	NN	_	21	compound
20	clinical	clinical	JJ	_	21	amod
21	trials	trial	NNS	_	14	nmod
22	.	.	.	_	12	punct

1	This	this	DT	_	2	det
2	study	study	NN	_	3	nsubj
3	investigates	investigate	VBZ	_	0	ROOT
4	the	the	DT	_	5	det
5	ability	ability	NN	_	3	dobj
6	of	of	IN	_	7	case
7	cyclooxygenase	cyclooxygenase	NN	_	5	nmod
8	-	-	:	_	7	punct
9	2	2	CD	_	10	nummod
10	inhibitors	inhibitor	NNS	_	7	dep
11	to	to	TO	_	12	mark
12	sensitize	sensitize	VB	_	5	acl
13	cells	cell	NNS	_	12	dobj
14	from	from	IN	_	16	case
15	different	different	JJ	_	16	amod
16	origins	origin	NNS	_	12	nmod
17	to	to	TO	_	20	case
18	several	several	JJ	_	20	amod
19	chemotherapeutic	chemotherapeutic	JJ	_	20	amod
20	agents	agent	NNS	_	12	nmod
21	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	17	nsubjpass
3	of	of	IN	_	8	case
4	the	the	DT	_	5	det
5	drug	drug	NN	_	8	nmod:poss
6	'	'	POS	_	5	case
7	s	s	NNS	_	8	compound
8	mechanism	mechanism	NN	_	2	nmod
9	of	of	IN	_	10	case
10	action	action	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	sequence	sequence	NN	_	10	conj
13	of	of	IN	_	14	case
14	administration	administration	NN	_	10	nmod
15	are	be	VBP	_	17	auxpass
16	also	also	RB	_	17	advmod
17	investigated	investigate	VBN	_	0	ROOT
18	.	.	.	_	17	punct

1	The	the	DT	_	2	det
2	sensitivity	sensitivity	NN	_	17	nsubj
3	,	,	,	_	2	punct
4	cell	cell	NN	_	5	compound
5	cycle	cycle	NN	_	2	conj
6	,	,	,	_	2	punct
7	apoptosis	apoptosis	NN	_	2	conj
8	and	and	CC	_	2	cc
9	DNA	dna	NN	_	10	compound
10	damage	damage	NN	_	2	conj
11	of	of	IN	_	16	case
12	five	five	CD	_	16	nummod
13	different	different	JJ	_	16	amod
14	cancer	cancer	NN	_	16	compound
15	cell	cell	NN	_	16	compound
16	lines	line	NNS	_	2	nmod
17	(	(	VBP	_	0	ROOT
18	HeLa	hela	NN	_	17	dobj
19	,	,	,	_	18	punct
20	HCT116	hct116	NN	_	18	conj
21	,	,	,	_	18	punct
22	HepG2	hepg2	NN	_	18	conj
23	,	,	,	_	18	punct
24	MCF7	mcf7	NN	_	18	conj
25	and	and	CC	_	18	cc
26	U251	u251	NN	_	18	conj
27	)	)	CD	_	29	compound
28	to	to	TO	_	29	dep
29	5	5	CD	_	26	nummod
30	-	-	:	_	18	punct
31	FU	FU	NNP	_	38	compound
32	,	,	,	_	31	punct
33	cisplatin	cisplatin	NN	_	31	conj
34	,	,	,	_	31	punct
35	doxorubicin	doxorubicin	NN	_	31	conj
36	and	and	CC	_	31	cc
37	etoposide	etoposide	NN	_	31	conj
38	celecoxib	celecoxib	NN	_	44	nsubjpass
39	following	follow	VBG	_	42	case
40	different	different	JJ	_	42	amod
41	incubation	incubation	NN	_	42	compound
42	schedules	schedule	NNS	_	38	nmod
43	were	be	VBD	_	44	auxpass
44	analyzed	analyze	VBN	_	18	dep
45	.	.	.	_	17	punct

1	We	we	PRP	_	2	nsubj
2	found	find	VBD	_	0	ROOT
3	antagonism	antagonism	NN	_	2	dobj
4	between	between	IN	_	5	case
5	celecoxib	celecoxib	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	the	the	DT	_	9	det
8	four	four	CD	_	9	nummod
9	drugs	drug	NNS	_	5	conj
10	in	in	IN	_	14	case
11	the	the	DT	_	14	det
12	breast	breast	NN	_	14	compound
13	cancer	cancer	NN	_	14	compound
14	cells	cell	NNS	_	9	nmod
15	MCF7	mcf7	NN	_	5	dep
16	following	follow	VBG	_	19	case
17	all	all	DT	_	19	det
18	incubation	incubation	NN	_	19	compound
19	schedules	schedule	NNS	_	2	nmod
20	and	and	CC	_	19	cc
21	between	between	IN	_	22	case
22	celecoxib	celecoxib	NN	_	19	conj
23	and	and	CC	_	22	cc
24	doxorubicin	doxorubicin	NN	_	22	conj
25	in	in	IN	_	28	case
26	all	all	DT	_	28	det
27	cell	cell	NN	_	28	compound
28	lines	line	NNS	_	22	nmod
29	except	except	IN	_	32	case
30	for	for	IN	_	32	case
31	two	two	CD	_	32	nummod
32	combinations	combination	NNS	_	2	nmod
33	in	in	IN	_	35	case
34	HCT116	hct116	NN	_	35	compound
35	cells	cell	NNS	_	32	nmod
36	.	.	.	_	2	punct

1	Celecoxib	celecoxib	NN	_	13	nsubj
2	with	with	IN	_	6	case
3	the	the	DT	_	6	det
4	other	other	JJ	_	6	amod
5	three	three	CD	_	6	nummod
6	drugs	drug	NNS	_	1	nmod
7	in	in	IN	_	12	case
8	the	the	DT	_	12	det
9	remaining	remain	VBG	_	12	amod
10	four	four	CD	_	12	nummod
11	cell	cell	NN	_	12	compound
12	lines	line	NNS	_	6	nmod
13	resulted	result	VBD	_	0	ROOT
14	in	in	IN	_	16	case
15	variable	variable	JJ	_	16	amod
16	interactions	interaction	NNS	_	13	nmod
17	.	.	.	_	13	punct

1	Mechanistic	mechanistic	JJ	_	2	amod
2	investigations	investigation	NNS	_	3	nsubj
3	revealed	reveal	VBD	_	0	ROOT
4	that	that	IN	_	6	mark
5	celecoxib	celecoxib	NN	_	6	nsubj
6	exerts	exert	VBZ	_	3	ccomp
7	different	different	JJ	_	9	amod
8	molecular	molecular	JJ	_	9	amod
9	effects	effect	NNS	_	6	dobj
10	in	in	IN	_	12	case
11	different	different	JJ	_	12	amod
12	cells	cell	NNS	_	6	nmod
13	.	.	.	_	3	punct

1	In	in	IN	_	3	case
2	some	some	DT	_	3	det
3	lines	line	NNS	_	6	nmod
4	,	,	,	_	6	punct
5	it	it	PRP	_	6	nsubj
6	abrogates	abrogate	VBZ	_	0	ROOT
7	the	the	DT	_	8	det
8	drug	drug	NN	_	6	dobj
9	-	-	:	_	8	punct
10	induced	induce	VBN	_	11	amod
11	G2	g2	NN	_	8	dep
12	/	/	:	_	8	punct
13	M	m	NN	_	14	compound
14	arrest	arrest	NN	_	8	dep
15	enhancing	enhance	VBG	_	14	acl
16	pre	pre	JJ	_	19	amod
17	-	-	:	_	19	punct
18	mature	mature	JJ	_	19	amod
19	entry	entry	NN	_	15	dobj
20	into	into	IN	_	21	case
21	mitosis	mitosis	NN	_	19	nmod
22	with	with	IN	_	24	case
23	damaged	damaged	JJ	_	24	amod
24	DNA	dna	NN	_	19	nmod
25	thus	thus	RB	_	26	advmod
26	increasing	increase	VBG	_	6	xcomp
27	apoptosis	apoptosis	NN	_	26	dobj
28	and	and	CC	_	26	cc
29	resulting	result	VBG	_	26	conj
30	in	in	IN	_	31	case
31	synergism	synergism	NN	_	29	nmod
32	.	.	.	_	6	punct

1	In	in	IN	_	3	case
2	other	other	JJ	_	3	amod
3	cells	cell	NNS	_	6	nmod
4	,	,	,	_	6	punct
5	it	it	PRP	_	6	nsubj
6	enhances	enhance	VBZ	_	0	ROOT
7	drug	drug	NN	_	10	compound
8	-	-	:	_	10	punct
9	induced	induce	VBN	_	10	amod
10	G2	g2	NN	_	6	dobj
11	/	/	:	_	10	punct
12	M	m	NN	_	13	compound
13	arrest	arrest	NN	_	10	dep
14	allowing	allow	VBG	_	13	acl
15	time	time	NN	_	14	dobj
16	to	to	TO	_	17	mark
17	repair	repair	VB	_	14	xcomp
18	drug	drug	NN	_	17	dobj
19	-	-	:	_	18	punct
20	induced	induce	VBN	_	22	amod
21	DNA	dna	NN	_	22	compound
22	damage	damage	NN	_	18	conj
23	before	before	IN	_	24	case
24	entry	entry	NN	_	22	nmod
25	into	into	IN	_	26	case
26	mitosis	mitosis	NN	_	24	nmod
27	and	and	CC	_	18	cc
28	decreasing	decrease	VBG	_	30	amod
29	cell	cell	NN	_	30	compound
30	death	death	NN	_	18	conj
31	resulting	result	VBG	_	18	acl
32	in	in	IN	_	33	case
33	antagonism	antagonism	NN	_	31	nmod
34	.	.	.	_	6	punct

1	In	in	IN	_	4	case
2	some	some	DT	_	4	det
3	synergistic	synergistic	JJ	_	4	amod
4	combinations	combination	NNS	_	9	nmod
5	,	,	,	_	9	punct
6	celecoxib	celecoxib	NN	_	9	dep
7	-	-	:	_	9	punct
8	induced	induce	VBN	_	9	amod
9	abrogation	abrogation	NN	_	0	ROOT
10	of	of	IN	_	11	case
11	G2	g2	NN	_	9	nmod
12	/	/	:	_	14	punct
13	M	m	NN	_	14	compound
14	arrest	arrest	NN	_	17	nsubjpass
15	was	be	VBD	_	17	auxpass
16	not	not	RB	_	17	neg
17	associated	associate	VBN	_	11	acl:relcl
18	with	with	IN	_	19	case
19	apoptosis	apoptosis	NN	_	17	nmod
20	but	but	CC	_	19	cc
21	permanent	permanent	JJ	_	22	amod
22	arrest	arrest	NN	_	19	conj
23	in	in	IN	_	25	case
24	G1	g1	NN	_	25	compound
25	phase	phase	NN	_	22	nmod
26	.	.	.	_	9	punct

1	These	these	DT	_	2	det
2	results	result	NNS	_	10	nsubj
3	,	,	,	_	10	punct
4	if	if	IN	_	5	mark
5	confirmed	confirm	VBN	_	10	advcl
6	in	in	IN	_	8	case
7	-	-	:	_	8	punct
8	vivo	vivo	FW	_	5	nmod
9	,	,	,	_	10	punct
10	indicate	indicate	VBP	_	0	ROOT
11	that	that	IN	_	17	mark
12	celecoxib	celecoxib	NN	_	17	nsubj
13	is	be	VBZ	_	17	cop
14	not	not	RB	_	17	neg
15	a	a	DT	_	17	det
16	suitable	suitable	JJ	_	17	amod
17	chemosensitizer	chemosensitizer	NN	_	10	ccomp
18	for	for	IN	_	20	case
19	breast	breast	NN	_	20	compound
20	cancer	cancer	NN	_	17	nmod
21	or	or	CC	_	20	cc
22	with	with	IN	_	23	case
23	doxorubicin	doxorubicin	NN	_	20	conj
24	for	for	IN	_	26	case
25	other	other	JJ	_	26	amod
26	cancers	cancer	NNS	_	23	nmod
27	.	.	.	_	10	punct

1	Moreover	moreover	RB	_	11	advmod
2	,	,	,	_	11	punct
3	combination	combination	NN	_	11	nsubjpass
4	of	of	IN	_	5	case
5	celecoxib	celecoxib	NN	_	3	nmod
6	with	with	IN	_	8	case
7	other	other	JJ	_	8	amod
8	drugs	drug	NNS	_	5	nmod
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	tailored	tailor	VBN	_	0	ROOT
12	to	to	TO	_	15	case
13	the	the	DT	_	15	det
14	tumor	tumor	NN	_	15	compound
15	type	type	NN	_	11	nmod
16	,	,	,	_	15	punct
17	drug	drug	NN	_	15	conj
18	and	and	CC	_	15	cc
19	administration	administration	NN	_	20	compound
20	schedule	schedule	NN	_	15	conj
21	.	.	.	_	11	punct

1	Antidepressant	antidepressant	JJ	_	15	dep
2	-	-	:	_	1	punct
3	warfarin	warfarin	NN	_	4	compound
4	interaction	interaction	NN	_	1	dep
5	and	and	CC	_	4	cc
6	associated	associate	VBN	_	9	amod
7	gastrointestinal	gastrointestinal	JJ	_	9	amod
8	bleeding	bleeding	NN	_	9	compound
9	risk	risk	NN	_	4	conj
10	in	in	IN	_	12	case
11	a	a	DT	_	12	det
12	case	case	NN	_	1	nmod
13	-	-	:	_	15	punct
14	control	control	JJ	_	15	amod
15	study	study	NN	_	0	ROOT
16	.	.	.	_	15	punct

1	Bleeding	bleeding	NN	_	9	nsubj
2	is	be	VBZ	_	9	cop
3	the	the	DT	_	9	det
4	most	most	RBS	_	5	advmod
5	common	common	JJ	_	9	amod
6	and	and	CC	_	5	cc
7	worrisome	worrisome	JJ	_	5	conj
8	adverse	adverse	JJ	_	9	amod
9	effect	effect	NN	_	0	ROOT
10	of	of	IN	_	12	case
11	warfarin	warfarin	NN	_	12	compound
12	therapy	therapy	NN	_	9	nmod
13	.	.	.	_	9	punct

1	One	one	CD	_	11	nsubj
2	of	of	IN	_	4	case
3	the	the	DT	_	4	det
4	factors	factor	NNS	_	1	nmod
5	that	that	WDT	_	7	nsubj
6	might	might	MD	_	7	aux
7	increase	increase	VB	_	4	acl:relcl
8	bleeding	bleeding	JJ	_	9	amod
9	risk	risk	NN	_	7	dobj
10	is	be	VBZ	_	11	cop
11	initiation	initiation	NN	_	0	ROOT
12	of	of	IN	_	14	case
13	interacting	interact	VBG	_	14	amod
14	drugs	drug	NNS	_	11	nmod
15	that	that	WDT	_	16	nsubj
16	potentiate	potentiate	VBP	_	14	acl:relcl
17	warfarin	warfarin	NN	_	16	dobj
18	.	.	.	_	11	punct

1	We	we	PRP	_	2	nsubj
2	sought	seek	VBD	_	0	ROOT
3	to	to	TO	_	4	mark
4	evaluate	evaluate	VB	_	2	xcomp
5	whether	whether	IN	_	4	dobj
6	initiation	initiation	NN	_	5	dep
7	of	of	IN	_	10	case
8	an	a	DT	_	10	det
9	antidepressant	antidepressant	JJ	_	10	amod
10	increases	increase	NNS	_	6	nmod
11	the	the	DT	_	12	det
12	risk	risk	NN	_	10	dep
13	of	of	IN	_	14	case
14	hospitalization	hospitalization	NN	_	12	nmod
15	for	for	IN	_	17	case
16	gastrointestinal	gastrointestinal	JJ	_	17	amod
17	bleeding	bleeding	NN	_	12	nmod
18	in	in	IN	_	20	case
19	warfarin	warfarin	NN	_	20	compound
20	users	user	NNS	_	17	nmod
21	.	.	.	_	2	punct

1	Medicaid	Medicaid	NNP	_	2	nsubj
2	claims	claim	VBZ	_	0	ROOT
3	data	datum	NNS	_	4	nsubj
4	(	(	VBP	_	2	ccomp
5	1999	1999	CD	_	10	dep
6	-	-	:	_	10	punct
7	2005	2005	CD	_	8	compound
8	)	)	CD	_	10	nsubjpass
9	were	be	VBD	_	10	auxpass
10	used	use	VBN	_	4	ccomp
11	to	to	TO	_	12	mark
12	perform	perform	VB	_	10	xcomp
13	an	a	DT	_	15	det
14	observational	observational	JJ	_	15	amod
15	case	case	NN	_	12	dobj
16	-	-	:	_	12	punct
17	control	control	JJ	_	18	amod
18	study	study	NN	_	12	dobj
19	nested	nested	JJ	_	18	amod
20	within	within	IN	_	21	case
21	person	person	NN	_	19	nmod
22	-	-	:	_	18	punct
23	time	time	NN	_	18	dep
24	exposed	expose	VBN	_	23	acl
25	to	to	TO	_	26	case
26	warfarin	warfarin	NN	_	24	nmod
27	in	in	IN	_	30	case
28	those	those	DT	_	30	det
29	18	18	CD	_	30	nummod
30	years	year	NNS	_	24	nmod
31	.	.	.	_	2	punct

1	In	in	IN	_	2	case
2	total	total	NN	_	7	nmod
3	,	,	,	_	7	punct
4	430,455	430,455	CD	_	6	nummod
5	warfarin	warfarin	NN	_	6	compound
6	users	user	NNS	_	7	nsubj
7	contributed	contribute	VBD	_	0	ROOT
8	407,370	407,370	CD	_	9	nummod
9	person	person	NN	_	7	dobj
10	-	-	:	_	9	punct
11	years	year	NNS	_	9	dep
12	of	of	IN	_	14	case
13	warfarin	warfarin	NN	_	14	compound
14	use	use	NN	_	11	nmod
15	.	.	.	_	7	punct

1	The	the	DT	_	3	det
2	incidence	incidence	NN	_	3	compound
3	rate	rate	NN	_	19	nsubj
4	of	of	IN	_	5	case
5	hospitalization	hospitalization	NN	_	3	nmod
6	for	for	IN	_	8	case
7	GI	gi	NN	_	8	compound
8	bleeding	bleeding	NN	_	3	nmod
9	among	among	IN	_	11	case
10	warfarin	warfarin	NN	_	11	compound
11	users	user	NNS	_	8	nmod
12	was	be	VBD	_	19	cop
13	4.48	4.48	CD	_	19	nsubj
14	per	per	IN	_	16	case
15	100	100	CD	_	16	nummod
16	person	person	NN	_	19	nmod
17	-	-	:	_	19	punct
18	years	year	NNS	_	19	nsubj
19	(	(	VBP	_	0	ROOT
20	95	95	CD	_	21	compound
21	%	%	NN	_	22	amod
22	CI	ci	NN	_	19	dobj
23	,	,	,	_	22	punct
24	4.42	4.42	CD	_	27	nummod
25	-	-	:	_	27	punct
26	4.55	4.55	CD	_	27	compound
27	)	)	CD	_	22	appos
28	.	.	.	_	19	punct

1	Each	each	DT	_	4	det
2	gastrointestinal	gastrointestinal	JJ	_	4	amod
3	bleeding	bleeding	NN	_	4	compound
4	cases	case	NNS	_	6	nsubjpass
5	was	be	VBD	_	6	auxpass
6	matched	match	VBN	_	0	ROOT
7	to	to	TO	_	9	case
8	50	50	CD	_	9	nummod
9	controls	control	NNS	_	6	nmod
10	based	base	VBN	_	13	case
11	on	on	IN	_	13	case
12	index	index	NN	_	13	compound
13	date	date	NN	_	9	nmod
14	and	and	CC	_	13	cc
15	state	state	NN	_	13	conj
16	.	.	.	_	6	punct

1	Warfarin	Warfarin	NNP	_	2	compound
2	users	user	NNS	_	3	nsubj
3	had	have	VBD	_	0	ROOT
4	an	a	DT	_	7	det
5	increased	increase	VBN	_	7	amod
6	odds	odds	NNS	_	7	compound
7	ratio	ratio	NN	_	3	dobj
8	of	of	IN	_	10	case
9	gastrointestinal	gastrointestinal	JJ	_	10	amod
10	bleeding	bleeding	NN	_	7	nmod
11	upon	upon	IN	_	12	case
12	initiation	initiation	NN	_	3	nmod
13	of	of	IN	_	16	case
14	citalopram	citalopram	NN	_	16	compound
15	(	(	CD	_	16	nummod
16	OR	or	NN	_	12	nmod
17	=	=	JJ	_	22	case
18	1.73	1.73	CD	_	20	compound
19	[	[	CD	_	20	compound
20	95	95	CD	_	21	dep
21	%	%	NN	_	22	dep
22	CI	ci	NN	_	12	nmod
23	,	,	,	_	22	punct
24	1.25	1.25	CD	_	28	nummod
25	-	-	:	_	28	punct
26	2.38	2.38	CD	_	27	compound
27	]	]	CD	_	28	nummod
28	)	)	NN	_	22	appos
29	,	,	,	_	22	punct
30	fluoxetine	fluoxetine	NN	_	32	compound
31	(	(	CD	_	32	nummod
32	OR	or	NN	_	22	appos
33	=	=	JJ	_	38	case
34	1.63	1.63	CD	_	36	compound
35	[	[	CD	_	36	compound
36	95	95	CD	_	37	dep
37	%	%	NN	_	38	dep
38	CI	ci	NN	_	32	nmod
39	,	,	,	_	38	punct
40	1.11	1.11	CD	_	44	nummod
41	-	-	:	_	44	punct
42	2.38	2.38	CD	_	43	compound
43	]	]	CD	_	44	nummod
44	)	)	NN	_	38	appos
45	,	,	,	_	38	punct
46	paroxetine	paroxetine	NN	_	48	compound
47	(	(	CD	_	48	nummod
48	OR	or	NN	_	38	appos
49	=	=	JJ	_	54	case
50	1.64	1.64	CD	_	52	compound
51	[	[	CD	_	52	compound
52	95	95	CD	_	53	dep
53	%	%	NN	_	54	dep
54	CI	ci	NN	_	48	nmod
55	,	,	,	_	54	punct
56	1.27	1.27	CD	_	60	nummod
57	-	-	:	_	60	punct
58	2.12	2.12	CD	_	59	compound
59	]	]	CD	_	60	nummod
60	)	)	NN	_	54	conj
61	,	,	,	_	54	punct
62	amitriptyline	amitriptyline	NNP	_	64	compound
63	(	(	NNP	_	64	compound
64	OR	or	NN	_	65	nsubj
65	=	=	JJ	_	54	acl:relcl
66	1.47	1.47	CD	_	68	compound
67	[	[	CD	_	68	compound
68	95	95	CD	_	69	dep
69	%	%	NN	_	70	dep
70	CI	ci	NN	_	65	dobj
71	,	,	,	_	70	punct
72	1.02	1.02	CD	_	76	nummod
73	-	-	:	_	76	punct
74	2.11	2.11	CD	_	75	compound
75	]	]	CD	_	76	nummod
76	)	)	NN	_	70	appos
77	.	.	.	_	3	punct

1	Also	also	RB	_	2	advmod
2	mirtazapine	mirtazapine	NN	_	13	nsubj
3	,	,	,	_	2	punct
4	which	which	WDT	_	7	nsubjpass
5	is	be	VBZ	_	7	auxpass
6	not	not	RB	_	7	neg
7	believed	believe	VBN	_	2	acl:relcl
8	to	to	TO	_	9	mark
9	interact	interact	VB	_	7	xcomp
10	with	with	IN	_	11	case
11	warfarin	warfarin	NN	_	9	nmod
12	,	,	,	_	2	punct
13	increased	increase	VBD	_	0	ROOT
14	the	the	DT	_	15	det
15	risk	risk	NN	_	13	dobj
16	of	of	IN	_	18	case
17	GI	gi	NN	_	18	compound
18	bleeding	bleeding	NN	_	15	nmod
19	(	(	CD	_	18	nummod
20	OR	or	NN	_	18	dep
21	=	=	JJ	_	13	dep
22	1.75	1.75	CD	_	24	compound
23	[	[	CD	_	24	compound
24	95	95	CD	_	25	dep
25	%	%	NN	_	26	dep
26	CI	ci	NN	_	21	dep
27	,	,	,	_	26	punct
28	1.30	1.30	CD	_	32	nummod
29	-	-	:	_	32	punct
30	2.35	2.35	CD	_	31	compound
31	]	]	CD	_	32	nummod
32	)	)	NN	_	26	appos
33	.	.	.	_	13	punct

1	Warfarin	Warfarin	NNP	_	2	compound
2	users	user	NNS	_	15	nsubj
3	who	who	WP	_	4	nsubj
4	initiated	initiate	VBD	_	2	acl:relcl
5	citalopram	citalopram	NN	_	4	dobj
6	,	,	,	_	5	punct
7	fluoxetine	fluoxetine	NN	_	5	conj
8	,	,	,	_	5	punct
9	paroxetine	paroxetine	NN	_	5	conj
10	,	,	,	_	5	punct
11	amitriptyline	amitriptyline	NNP	_	5	conj
12	,	,	,	_	5	punct
13	or	or	CC	_	5	cc
14	mirtazapine	mirtazapine	NN	_	5	conj
15	had	have	VBD	_	0	ROOT
16	an	a	DT	_	18	det
17	increased	increase	VBN	_	18	amod
18	risk	risk	NN	_	15	dobj
19	of	of	IN	_	20	case
20	hospitalization	hospitalization	NN	_	18	nmod
21	for	for	IN	_	23	case
22	gastrointestinal	gastrointestinal	JJ	_	23	amod
23	bleeding	bleeding	NN	_	18	nmod
24	.	.	.	_	15	punct

1	However	however	RB	_	8	advmod
2	,	,	,	_	8	punct
3	the	the	DT	_	5	det
4	elevated	elevated	JJ	_	5	amod
5	risk	risk	NN	_	8	nsubj
6	with	with	IN	_	7	case
7	mirtazapine	mirtazapine	NN	_	5	nmod
8	suggests	suggest	VBZ	_	0	ROOT
9	that	that	IN	_	25	mark
10	a	a	DT	_	19	det
11	drug	drug	NN	_	19	dep
12	-	-	:	_	19	punct
13	drug	drug	NN	_	14	compound
14	interaction	interaction	NN	_	19	nsubj
15	may	may	MD	_	19	aux
16	not	not	RB	_	19	neg
17	have	have	VB	_	19	aux
18	been	be	VBN	_	19	cop
19	responsible	responsible	JJ	_	25	nsubj
20	for	for	IN	_	21	case
21	all	all	DT	_	19	nmod
22	of	of	IN	_	24	case
23	the	the	DT	_	24	det
24	observed	observe	VBN	_	21	nmod
25	increased	increase	VBD	_	8	ccomp
26	risk	risk	NN	_	25	dobj
27	.	.	.	_	8	punct

1	Ephedrine	ephedrine	NN	_	2	nsubj
2	enhances	enhance	VBZ	_	0	ROOT
3	the	the	DT	_	5	det
4	antinociceptive	antinociceptive	JJ	_	5	amod
5	effect	effect	NN	_	2	dobj
6	of	of	IN	_	7	case
7	dexmedetomidine	dexmedetomidine	NN	_	5	nmod
8	in	in	IN	_	9	case
9	mice	mouse	NNS	_	5	nmod
10	.	.	.	_	2	punct

1	Dexmedetomidine	Dexmedetomidine	NNP	_	0	ROOT
2	,	,	,	_	1	punct
3	a	a	DT	_	6	det
4	highly	highly	RB	_	5	advmod
5	selective	selective	JJ	_	6	amod
6	alpha	alpha	NN	_	1	appos
7	-	-	:	_	1	punct
8	2	2	LS	_	11	dep
9	-	-	:	_	11	punct
10	adrenoceptor	adrenoceptor	NN	_	11	compound
11	agonist	agonist	NN	_	15	nsubjpass
12	,	,	,	_	11	punct
13	was	be	VBD	_	15	auxpass
14	recently	recently	RB	_	15	advmod
15	introduced	introduce	VBN	_	1	dep
16	into	into	IN	_	18	case
17	clinical	clinical	JJ	_	18	amod
18	practice	practice	NN	_	15	nmod
19	for	for	IN	_	21	case
20	its	its	PRP$	_	21	nmod:poss
21	sedative	sedative	NN	_	15	nmod
22	and	and	CC	_	21	cc
23	analgesic	analgesic	JJ	_	24	amod
24	properties	property	NNS	_	21	conj
25	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	purpose	purpose	NN	_	6	nsubj
3	of	of	IN	_	5	case
4	this	this	DT	_	5	det
5	study	study	NN	_	2	nmod
6	was	be	VBD	_	0	ROOT
7	to	to	TO	_	8	mark
8	evaluate	evaluate	VB	_	6	xcomp
9	whether	whether	IN	_	14	mark
10	the	the	DT	_	13	det
11	psychostimulant	psychostimulant	NN	_	13	compound
12	drug	drug	NN	_	13	compound
13	ephedrine	ephedrine	NN	_	14	nsubj
14	has	have	VBZ	_	8	ccomp
15	any	any	DT	_	16	det
16	effect	effect	NN	_	14	dobj
17	on	on	IN	_	18	case
18	dexmedetomidine	dexmedetomidine	NN	_	16	nmod
19	-	-	:	_	8	punct
20	induced	induce	VBN	_	21	amod
21	antinociception	antinociception	NN	_	8	dep
22	and	and	CC	_	21	cc
23	locomotor	locomotor	NN	_	25	compound
24	inhibitor	inhibitor	NN	_	25	compound
25	activity	activity	NN	_	21	conj
26	in	in	IN	_	27	case
27	mice	mouse	NNS	_	21	nmod
28	in	in	IN	_	30	case
29	acute	acute	JJ	_	30	amod
30	application	application	NN	_	21	nmod
31	.	.	.	_	6	punct

1	In	in	IN	_	3	case
2	both	both	DT	_	3	det
3	sexes	sex	NNS	_	0	ROOT
4	of	of	IN	_	7	case
5	swiss	swiss	JJ	_	7	amod
6	albino	albino	NN	_	7	compound
7	mice	mouse	NNS	_	3	nmod
8	;	;	:	_	3	punct

1	antinociception	antinociception	NN	_	3	nsubjpass
2	was	be	VBD	_	3	auxpass
3	assessed	assess	VBN	_	16	csubjpass
4	with	with	IN	_	8	case
5	hot	hot	JJ	_	8	amod
6	-	-	:	_	8	punct
7	plate	plate	NN	_	8	compound
8	test	test	NN	_	3	nmod
9	and	and	CC	_	8	cc
10	the	the	DT	_	11	det
11	locomotor	locomotor	NN	_	8	conj
12	,	,	,	_	8	punct
13	exploratory	exploratory	JJ	_	14	amod
14	activities	activity	NNS	_	8	conj
15	were	be	VBD	_	16	auxpass
16	assessed	assess	VBN	_	0	ROOT
17	with	with	IN	_	21	case
18	holed	hole	VBN	_	21	amod
19	open	open	JJ	_	21	amod
20	field	field	NN	_	21	compound
21	test	test	NN	_	16	nmod
22	.	.	.	_	16	punct

1	The	the	DT	_	2	det
2	animals	animal	NNS	_	4	nsubjpass
3	were	be	VBD	_	4	auxpass
4	received	receive	VBN	_	0	ROOT
5	;	;	:	_	4	punct

1	saline	saline	NN	_	0	ROOT
2	+	+	CC	_	1	cc
3	saline	saline	NN	_	1	conj
4	,	,	,	_	1	punct
5	ephedrine	ephedrine	NN	_	1	appos
6	(	(	CD	_	7	compound
7	10	10	CD	_	8	nummod
8	mg	mg	NN	_	5	dep
9	/	/	:	_	8	punct
10	kg	kg	NN	_	11	compound
11	)	)	NN	_	8	dep
12	+	+	CC	_	11	cc
13	saline	saline	NN	_	11	conj
14	,	,	,	_	8	punct
15	saline	saline	NN	_	8	appos
16	+	+	CC	_	15	cc
17	dexmedetomidine	dexmedetomidine	NN	_	15	conj
18	(	(	CD	_	19	compound
19	15	15	CD	_	20	nummod
20	g	g	NN	_	17	dep
21	/	/	:	_	20	punct
22	kg	kg	NN	_	23	compound
23	)	)	NN	_	20	dep
24	and	and	CC	_	23	cc
25	ephedrine	ephedrine	NN	_	23	conj
26	(	(	CD	_	27	compound
27	10	10	CD	_	28	nummod
28	mg	mg	NN	_	25	dep
29	/	/	:	_	28	punct
30	kg	kg	NN	_	31	compound
31	)	)	NN	_	28	dep
32	+	+	CC	_	31	cc
33	dexmedetomidine	dexmedetomidine	NN	_	31	conj
34	(	(	CD	_	35	compound
35	15	15	CD	_	36	nummod
36	g	g	NN	_	33	dep
37	/	/	:	_	36	punct
38	kg	kg	NN	_	39	compound
39	)	)	NN	_	36	dep
40	,	,	,	_	36	punct
41	intraperitoneally	intraperitoneally	RB	_	36	advmod
42	,	,	,	_	36	punct
43	30	30	CD	_	44	nummod
44	min	min	NN	_	36	conj
45	before	before	IN	_	47	case
46	hot	hot	JJ	_	47	amod
47	plate	plate	NN	_	44	nmod
48	or	or	CC	_	36	cc
49	holed	hole	VBD	_	36	conj
50	open	open	JJ	_	52	amod
51	field	field	NN	_	52	compound
52	tests	test	NNS	_	49	dobj
53	.	.	.	_	1	punct

1	In	in	IN	_	5	case
2	the	the	DT	_	5	det
3	hot	hot	JJ	_	5	amod
4	plate	plate	NN	_	5	compound
5	test	test	NN	_	11	nmod
6	in	in	IN	_	7	case
7	mice	mouse	NNS	_	5	nmod
8	,	,	,	_	11	punct
9	co	co	SYM	_	11	dep
10	-	-	:	_	11	punct
11	administration	administration	NN	_	0	ROOT
12	of	of	IN	_	14	case
13	15	15	CD	_	14	nummod
14	g	g	NN	_	11	nmod
15	/	/	:	_	14	punct
16	kg	kg	NN	_	17	compound
17	dexmedetomidine	dexmedetomidine	NN	_	14	dep
18	with	with	IN	_	20	case
19	10	10	CD	_	20	nummod
20	mg	mg	NN	_	17	nmod
21	/	/	:	_	14	punct
22	kg	kg	NN	_	23	compound
23	ephedrine	ephedrine	NN	_	14	dep
24	intraperitoneally	intraperitoneally	RB	_	27	advmod
25	not	not	RB	_	26	neg
26	only	only	RB	_	27	cc:preconj
27	enhanced	enhance	VBN	_	23	acl
28	,	,	,	_	27	punct
29	but	but	CC	_	27	cc
30	also	also	RB	_	31	advmod
31	prolonged	prolong	VBD	_	27	conj
32	the	the	DT	_	33	det
33	duration	duration	NN	_	31	dobj
34	of	of	IN	_	35	case
35	antinociception	antinociception	NN	_	33	nmod
36	induced	induce	VBN	_	35	acl
37	by	by	IN	_	38	case
38	dexmedetomidine	dexmedetomidine	NN	_	36	nmod
39	.	.	.	_	11	punct

1	At	at	IN	_	4	case
2	the	the	DT	_	4	det
3	same	same	JJ	_	4	amod
4	time	time	NN	_	13	nmod
5	,	,	,	_	13	punct
6	the	the	DT	_	9	det
7	locomotor	locomotor	NN	_	9	compound
8	inhibitory	inhibitory	JJ	_	9	amod
9	effect	effect	NN	_	13	nsubjpass
10	of	of	IN	_	11	case
11	dexmedetomidine	dexmedetomidine	NN	_	9	nmod
12	was	be	VBD	_	13	auxpass
13	counteracted	counteract	VBN	_	0	ROOT
14	by	by	IN	_	15	case
15	ephedrine	ephedrine	NN	_	13	nmod
16	.	.	.	_	13	punct

1	We	we	PRP	_	2	nsubj
2	concluded	conclude	VBD	_	0	ROOT
3	that	that	IN	_	12	mark
4	the	the	DT	_	6	det
5	combined	combined	JJ	_	6	amod
6	administration	administration	NN	_	12	nsubj
7	of	of	IN	_	8	case
8	dexmedetomidine	dexmedetomidine	NN	_	6	nmod
9	with	with	IN	_	10	case
10	ephedrine	ephedrine	NN	_	6	nmod
11	may	may	MD	_	12	aux
12	have	have	VB	_	2	ccomp
13	beneficial	beneficial	JJ	_	14	amod
14	effects	effect	NNS	_	12	dobj
15	in	in	IN	_	17	case
16	the	the	DT	_	17	det
17	treatment	treatment	NN	_	12	nmod
18	of	of	IN	_	19	case
19	pain	pain	NN	_	17	nmod
20	without	without	IN	_	21	mark
21	causing	cause	VBG	_	12	advcl
22	sedation	sedation	NN	_	21	dobj
23	,	,	,	_	22	punct
24	which	which	WDT	_	25	nsubj
25	limits	limit	VBZ	_	22	acl:relcl
26	the	the	DT	_	27	det
27	use	use	NN	_	25	dobj
28	of	of	IN	_	29	case
29	dexmedetomidine	dexmedetomidine	NN	_	27	nmod
30	as	as	IN	_	32	case
31	an	a	DT	_	32	det
32	analgesic	analgesic	JJ	_	25	nmod
33	in	in	IN	_	34	case
34	humans	human	NNS	_	32	nmod
35	.	.	.	_	2	punct

1	Interaction	interaction	NN	_	2	compound
2	study	study	NN	_	0	ROOT
3	of	of	IN	_	4	case
4	moxifloxacin	moxifloxacin	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	lomefloxacin	lomefloxacin	NN	_	4	conj
7	with	with	IN	_	8	case
8	co	co	NN	_	2	nmod
9	-	-	:	_	2	punct
10	administered	administer	VBN	_	11	amod
11	drugs	drug	NNS	_	2	dep
12	.	.	.	_	2	punct

1	Moxifloxacin	Moxifloxacin	NNP	_	6	nsubj
2	and	and	CC	_	1	cc
3	lomefloxacin	lomefloxacin	NN	_	1	conj
4	are	be	VBP	_	6	cop
5	fluoroquinolone	fluoroquinolone	JJ	_	6	amod
6	antibiotics	antibiotic	NNS	_	0	ROOT
7	used	use	VBN	_	6	acl
8	in	in	IN	_	9	mark
9	treating	treat	VBG	_	7	advcl
10	urinary	urinary	JJ	_	14	amod
11	and	and	CC	_	10	cc
12	respiratory	respiratory	JJ	_	10	conj
13	tract	tract	NN	_	14	compound
14	infections	infection	NNS	_	9	dobj
15	.	.	.	_	6	punct

1	Fluoroquinolones	fluoroquinolone	NNS	_	3	nsubjpass
2	are	be	VBP	_	3	auxpass
3	known	know	VBN	_	0	ROOT
4	to	to	TO	_	5	mark
5	have	have	VB	_	3	xcomp
6	interactions	interaction	NNS	_	5	dobj
7	with	with	IN	_	8	case
8	drugs	drug	NNS	_	6	nmod
9	that	that	WDT	_	11	nsubj
10	are	be	VBP	_	11	cop
11	active	active	JJ	_	8	acl:relcl
12	in	in	IN	_	15	case
13	gastro	gastro	NN	_	15	compound
14	intestinal	intestinal	JJ	_	15	amod
15	tract	tract	NN	_	11	nmod
16	.	.	.	_	3	punct

1	Being	be	VBG	_	0	ROOT
2	moxifloxacin	moxifloxacin	NN	_	5	compound
3	and	and	CC	_	2	cc
4	lomefloxacin	lomefloxacin	NN	_	2	conj
5	fluoroquinolones	fluoroquinolone	NNS	_	1	dobj
6	the	the	DT	_	8	det
7	interaction	interaction	NN	_	8	compound
8	study	study	NN	_	5	dobj
9	of	of	IN	_	11	mark
10	was	be	VBD	_	11	auxpass
11	carried	carry	VBN	_	8	acl
12	out	out	RP	_	11	compound:prt
13	with	with	IN	_	14	case
14	sucralfate	sucralfate	NN	_	11	nmod
15	,	,	,	_	14	punct
16	gelusil	gelusil	NN	_	14	conj
17	,	,	,	_	14	punct
18	erythromycin	erythromycin	NN	_	14	conj
19	and	and	CC	_	14	cc
20	multi	multus	NNS	_	21	compound
21	minerals	mineral	NNS	_	14	conj
22	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	interaction	interaction	NN	_	4	nsubjpass
3	was	be	VBD	_	4	auxpass
4	studied	study	VBN	_	0	ROOT
5	at	at	IN	_	11	case
6	neutral	neutral	JJ	_	11	amod
7	,	,	,	_	6	punct
8	acidic	acidic	JJ	_	6	conj
9	and	and	CC	_	6	cc
10	basic	basic	JJ	_	6	conj
11	conditions	condition	NNS	_	4	nmod
12	both	both	CC	_	15	cc:preconj
13	at	at	IN	_	15	case
14	room	room	NN	_	15	compound
15	temperature	temperature	NN	_	11	nmod
16	and	and	CC	_	15	cc
17	37	37	CD	_	18	nummod
18	C	c	NN	_	15	conj
19	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	16	nsubjpass
3	of	of	IN	_	5	case
4	dissolution	dissolution	NN	_	5	compound
5	medium	medium	NN	_	2	nmod
6	simulating	simulate	VBG	_	5	acl
7	various	various	JJ	_	9	amod
8	body	body	NN	_	9	compound
9	environments	environment	NNS	_	6	dobj
10	with	with	IN	_	11	case
11	response	response	NN	_	6	nmod
12	to	to	TO	_	13	case
13	pH	ph	NN	_	11	nmod
14	has	have	VBZ	_	16	aux
15	been	be	VBN	_	16	auxpass
16	examined	examine	VBN	_	0	ROOT
17	in	in	IN	_	20	mark
18	order	order	NN	_	17	mwe
19	to	to	TO	_	20	mark
20	elucidate	elucidate	VB	_	16	advcl
21	the	the	DT	_	22	det
22	interactions	interaction	NNS	_	20	dobj
23	.	.	.	_	16	punct

1	The	the	DT	_	2	det
2	response	response	NN	_	0	ROOT
3	of	of	IN	_	4	case
4	moxifloxacin	moxifloxacin	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	lomefloxacin	lomefloxacin	NN	_	4	conj
7	after	after	IN	_	8	case
8	interaction	interaction	NN	_	2	nmod
9	with	with	IN	_	10	case
10	co	co	NN	_	8	nmod
11	-	-	:	_	2	punct
12	administered	administer	VBN	_	13	amod
13	drugs	drug	NNS	_	20	nsubjpass
14	at	at	IN	_	16	case
15	different	different	JJ	_	16	amod
16	conditions	condition	NNS	_	13	nmod
17	and	and	CC	_	16	cc
18	temperature	temperature	NN	_	16	conj
19	were	be	VBD	_	20	auxpass
20	noted	note	VBN	_	2	dep
21	using	use	VBG	_	20	xcomp
22	a	a	DT	_	25	det
23	Shimadzu	Shimadzu	NNP	_	25	compound
24	HPLC	hplc	NN	_	25	compound
25	system	system	NN	_	21	dobj
26	with	with	IN	_	28	case
27	PDA	pda	NN	_	28	compound
28	detector	detector	NN	_	25	nmod
29	.	.	.	_	2	punct

1	It	it	PRP	_	3	nsubjpass
2	was	be	VBD	_	3	auxpass
3	seen	see	VBN	_	0	ROOT
4	that	that	IN	_	13	mark
5	interaction	interaction	NN	_	13	nsubj
6	of	of	IN	_	8	case
7	these	these	DT	_	8	det
8	fluoroquinolones	fluoroquinolone	NNS	_	5	nmod
9	was	be	VBD	_	13	cop
10	more	more	RBR	_	13	advmod
11	at	at	IN	_	13	case
12	37	37	CD	_	13	nummod
13	C	c	NN	_	3	ccomp
14	than	than	IN	_	17	case
15	at	at	IN	_	17	case
16	room	room	NN	_	17	compound
17	temperature	temperature	NN	_	13	nmod
18	.	.	.	_	3	punct

1	Moxifloxacin	Moxifloxacin	NNP	_	4	nsubj
2	and	and	CC	_	1	cc
3	Lomefloxacin	Lomefloxacin	NNP	_	1	conj
4	reacts	react	VBZ	_	0	ROOT
5	faster	faster	RBR	_	4	advmod
6	with	with	IN	_	7	case
7	sucralfate	sucralfate	NN	_	4	nmod
8	and	and	CC	_	7	cc
9	gelusil	gelusil	NN	_	7	conj
10	in	in	IN	_	12	case
11	acidic	acidic	JJ	_	12	amod
12	media	media	NNS	_	7	nmod
13	whereas	whereas	IN	_	4	dep
14	with	with	IN	_	15	case
15	erythromycin	erythromycin	NN	_	13	nmod
16	in	in	IN	_	18	case
17	basic	basic	JJ	_	18	amod
18	media	media	NNS	_	15	nmod
19	and	and	CC	_	18	cc
20	multi	multus	NNS	_	18	conj
21	-	-	:	_	18	punct
22	minerals	mineral	NNS	_	18	dep
23	in	in	IN	_	25	case
24	neutral	neutral	JJ	_	25	amod
25	media	media	NNS	_	22	nmod
26	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	study	study	NN	_	3	nsubj
3	ensures	ensure	VBZ	_	0	ROOT
4	the	the	DT	_	5	det
5	interaction	interaction	NN	_	3	dobj
6	of	of	IN	_	7	case
7	fluoroquinolones	fluoroquinolone	NNS	_	5	nmod
8	with	with	IN	_	10	case
9	selected	select	VBN	_	10	amod
10	class	class	NN	_	5	nmod
11	of	of	IN	_	12	case
12	drugs	drug	NNS	_	10	nmod
13	.	.	.	_	3	punct

1	In	in	IN	_	4	mark
2	order	order	NN	_	1	mwe
3	to	to	TO	_	4	mark
4	achieve	achieve	VB	_	0	ROOT
5	the	the	DT	_	8	det
6	effective	effective	JJ	_	8	amod
7	therapeutic	therapeutic	JJ	_	8	amod
8	effect	effect	NN	_	4	dobj
9	appropriate	appropriate	JJ	_	11	amod
10	time	time	NN	_	11	compound
11	intervals	interval	NNS	_	17	nsubj
12	between	between	IN	_	13	case
13	administrations	administration	NNS	_	11	nmod
14	of	of	IN	_	15	case
15	drugs	drug	NNS	_	13	nmod
16	is	be	VBZ	_	17	cop
17	essential	essential	JJ	_	8	acl:relcl
18	.	.	.	_	4	punct

